0001701541-24-000022.txt : 20240509 0001701541-24-000022.hdr.sgml : 20240509 20240509071335 ACCESSION NUMBER: 0001701541-24-000022 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 64 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Black Diamond Therapeutics, Inc. CENTRAL INDEX KEY: 0001701541 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39200 FILM NUMBER: 24928543 BUSINESS ADDRESS: STREET 1: ONE MAIN STREET, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-417-5868 MAIL ADDRESS: STREET 1: ONE MAIN STREET, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Aset Therapeutics, Inc. DATE OF NAME CHANGE: 20170321 10-Q 1 bdtx-20240331.htm 10-Q bdtx-20240331
FALSEQ12024000170154112-31http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrentP5YP5Y365365xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:purebdtx:contractutr:sqft00017015412024-01-012024-03-3100017015412024-05-0600017015412024-03-3100017015412023-12-3100017015412023-01-012023-03-3100017015412022-12-3100017015412023-03-310001701541us-gaap:CommonStockMember2022-12-310001701541us-gaap:AdditionalPaidInCapitalMember2022-12-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001701541us-gaap:RetainedEarningsMember2022-12-310001701541us-gaap:CommonStockMember2023-01-012023-03-310001701541us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001701541us-gaap:RetainedEarningsMember2023-01-012023-03-310001701541us-gaap:CommonStockMember2023-03-310001701541us-gaap:AdditionalPaidInCapitalMember2023-03-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001701541us-gaap:RetainedEarningsMember2023-03-310001701541us-gaap:CommonStockMember2023-12-310001701541us-gaap:AdditionalPaidInCapitalMember2023-12-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001701541us-gaap:RetainedEarningsMember2023-12-310001701541us-gaap:CommonStockMember2024-01-012024-03-310001701541us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001701541us-gaap:RetainedEarningsMember2024-01-012024-03-310001701541us-gaap:CommonStockMember2024-03-310001701541us-gaap:AdditionalPaidInCapitalMember2024-03-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001701541us-gaap:RetainedEarningsMember2024-03-310001701541bdtx:ShelfRegistrationStatementMember2022-11-142022-11-140001701541bdtx:AtMarketEquityProgramMember2022-11-142022-11-140001701541bdtx:AtMarketEquityProgramMember2024-01-012024-03-310001701541bdtx:FollowOnOfferingMember2023-07-052023-07-050001701541bdtx:FollowOnOfferingMember2023-07-050001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-03-310001701541us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001701541us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001701541us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-03-310001701541us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001701541us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001701541us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2024-03-310001701541us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel2Member2024-03-310001701541us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2024-03-310001701541us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2024-03-310001701541us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001701541us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-03-310001701541us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001701541us-gaap:FairValueMeasurementsRecurringMember2024-03-310001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001701541us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001701541us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001701541us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001701541us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001701541us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001701541us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2023-12-310001701541us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001701541us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2023-12-310001701541us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateBondSecuritiesMember2023-12-310001701541us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001701541us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001701541us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001701541us-gaap:FairValueMeasurementsRecurringMember2023-12-310001701541us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2024-03-310001701541us-gaap:CorporateBondSecuritiesMember2024-03-310001701541us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2023-12-310001701541us-gaap:CorporateBondSecuritiesMember2023-12-3100017015412023-01-012023-12-310001701541us-gaap:FurnitureAndFixturesMember2024-03-310001701541us-gaap:FurnitureAndFixturesMember2023-12-310001701541us-gaap:LeaseholdImprovementsMember2024-03-310001701541us-gaap:LeaseholdImprovementsMember2023-12-310001701541bdtx:LaunchpadTherapeuticsIncMember2022-12-310001701541bdtx:LaunchpadTherapeuticsIncMember2024-03-310001701541bdtx:LaunchpadTherapeuticsIncMember2022-12-0100017015412022-01-012022-12-310001701541bdtx:LaunchpadTherapeuticsIncMember2022-01-012022-12-310001701541bdtx:A2020StockOptionPlanMember2020-01-140001701541bdtx:A2020StockOptionPlanMember2024-01-012024-01-010001701541bdtx:A2020StockOptionPlanMember2024-01-010001701541bdtx:A2020EmployeeStockPurchasePlanMember2020-01-140001701541bdtx:A2020EmployeeStockPurchasePlanMember2024-01-012024-01-010001701541us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001701541us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001701541us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001701541us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001701541bdtx:OtherAwardTypeMember2024-01-012024-03-310001701541bdtx:OtherAwardTypeMember2023-01-012023-03-310001701541us-gaap:EmployeeStockOptionMemberbdtx:A2020StockOptionPlanMember2024-01-012024-03-310001701541us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310001701541us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001701541us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-03-310001701541us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-310001701541us-gaap:RestrictedStockMember2023-12-310001701541us-gaap:RestrictedStockMember2024-01-012024-03-310001701541us-gaap:RestrictedStockMember2024-03-310001701541us-gaap:RestrictedStockUnitsRSUMember2024-03-310001701541us-gaap:PerformanceSharesMember2023-12-310001701541bdtx:PerformanceRestrictedStockUnitsMember2024-01-012024-03-310001701541us-gaap:PerformanceSharesMember2024-01-012024-03-310001701541bdtx:PerformanceRestrictedStockUnitsMember2024-03-310001701541us-gaap:EmployeeStockMemberbdtx:A2020EmployeeStockPurchasePlanMember2024-01-012024-03-310001701541us-gaap:EmployeeStockMemberbdtx:A2020EmployeeStockPurchasePlanMember2024-03-310001701541us-gaap:EmployeeStockMemberbdtx:A2020EmployeeStockPurchasePlanMember2023-01-012023-03-310001701541us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001701541us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001701541us-gaap:RestrictedStockMember2024-01-012024-03-310001701541us-gaap:RestrictedStockMember2023-01-012023-03-310001701541us-gaap:EmployeeStockMember2024-01-012024-03-310001701541us-gaap:EmployeeStockMember2023-01-012023-03-310001701541us-gaap:PerformanceSharesMember2024-01-012024-03-310001701541us-gaap:PerformanceSharesMember2023-01-012023-03-310001701541us-gaap:WarrantMember2024-01-012024-03-310001701541us-gaap:WarrantMember2023-01-012023-03-310001701541bdtx:OperatingLeasePrincipalOfficeTwoMember2020-07-310001701541bdtx:OperatingLeasePrincipalOfficeTwoMember2023-08-310001701541bdtx:OperatingLeaseOfficeAndLaboratorySpaceNYMember2020-12-310001701541us-gaap:SubsequentEventMemberbdtx:AtMarketEquityProgramMember2024-04-012024-04-300001701541us-gaap:SubsequentEventMemberbdtx:AtMarketEquityProgramMember2024-05-012024-05-090001701541bdtx:FangNiMember2024-01-012024-03-310001701541bdtx:FangNiMember2024-03-310001701541bdtx:BrentHatzisSchochMember2024-01-012024-03-310001701541bdtx:BrentHatzisSchochMember2024-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________________________________________
FORM 10-Q
_______________________________________________________________________________
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED March 31, 2024
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM _ TO _
COMMISSION FILE NUMBER 001-38501
___________________________________________
BLACK DIAMOND THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
________________________________________________________________________________
Delaware81-4254660
(State or other jurisdiction
of incorporation or organization)
(I.R.S. Employer
Identification No.)
One Main Street, 14th Floor
Cambridge, Massachusetts
(Address of principal executive offices)
02142
(Zip Code)
(617) 252-0848
(Registrant’s telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.0001BDTXThe Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☐Accelerated filer☐




Non-accelerated filer☒Smaller reporting company☒






Emerging growth company☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒
As of May 6, 2024, the registrant had 56,252,794 shares of common stock, $0.0001 par value per share, outstanding.


SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q (this Quarterly Report) contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “could”, “should”, “expects”, “intends”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, “continue” or the negative of these terms or other comparable terminology. These statements are not guarantees of future results or performance and involve substantial risks and uncertainties. Forward-looking statements in this Quarterly Report include, but are not limited to, statements about:
•the progress, timing and success of our clinical trials of BDTX-1535, BDTX-4933 and any other product candidates, including the availability, timing and announcement of data and results of such trials;
•the scope, timing, progress and results of our clinical trials and Investigational New Drug (IND) applications, development efforts and other regulatory submissions;
•our ability to obtain and maintain regulatory approval for BDTX-1535 and BDTX-4933 or any of our future product candidates that we may identify or develop;
•the effects of competition with respect to BDTX-1535, BDTX-4933 or any of our other current or future product candidates, as well as innovations by current and future competitors in our industry;
•our evaluation of strategic alternatives for BDTX-4876 and one other preclinical program, including our ability to execute and realize the anticipated benefits of any strategic alternatives we may pursue;
•our need to raise additional funding before we can expect to generate any revenues from product sales;
•our ability to develop our current product candidates for the treatment of various cancers;
•the rate and degree of market acceptance and clinical utility for any current or future product candidates we may develop;
•the implementation of our strategic plans for our business and any product candidates we may develop based on our Mutation-Allostery-Pharmacology (MAP) drug discovery engine;
•our ability to successfully develop companion diagnostics for use with our current or future product candidates;
•our intellectual property position, including the scope of protection we are able to establish, maintain and enforce for intellectual property rights covering our product candidates and MAP drug discovery engine;
•our ability to obtain additional funding for our operations, when needed, including funding necessary to complete further development and commercialization of our product candidates, if approved;
•the period over which we expect our existing cash, cash equivalents and investments will be sufficient to fund our operating expenses and capital expenditure requirements;
•the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
•our future financial performance and our ability to effectively manage our anticipated growth;
•our estimates regarding the market opportunities for our product candidates, including our competitive position and the success of competing therapies that are or may become available;
•our need for and ability to attract and retain key scientific, management and other personnel and to identify, hire and retain additional qualified professionals;
•the potential for our business development efforts to maximize the value of our platform and product candidates;
2
•the size and growth potential of the markets for our product candidates, and our ability to serve those markets, either alone or in partnership with others;
•our ability to establish or maintain collaborations or strategic relationships and the ability and willingness of our third-party strategic collaborators to undertake research and development activities relating to our current or future product candidates;
•our expectations regarding the period during which we will remain an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the JOBS Act);
•our ability to maintain an effective system of internal controls;
•the impact of global economic and political developments on our business, including rising inflation and capital market disruptions, economic sanctions and economic slowdowns or recessions that may result from such developments which could harm our research and development efforts as well as the value of our common stock and our ability to access capital markets; and
•the ultimate impact of health epidemics, pandemics, and other widespread outbreaks of contagious disease, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our clinical trials, our research programs, healthcare systems or the global economy as a whole.
Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events and with respect to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part I, Item 1A, “Risk Factors” and elsewhere in our most recent Annual Report on Form 10-K for the year ended December 31, 2023 (the Annual Report) and in other Securities and Exchange Commission (SEC) filings. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.
All of our forward-looking statements are as of the date of this Quarterly Report only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of or any material adverse change in one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the SEC, could materially and adversely affect our business, prospects, financial condition and results of operations. Some of these risks and uncertainties may in the future be amplified by global health crises, and there may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report that modify or impact any of the forward-looking statements contained in this Quarterly Report will be deemed to modify or supersede such statements in this Quarterly Report.
This Quarterly Report contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed as exhibits to this Quarterly Report. In this Quarterly Report, the terms “Black Diamond Therapeutics”, “Black Diamond”, the “Company”, “we”, “us”, “our” and similar designations refer to Black Diamond Therapeutics, Inc. and, where appropriate, our wholly-owned subsidiary.
3
We may from time to time provide estimates, projections and other information concerning our industry, the general business environment, and the markets for certain diseases, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events, circumstances or numbers, including actual disease prevalence rates and market size, may differ materially from the information reflected in this Quarterly Report. Unless otherwise expressly stated, we obtained this industry, business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources, in some cases applying our own assumptions and analysis that may, in the future, prove not to have been accurate.
4
TABLE OF CONTENTS

Page
PART I - FINANCIAL INFORMATION
PART II - OTHER INFORMATION

We have applied for various trademarks that we use in connection with the operation of our business. This Quarterly Report may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties’ trademarks, service marks, trade names or products in this Quarterly Report is not intended to, and does not, imply a relationship with, or endorsement or sponsorship by, us. Solely for convenience, the trademarks, service marks and trade names referred to in this Quarterly Report may appear without the ®, TM or SM symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner of these trademarks, service marks and trade names will not assert, to the fullest extent under applicable law, its rights.
From time to time, we may use our website or our LinkedIn profile at www.linkedin.com/company/black-diamond-therapeutics to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at www.blackdiamondtherapeutics.com. Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website or our LinkedIn page is not incorporated into, and does not form a part of, this Quarterly Report.

Part I - FINANCIAL INFORMATION
Item I. Condensed Consolidated Financial Statements (Unaudited)
Black Diamond Therapeutics, Inc.
Condensed Consolidated Balance Sheets (Unaudited)
(in thousands, except share and per share data)

As of

March 31,
2024		December 31,
2023
Assets



Current assets:



Cash and cash equivalents$25,422 

$56,221 
Investments89,777 75,179 
Prepaid expenses and other current assets3,607 

2,634 
Total current assets118,806 

134,034 
Property and equipment, net1,644 

1,730 
Restricted cash819 

823 
Right-of-use assets21,252 21,980 
Total assets$142,521 

$158,567 
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable$1,176 

$2,324 
Accrued expenses and other current liabilities15,678 

17,322 
Total current liabilities16,854 

19,646 
Non-current operating lease liabilities21,361 22,185 
Total liabilities38,215 

41,831 
Commitments and contingencies (Note 11)
Stockholders' equity:

Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued or outstanding at March 31, 2024 and December 31, 2023
— — 
Common stock; $0.0001 par value; 500,000,000 shares authorized at March 31, 2024 and December 31, 2023; 52,527,626 shares issued and outstanding at March 31, 2024 and 51,645,557 shares issued and outstanding at December 31, 2023
7 

7 
Additional paid-in capital540,050 

534,187 
Accumulated other comprehensive loss(95)(27)
Accumulated deficit(435,656)

(417,431)
Total stockholders' equity104,306 

116,736 
Total liabilities and stockholders' equity$142,521 

$158,567 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
6
Black Diamond Therapeutics, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(in thousands, except share and per share data)

Three Months Ended
March 31,

20242023
Operating expenses:
Research and development$13,545 $14,753 
General and administrative6,701 6,808 
Total operating expenses20,246 21,561 
Loss from operations(20,246)(21,561)
Other income (expense):
Interest income637 622 
Other income (expense)1,384 64 
Total other income (expense), net2,021 686 
Net loss$(18,225)$(20,875)
Net loss per share, basic and diluted$(0.35)$(0.57)
Weighted average common shares outstanding, basic and diluted51,808,849 36,483,878 
Comprehensive loss:
Net loss$(18,225)$(20,875)
Other comprehensive income (loss):
Unrealized gain (loss) on investments, net(68)648 
Comprehensive loss$(18,293)$(20,227)
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
7
Black Diamond Therapeutics, Inc.
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
Three Months Ended
March 31,
2024

2023
Cash flows from operating activities:



Net loss$(18,225)$(20,875)
Adjustment to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense1,713 2,671 
Depreciation expense86 122 
(Accretion) amortization on investments(932)109 
Noncash rent expense728 690 
Loss on sale of equipment— 37 
Changes in current assets and liabilities:
Prepaid expenses and other current assets(973)383 
Accounts payable(1,128)1,169 
Accrued expenses and other current liabilities(1,644)(3,583)
Non-current operating lease liabilities(824)(754)
Net cash used in operating activities(21,199)(20,031)
Cash flows from investing activities:
Proceeds from sales and maturities of investments38,500 24,806 
Purchases of investments(52,234)— 
Net cash (used in) provided by investing activities(13,734)24,806 
Cash flows from financing activities:
Proceeds from exercise of common stock options and ESPP150 51 
Proceeds from issuance of common stock, net of issuance costs3,980 — 
Net cash provided by financing activities4,130 51 
Net increase (decrease) in cash and cash equivalents(30,803)4,826 
Cash, cash equivalents and restricted cash, beginning of period57,044 35,483 
Cash, cash equivalents and restricted cash, end of period$26,241 $40,309 
Cash and cash equivalents, end of period$25,422 $39,141 
Restricted cash, end of period819 1,168 
Cash, cash equivalents and restricted cash, end of period$26,241 $40,309 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
8
Black Diamond Therapeutics, Inc.
Condensed Consolidated Statements of Stockholders' Equity (Unaudited)
(in thousands, except share data)

Common stock

Additional
paid-in capital

Accumulated other comprehensive income (loss)Accumulated deficit

Total
stockholders’
equity

Shares

Par Value



BALANCE - December 31, 202236,434,297 $5 $452,503 $(1,824)$(334,989)$115,695 
Vesting of restricted stock units23,575 — — — — — 
Surrender of shares for taxes(3,903)— — — — — 
Issuance of common stock related to ESPP33,202 — 51 — — 51 
Stock-based compensation24,776 — 2,671 — — 2,671 
Unrealized gain (loss) on investments— — — 648 — 648 
Net loss— — — — (20,875)(20,875)
BALANCE - March 31, 202336,511,947 5 455,225 (1,176)(355,864)98,190 
BALANCE - December 31, 202351,645,557 $7 $534,187 $(27)$(417,431)$116,736 
Issuance of common stock, net of issuance costs800,000 — 4,000 — — 4,000 
Exercise of common stock options47,741 — 86 — — 86 
Vesting of restricted stock units1,250 — — — — — 
Issuance of common stock related to ESPP26,659 — 64 — — 64 
Stock-based compensation6,419 — 1,713 — — 1,713 
Unrealized gain (loss) on investments— — — (68)— (68)
Net loss— — — — (18,225)(18,225)
BALANCE - March 31, 202452,527,626 $7 $540,050 $(95)$(435,656)$104,306 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
9
Black Diamond Therapeutics, Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(Amounts in thousands, except share and per share amounts)
1. NATURE OF BUSINESS AND BASIS OF PRESENTATION
Black Diamond Therapeutics, Inc. (the Company) is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing and incurring research and development costs related to the development and advancement of its product candidates identified by its Mutation-Allostery-Pharmacology (MAP) drug discovery engine.
The Company is subject to risks and uncertainties common to clinical-stage companies in the biotechnology industry. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.
On November 14, 2022, the Company filed a shelf registration statement on Form S-3 (the Shelf Registration Statement), with the Securities and Exchange Commission (the SEC), which covers the offering, issuance and sale of the Company’s common stock, preferred stock, debt securities, warrants and/or units of any combination thereof up to a maximum offering price of $500 million. The Company simultaneously entered into an Open Market Sale AgreementSM with Jefferies LLC (Jefferies), as sales agent, to provide for the issuance and sale by the Company of up to $150 million of its common stock from time to time through Jefferies (the ATM Program). The Shelf Registration Statement became effective on November 22, 2022. As of March 31, 2024, the Company sold 800,000 shares of its common stock pursuant to the ATM Program, resulting in gross proceeds to the Company of approximately $4.0 million ($3.9 million net of offering costs).
On July 5, 2023, the Company completed an underwritten public offering (the Follow-on Offering) of 15,000,000 shares of the Company’s common stock at a price to the public of $5.00 per share. The aggregate net proceeds from the Follow-on Offering totaled approximately $71.9 million, after deducting underwriting discounts and commissions.
The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. Historically, the Company has funded its operations primarily with proceeds from the sale of common stock and preferred stock. The Company has had recurring losses and negative cash flows from operations in all periods since inception and had an accumulated deficit of $435.7 million as of March 31, 2024. The Company expects to continue to generate operating losses for the foreseeable future.
As of May 9, 2024, the issuance date of the condensed consolidated financial statements, the Company expects that its cash, cash equivalents and investments will be sufficient to fund its currently planned operations for at least the next 12 months from the filing date of these condensed consolidated financial statements.
10
The Company will seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, or reduce headcount and general and administrative costs, which could adversely affect its business prospects. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The following is a summary of significant accounting policies followed in the preparation of these condensed consolidated financial statements.
Principles of consolidation
The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics Security Corporation and Black Diamond Therapeutics (Canada), Inc., after elimination of all significant intercompany accounts and transactions. On October 10, 2023, Black Diamond Therapeutics (Canada), Inc. was dissolved by way of voluntary dissolution.
Unaudited interim financial information
The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. In the opinion of the Company’s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.
Use of estimates
The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
11
The Company continues to monitor the impact of global economic developments, political unrest, high inflation, disruptions in capital markets, changes in international trade relationships and military conflicts, and health crises, on all aspects of its business, and has considered the impact of these factors on estimates within its financial statements. The extent to which future developments may impact the Company’s business, results of operations or financial condition are uncertain and cannot be predicted with confidence and there may be changes to estimates in future periods. As of the date of issuance of these condensed consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of these factors and is not aware of any specific related event or circumstance that would require it to update its estimates.
Recently issued accounting pronouncements
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09). ASU 2023-09 requires that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate). The standard is effective for annual and interim periods beginning after December 15, 2024. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The adoption is not expected to have a material impact on the Company’s consolidated financial statements.
In November 2023, the FASB issued ASU 2023-07, Improvements to Reportable Segment Disclosures (Topic 280) (ASU 2023-07) which requires enhanced disclosure of (1) significant segment expenses that are regularly provided to the chief operating decision maker (CODM) and included within each reported measure of segment profit or loss, (2) the amount and description of the composition of other segment items which reconcile to segment profit or loss, and (3) the title and position of the entity’s CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and allocating resources. The amendments also expand the interim segment disclosure requirements. This new guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this ASU apply retrospectively to all prior periods presented in the financial statements. The Company is in the process of assessing the impact on its financial statements from the adoption of the new guidance and the period in which the new guidance will be adopted.
In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements - Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative (ASU 2023-06). The standard is effective for annual and interim periods beginning after December 15, 2024. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The adoption is not expected to have a material impact on the Company’s consolidated financial statements.
12
3. FAIR VALUE MEASUREMENTS
The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:

Fair value measurements at March 31, 2024 using:

Level 1

Level 2Level 3Total
Assets:





Cash equivalents:
Money market funds$20,498 $— $— $20,498 
Investments:
Commercial paper— 82,830 — 82,830 
Corporate bonds— 6,947 — 6,947 
Total$20,498 $89,777 $— $110,275 

Fair value measurements at December 31, 2023 using:

Level 1

Level 2Level 3Total
Assets:





Cash equivalents:
Money market funds$30,803 $— $— $30,803 
Investments:
Commercial paper— 44,871 — 44,871 
Corporate bonds— 30,308 — 30,308 
Total$30,803 $75,179 $— $105,982 
When developing fair value estimates, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. When available, the Company uses quoted market prices to measure fair value. The valuation technique used to measure fair value for the Company's Level 1 and Level 2 assets is a market approach, using prices and other relevant information generated by market transactions involving identical or comparable assets. If market prices are not available, the fair value measurement is based on models that use primarily market-based parameters including yield curves, volatilities, credit ratings and currency rates. In certain cases where market rate assumptions are not available, the Company is required to make judgments about assumptions market participants would use to estimate the fair value of a financial instrument.
There were no transfers in or out of Level 3 categories in the periods presented.
13
4. INVESTMENTS
As of March 31, 2024, investments were comprised of the following:
Amortized Cost

Unrealized GainsUnrealized LossesFair Value
Commercial paper$82,921 $— $(91)$82,830 
Corporate bonds6,951 — (4)6,947 
Total$89,872 $— $(95)$89,777 
As of December 31, 2023, investments were comprised of the following:
Amortized Cost

Unrealized GainsUnrealized LossesFair Value
Commercial paper$44,880 $4 $(13)$44,871 
Corporate bonds30,326 — (18)30,308 
Total$75,206 $4 $(31)$75,179 
As of March 31, 2024, all marketable securities held by the Company had remaining contractual maturities of one year or less.
As of December 31, 2023, all marketable securities held by the Company had remaining contractual maturities of one year or less.
As of March 31, 2024, the Company reviewed its investment portfolio to assess the unrealized losses on its available-for-sale investments. The Company evaluated whether it intended to sell the security and whether it was more likely than not that the Company would be required to sell the security before recovering its amortized cost basis. The Company also determined no portion of the unrealized losses relate to a credit loss. There have been no impairments of the Company’s assets measured and carried at fair value during the three months ended March 31, 2024 and the year ended December 31, 2023.
5. PROPERTY AND EQUIPMENT
Property and equipment, net consisted of the following:

March 31,
2024

December 31,
2023
Furniture and fixtures$17 $17 
Leasehold improvements2,512 2,512 
Property and equipment2,529 2,529 
Less: accumulated depreciation(885)(799)
Total Property and Equipment, net$1,644 $1,730 

Depreciation expense for the three months ended March 31, 2024 and 2023 was $86 and $122, respectively.
14
6. EQUITY METHOD INVESTMENT
In December 2022, the Company received 9,000,000 shares of common stock in a newly formed antibody-focused precision oncology company, Launchpad Therapeutics, Inc. (Launchpad), in exchange for contributing early discovery-stage antibody programs and granting Launchpad a license to use its MAP drug discovery engine to discover, develop and commercialize large molecule therapeutics. As of the transaction date and as of March 31, 2024, the Company has a 39.1% voting interest in Launchpad and one seat on Launchpad’s Board of Directors which provide the Company with significant influence over Launchpad. The remaining voting interest in Launchpad is held by Versant Ventures and New Enterprise Associates (NEA), who are shareholders of the Company.
The Company accounted for the transaction under the equity method and recorded the carrying value of the Company’s investment in Launchpad common shares of $2,250 in equity method investments in the consolidated balance sheets. The contributed in process research and development (IPR&D) had zero basis on the Company’s books prior to the transaction, therefore the Company recognized a gain on sale of IPR&D of $2,232 in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2022. The Company also recognized a loss from investments in equity method investee of $1,540 in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2022, associated with the Company’s proportionate share of Launchpad’s losses. The assets contributed by the Company were principally IPR&D and were not deemed a business by Launchpad, therefore the Company determined its remaining basis difference of $710 was substantially related to IPR&D and immediately expensed it. As of December 31, 2022, the carrying value of the investment in Launchpad was reduced to zero. Since the Company has no obligation to provide financing support to Launchpad, the Company is not required to record further losses exceeding the carrying value of the investment. The Company also determined that its investment in Launchpad is not material or significant to its operations or financial position. As of March 31, 2024, the carrying value of the investment in Launchpad was zero.
7. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued expenses and other current liabilities consisted of the following:

March 31,
2024

December 31,
2023
Contracted research services$8,984 $8,071 
Payroll and related expenses2,510 5,175 
Professional and consulting fees1,000 963 
Current portion of operating lease liability3,184 3,113 
Total accrued expenses and other current liabilities$15,678 $17,322 

8. STOCK-BASED COMPENSATION
2020 Stock Option and Incentive Plan
The 2020 Stock Option and Incentive Plan (the 2020 Plan) was approved by the Company’s board of directors on December 5, 2019, and the Company’s stockholders on January 14, 2020 and became effective on the date immediately prior to the date on which the registration statement for the Company’s initial public offering (IPO) was declared effective. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company’s officers, employees, directors and consultants. The 2020 Plan provides for an annual increase, to be added on the first day of each fiscal year, by up to 4% of the Company’s outstanding shares of common stock as of the last day of the prior year. On January 1, 2024, 2,065,822 shares of common stock, representing 4% of the Company’s outstanding shares of common stock as of December 31, 2023, were added to the 2020 Plan.
15
2020 Employee Stock Purchase Plan
The 2020 Employee Stock Purchase Plan (the 2020 ESPP) was approved by the Company’s board of directors on December 5, 2019, and the Company’s stockholders on January 14, 2020, and became effective on the date immediately prior to the date on which the registration statement for the Company’s IPO was declared effective. The 2020 ESPP provides for an annual increase, to be added on the first day of each fiscal year, by up to 1% of the number of shares of the Company’s common stock outstanding on the immediately preceding December 31. The number of authorized shares reserved for issuance under the 2020 ESPP was increased by 326,364 shares effective as of January 1, 2024.
Stock-based compensation expense
The Company recorded stock-based compensation expense in the following award type categories included within the condensed consolidated statements of operations and comprehensive loss:
Three Months Ended
March 31,

20242023
Stock options$1,623 $2,455 
Restricted stock units16 112 
Employee Stock Purchase Plan and Other74 104 

$1,713 $2,671 
For the three months ended March 31, 2024, the Company issued 6,419 shares of common stock under its 2020 Plan in accordance with its policy where non-employee directors may elect to receive their compensation in the form of common stock in lieu of cash.
The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:
Three Months Ended
March 31,

2024

2023
Research and development$635 

$949 
General and administrative1,078 

1,722 

$1,713 

$2,671 
16
Options
The following table summarizes the stock option activity under the Company’s equity awards plans:

Options

Weighted
Average
Exercise
Price

Weighted
Average
Remaining
Life
(in Years)

Intrinsic
Value
(in thousands)
Outstanding December 31, 20238,135,711 $7.85 8.0$1,146 
Granted2,895,550 $4.85 
Exercised(47,741)$1.78 
Cancelled or forfeited(16,500)$1.82 
Expired(300)$7.73 
Outstanding March 31, 202410,966,720 $7.09 8.3$11,996 
Options vested or expected to vest at March 31, 202410,966,720 $7.09 8.3$11,996 
Options exercisable at March 31, 20244,242,313 $11.65 6.7$3,488 
For the three months ended March 31, 2024, total unrecognized compensation cost related to the unvested stock-options was $18,345, which is expected to be recognized over a weighted average period of 3.1 years.
Restricted stock units
The fair values of restricted stock units are based on the market value of the Company’s stock on the date of the grant. Under terms of the time-based restricted stock agreements covering the common stock, shares of restricted common stock are subject to a vesting schedule. The following table summarizes time-based restricted stock activity since January 1, 2024:

Number of
shares
Weighted
average
grant date
fair value
Unvested restricted common stock as of December 31, 202320,799 $2.41 
Vested(1,250)$3.79 
Unvested restricted common stock as of March 31, 202419,549 $2.32 
The total fair value of time-based restricted stock units vested during the three months ended March 31, 2024 was $5.
For the three months ended March 31, 2024, total unrecognized compensation cost related to the time-based unvested restricted stock units was $6, which is expected to be recognized over a weighted average period of 0.1 years.
The Company had 19,000 performance restricted stock units outstanding at the year ended December 31, 2023. For the three months ended March 31, 2024, the Company granted no performance restricted stock units to its employees, released no performance restricted stock units due to the achievement of certain financing milestones, and had no performance restricted stock units forfeited. As of March 31, 2024, the Company had 19,000 performance restricted stock units outstanding.

Recognition of stock-based compensation expense associated with performance restricted stock units commences when the performance conditions are considered probable of achievement, using management’s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones.
17
As of March 31, 2024, for performance-based restricted stock units that were outstanding, the achievement of the milestones that had not been met was considered not probable, and therefore no expense has been recognized related to these awards in the three months ended March 31, 2024.
Employee stock purchase plan
The 2020 ESPP enables eligible employees to purchase shares of the Company's common stock at the end of each six-month offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Eligible employees generally included all employees. Offering periods begin on the first trading day of January and July of each year and end on the last trading day in June and December of each year, except for the first offering period which began on the first trading day in March and ended on the last trading day in June. Share purchases are funded through payroll deductions of up to 10% of an employee’s eligible compensation for each payroll period, up to $25 each calendar year.
During the three months ended March 31, 2024 and 2023, there were 26,659 and 33,202 shares, respectively, issued under the 2020 ESPP.
9. NET LOSS PER SHARE
Net loss per share
The following table summarizes the computation of basic and diluted net loss per share attributable to common shareholders of the Company (in thousands, except share and per share amounts):

Three Months Ended
March 31,

2024

2023
Net loss$(18,225)

$(20,875)
Weighted average common shares outstanding, basic and diluted51,808,849 

36,483,878 
Net loss per share, basic and diluted$(0.35)

$(0.57)

The Company’s potentially dilutive securities, which include options, unvested restricted stock and warrants to purchase common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:
Three Months Ended
March 31,

20242023
Options to purchase common stock10,966,720 7,710,285 
Unvested restricted stock19,549 86,290 
Shares issuable under employee stock purchase plan86,858 102,351 
Unvested performance restricted stock units19,000 229,859 
Warrants to purchase common stock10,757 10,757 

11,102,884 8,139,542 
18
10. LEASES
The Company has historically entered into lease arrangements for its facilities. As of March 31, 2024, the Company had two operating leases with required future minimum payments. The Company determined the classification of these leases to be operating leases and recorded right-of-use assets and lease liabilities as of the effective dates. The Company’s leases generally do not include termination or purchase options.
Operating leases
In July 2020, the Company entered into a seven-year agreement with an option to extend for five additional years to lease two floors totaling approximately 25,578 square feet of office space for its principal office, which is located in Cambridge, MA. The lease on the first floor commenced on August 1, 2020 and the lease on the second floor commenced March 9, 2021. The Company recognized the respective lease balances on the condensed consolidated balance sheets when the lease of each floor commenced. Under the terms of the lease, the Company was required to issue a $1,168 letter of credit as security for the lease, which was reduced to $779 in August 2023 pursuant to the terms of the lease agreement. Additionally, on December 12, 2022, the Company entered into a sublease for one floor of its Cambridge, Massachusetts office space. The sublease terminates on August 31, 2028, which is also the date on which the Company's lease terminates. Sublease income is recognized on a straight-line basis over the term of the sublease agreement. The Company was not relieved of its primary obligation under the Cambridge office lease as a result of the sublease.
In December 2020, the Company entered into an eleven-year agreement to lease approximately 18,120 square feet of office and laboratory space in New York, NY. The Company has an option to extend the lease for five additional years. The lease commenced August 26, 2021 and the related lease balance was recognized on the condensed consolidated balance sheet.
The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating lease for the three months ended March 31, 2024 and 2023:
Three Months Ended March 31,
20242023
Lease Cost
Operating lease cost$1,054 $1,054 
Short-term lease cost17 17 
Variable lease cost237 256 
Sublease income(456)(135)
Total lease cost$852 $1,192 
Other Operating Lease InformationMarch 31, 2024March 31, 2023
Cash paid for amounts included in the measurement of lease liability$1,080 $1,051 
Weighted-average remaining lease term6.77.6
Weighted-average discount rate5.3 %5.3 %
The variable lease costs for the three months ended March 31, 2024 and 2023 include common area maintenance and other operating charges. As the Company’s leases do not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.
19
Future minimum lease payments under the Company’s operating leases as of March 31, 2024 were as follows:
As of March 31, 2024
2024 (excluding the three months ended March 31, 2024)
$3,279 
20254,477 
20264,599 
20274,724 
20283,926 
Thereafter8,324 
Total lease payments29,329 
Less: interest(4,784)
Total lease liability$24,545 

11. COMMITMENTS AND CONTINGENCIES
The Company enters into contracts in the normal course of business with contract research organizations (CROs), contract manufacturing organizations (CMOs) and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of service providers, up to the date of cancellation.
License agreements
The Company is a party to license agreements, which include contingent payments. These payments will become payable if and when certain development, regulatory and commercial milestones are achieved. As of March 31, 2024, the satisfaction and timing of the contingent payments is uncertain and not reasonably estimable.
Indemnification agreements
In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of March 31, 2024 or December 31, 2023.
Legal proceedings
The Company is not currently party to and is not aware of any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.
20
12. BENEFIT PLANS
The Company has a tax-qualified 401(k) and Profit Sharing defined contribution plan (the 401(k) Plan). Under the 401(k) Plan, the Company provides an employer safe harbor matching contribution equal to 100% of a participant’s eligible contributions of up to 6% of eligible compensation, subject to limits established by the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the Code). All matching contributions are fully vested when made. During the three months ended March 31, 2024 and 2023, the Company contributed $348 and $376, respectively, to the 401(k) Plan.
13. SUBSEQUENT EVENTS
In April 2024, the Company sold 1,000,000 shares of its common stock pursuant to the ATM Program, resulting in gross proceeds to the Company of approximately $5.4 million ($5.3 million net of offering costs).
In May 2024, the Company sold 2,690,853 shares of its common stock pursuant to the ATM Program, resulting in gross proceeds to the Company of approximately $15.6 million ($15.3 million net of offering costs).
21
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis should be read in conjunction with the unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report and our audited consolidated financial statements and related notes thereto for the year ended December 31, 2023, as well as Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on March 12, 2024. This discussion and analysis and other parts of this Quarterly Report contain forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth in our Annual Report on Form 10-K and in other SEC filings.
Overview
We are a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of our company is built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Our MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain-penetrant to treat central nervous system (CNS) disease. Our compounds target families of oncogenic mutations in clinically validated pathways. We are advancing two clinical-stage programs: BDTX-1535, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, targeting epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and BDTX-4933, a brain-penetrant, RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors.
We believe that our lead product candidate, BDTX-1535, has the potential to treat newly diagnosed patients with EGFRm NSCLC, as well as those with recurrent disease, based upon BDTX-1535’s ability to address greater than 50 classical and non-classical oncogenic driver mutations with greater potency than other EGFR tyrosine kinase inhibitors (TKIs), as well as uniquely target the C797S resistance mutation which can be acquired after treatment with osimertinib. In our Phase 1 trial in patients with recurrent EGFRm NSCLC, BDTX-1535 was shown to be well tolerated and achieve durable clinical responses in patients whose tumors expressed a range of mutation subtypes, including the acquired C797S resistance mutation and a spectrum of non-classical mutations.
In April 2024, at the American Association of Cancer Research (AACR) annual meeting, we described real world evidence of the evolving EGFR mutation landscape in patients with NSCLC and the potential of BDTX-1535 to address a broader range of mutations compared to existing therapies. The analyses revealed a broad spectrum of non-classical mutations, as well as an increased prevalence of the acquired resistance mutation, C797S. These non-classical EGFR mutations were present in 22-30% of newly diagnosed EGFRm NSCLC patients.
We are currently evaluating BDTX-1535 in a Phase 2 clinical trial in patients with EGFRm NSCLC in the second- and third-line settings with non-classical driver mutations and acquired C797S resistance mutation, and in the first-line setting in patients with EGFRm NSCLC harboring non-classical EGFR mutations. We expect to announce results from the second- and third-line cohorts in the third quarter of 2024 and results from the first-line cohort in the first quarter of 2025. We are also assessing the potential development of BDTX-1535 for patients with EGFRm NSCLC following adjuvant treatment with osimertinib, where the broad mutation coverage of BDTX-1535 of C797S and non-classical mutations may be of benefit.
22
We released top-line GBM results from the BDTX-1535 Phase 1 dose escalation study in the fourth quarter of 2023, showing clinical activity in heavily pretreated patients with GBM. BDTX-1535 was shown to be generally well tolerated and no new safety signals were observed. In the fourth quarter of 2023, enrollment began in a “window of opportunity” (also known as a Phase 0/1 “Trigger”) trial sponsored by the Ivy Brain Tumor Center, in patients with recurrent high-grade glioma (HGG). We plan to present Phase 1 dose escalation data and “window of opportunity” results at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024, which will inform potential next steps in the development of BDTX-1535 in GBM.
Our second product candidate, BDTX-4933, is designed to be a potent and selective, reversible oral inhibitor that targets broad families of oncogenic BRAF, KRAS and NRAS alterations. BDTX-4933 selectively targets constitutively active RAF dimers resulting from either BRAF mutations or other upstream oncogenic MAPK pathway alterations, such as KRAS and NRAS alterations. In preclinical tumor models, we observed that BDTX-4933 demonstrated brain-penetrant activity and achieved regression of tumors carrying a broad spectrum of KRAS mutations, NRAS alterations, as well as BRAF Class I, II, and III mutations. We initiated a Phase 1 clinical trial for BDTX-4933 in the second quarter of 2023 in patients with BRAF and select KRAS and NRAS mutation-positive cancers, with an emphasis on patients with non-G12C KRAS mutant NSCLC. The trial is currently in dose escalation with an update anticipated in the fourth quarter of 2024.
Since our inception in 2014, we have devoted substantially all of our efforts and financial resources to organizing and staffing our company, business planning, raising capital, discovering product candidates and securing related intellectual property rights while conducting research and development activities for our programs. We do not have any products approved for sale and have not generated any revenue from product sales. We may never be able to develop or commercialize a marketable product. We have not yet successfully completed any pivotal clinical trials, obtained any regulatory approvals, manufactured a commercial-scale drug, or conducted sales and marketing activities.
To date, we have funded our operations with proceeds from the sale of common stock and preferred stock. Since inception, we have incurred significant operating losses. Our net losses were $18.2 million and $20.9 million for the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024, we had an accumulated deficit of $435.7 million. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates. We expect that our expenses and capital requirements will increase substantially in connection with our ongoing activities, particularly if and as we:
•advance clinical trials for BDTX-1535 and BDTX-4933;
•obtain, maintain, expand, enforce and protect our intellectual property portfolio;
•attract and retain key clinical, scientific, management and commercial personnel;
•seek marketing approvals for our product candidates that successfully complete clinical trials, if any; and
•acquire or in-license additional product candidates.
As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our product candidates, and reduce headcount and general and administrative costs.
23
Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.
Additionally, we continue to actively monitor macroeconomic conditions and market volatility resulting from global economic developments, political unrest, high inflation, disruptions in capital markets, changes in international trade relationships and military conflicts, and health crises. While we believe such factors have had no significant impact on our business or financial results during the periods presented, future developments and potential impacts on our business are uncertain and cannot be predicted with confidence.
As of March 31, 2024, we had cash, cash equivalents and investments of approximately $115.2 million, which we believe will enable us to fund our operating expenses and capital expenditure requirements into the third quarter of 2025. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See “—Liquidity and capital resources.” To finance our operations beyond that point, we will need to raise additional capital, which cannot be assured. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives.
Components of our results of operations
Revenue
To date, we have not generated any revenue from any sources, including from product sales, and we do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, or license agreements with third parties, we may generate revenue in the future from product sales. However, there can be no assurance as to when we will generate such revenue, if at all.
Operating expenses
Research and development expenses
Research and development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts and the development of our product candidates. We expense research and development costs as incurred, which include:
•expenses incurred to conduct the necessary preclinical studies and clinical trials required to obtain regulatory approval;
•expenses incurred under agreements with contract research organizations (CROs) that are primarily engaged in the oversight and conduct of our drug discovery efforts, preclinical studies, and clinical trials as well as under agreements with contract manufacturing organizations (CMOs) that are primarily engaged to provide preclinical and clinical drug substance and product for our research and development programs;
•other costs related to the conduct of preclinical studies, clinical trials, and our drug discovery efforts, including acquiring and manufacturing materials, manufacturing validation batches, fees to investigative sites and consultants that conduct our clinical trials, preclinical studies and other scientific development support services;
•payments made in cash or equity securities under third-party licensing, acquisition and option agreements;
•employee-related expenses, including salaries and benefits, travel and stock-based compensation expense for employees engaged in research and development functions;
•costs related to compliance with regulatory requirements; and
24
•allocated facilities-related costs, depreciation and other expenses, which include rent and utilities.
We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. Any nonrefundable advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are expensed as the related goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered or the services rendered.
Our direct external research and development expenses consist primarily of external costs, such as fees paid to outside consultants, CROs, CMOs and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. Our direct research and development expenses also include fees incurred under license, acquisition and option agreements. We do not allocate employee costs, costs associated with our discovery efforts, laboratory supplies, and facilities, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to conduct our research and discovery as well as for managing our preclinical development, process development, manufacturing and clinical development activities. These employees work across multiple programs and, therefore, we do not track their costs by program.
Development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research and development expenses will increase substantially over the next several years as we continue our clinical trials for BDTX-1535 and BDTX-4933. In addition, we may incur additional expenses related to milestone and royalty payments payable to third parties with whom we may enter into license, acquisition and option agreements to acquire the rights to future product candidates.
At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the clinical development of any of our product candidates or when, if ever, material net cash inflows may commence from any of our product candidates. The successful development and commercialization of our product candidates is highly uncertain. This uncertainty is due to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of the following:
•the scope, progress, outcome and costs of our clinical trials and other development activities;
•successful patient enrollment in and the initiation and completion of clinical trials;
•the timing, receipt and terms of any marketing approvals from applicable regulatory authorities including the U.S. Food and Drug Administration (FDA) and non-U.S. regulators;
•the extent of any required post-marketing approval commitments to applicable regulatory authorities;
•establishing clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers in order to ensure that we or our third-party manufacturers are able to make product successfully;
•development and timely delivery of clinical-grade and commercial-grade drug formulations that can be used in our clinical trials and for commercial launch;
•obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;
•significant and changing government regulation;
•launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; and
25
•maintaining a continued acceptable safety profile of our product candidates following approval, if any, of our product candidates.
Any changes in the outcome of any of these variables with respect to the development of our product candidates could mean a significant change in the costs and timing associated with the development of these product candidates. For example, if the FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate.
General and administrative expenses
General and administrative expenses consist primarily of salaries and benefits, travel and stock-based compensation expense for personnel in executive, business development, finance, human resources, legal, information technology, pre-commercial and support personnel functions. General and administrative expenses also include direct and allocated facility-related costs as well as insurance costs and professional fees for legal, patent, consulting, investor and public relations, accounting and audit services.
We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support continued development of our product candidates and prepare for potential commercialization activities. Additionally, if and when we believe a regulatory approval of a product candidate appears likely, we anticipate an increase in payroll and other employee-related expenses as a result of our preparation for commercial operations, especially as it relates to the sales and marketing of that product candidate.
Other income (expense)
Other income (expense) consists primarily of interest income earned on our cash equivalents and investment balances, sublease income, realized and unrealized foreign currency transaction gains and losses, and gain (loss) on sale of IP related to equity method investment.
Equity in (losses) of unconsolidated entity
Equity in (losses) of unconsolidated entity consists of our share of equity method investee losses on the basis of our equity ownership percentage and IPR&D charges resulting from basis differences.
26
Results of operations
Comparison of the three months ended March 31, 2024 and 2023
The following table summarizes our results of operations for the three months ended March 31, 2024 and 2023:

Three Months Ended
March 31,



2024

2023

Change

(in thousands)
Operating expenses:
Research and development$13,545 $14,753 $(1,208)
General and administrative6,701 6,808 (107)
Total operating expenses20,246 21,561 (1,315)
Loss from operations(20,246)(21,561)1,315 
Other income (expense):
Interest income637 622 15 
Other (expense) income1,384 64 1,320 
Total other income (expense), net2,021 686 1,335 
Net loss$(18,225)$(20,875)$2,650 
Research and development
Research and development expenses were $13.5 million for the three months ended March 31, 2024, compared to $14.8 million for the three months ended March 31, 2023. The following table summarizes our research and development expenses for the three months ended March 31, 2024 and 2023:

Three Months Ended
March 31,



2024

2023

Change

(in thousands)
BDTX-1535 research and development expenses$5,742 $3,733 $2,009 
BDTX-4933 research and development expenses1,507 1,679 (172)
Other research programs and platform development expenses602 2,787 (2,185)
Personnel expenses4,528 5,109 (581)
Allocated facility expenses860 1,009 (149)
Other expenses306 436 (130)
$13,545 $14,753 $(1,208)
The decrease of $1.2 million for the three months ended March 31, 2024 was primarily due to an increase of $2.0 million related to the progression of our clinical trial for BDTX-1535, offset by decreased spend relating to other research programs and platform development of $2.2 million due to reduced spending on early discovery projects as we deepen our focus on our clinical-stage assets, compared to the three months ended March 31, 2023. In addition, personnel expenses decreased by $0.6 million as we continue to capitalize on workforce efficiencies and focus on our development programs.
27
General and administrative
General and administrative expenses were $6.7 million for the three months ended March 31, 2024 compared to $6.8 million for the three months ended March 31, 2023. This was primarily a result of a decrease in personnel-related costs, legal and other professional fees.
Other income (expense)
Other income was $2.0 million for the three months ended March 31, 2024, compared to $0.7 million for the three months ended March 31, 2023. The increase was primarily attributable to accretion on investments increasing at a higher rate in 2024 compared to 2023.
Liquidity and capital resources
Sources of liquidity
Since our inception, we have not generated any revenue from any product sales or any other sources and have incurred significant operating losses and negative cash flows from our operations. We have not yet commercialized any of our product candidates, and we do not expect to generate revenue from sales of any product candidates for several years, if at all. We have funded our operations to date primarily with proceeds from the sale of common and preferred stock.
On February 3, 2020, we completed an IPO of 12,174,263 shares of our common stock, including the exercise in full by the underwriters of their option to purchase up to 1,587,947 additional shares of common stock, for aggregate gross proceeds of $231.3 million. We received $212.1 million in net proceeds after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. Through March 31, 2024, we had received net cash proceeds of $200.6 million from previous sales of our preferred stock and as of March 31, 2024, we had cash, cash equivalents and investments of $115.2 million.
On November 14, 2022, we filed a shelf registration statement on Form S-3 (the Shelf Registration Statement) with the SEC, which covers the offering, issuance and sale of our common stock, preferred stock, debt securities, warrants and/or units of any combination thereof up to a maximum price of $500 million. We simultaneously entered into an Open Market Sale AgreementSM (the Sales Agreement) with Jefferies LLC (Jefferies), as sales agent, to provide for the issuance and sale by us of up to $150 million of our common stock, or the Shares, from time to time through Jefferies as our sales agent (the ATM Program). The Shelf Registration Statement became effective on November 22, 2022. Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, Jefferies may sell the Shares by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act. We may sell the Shares in amounts and at times to be determined by us from time to time subject to the terms and conditions of the Sales Agreement, but we have no obligation to sell any Shares under the Sales Agreement. We or Jefferies may suspend or terminate the offering of Shares upon notice to the other party and subject to other conditions. As of March 31, 2024, we sold 800,000 shares of our common stock pursuant to the ATM Program, resulting in gross proceeds to us of approximately $4.0 million ($3.9 million net of offering costs).
On July 5, 2023, we completed an underwritten public offering (the Follow-on Offering) of 15,000,000 shares of our common stock at a price to the public of $5.00 per share. The aggregate net proceeds from the Follow-on Offering totaled approximately $71.6 million after deducting underwriting discounts and commissions, as well as other offering expenses. The underwriters did not exercise any portion of their 30-day overallotment option to purchase up to an additional 2,250,000 shares of our common stock at the public offering price, which expired on July 29, 2023, and therefore no additional proceeds from the Follow-on Offering were received.
28
Cash flows
The following table summarizes our sources and uses of cash for each of the periods presented (in thousands):

Three Months Ended
March 31,

2024

2023
Cash used in operating activities$(21,199)

$(20,031)
Cash (used in) provided by investing activities
(13,734)

24,806 
Cash provided by financing activities
4,130 

51 
Net increase (decrease) in cash and cash equivalents
$(30,803)

$4,826 
Operating activities
During the three months ended March 31, 2024, we used cash in operating activities of $21.2 million, primarily resulting from our net loss of $18.2 million, partially offset by the non-cash charge related to stock compensation expense of $1.7 million.
During the three months ended March 31, 2023, we used cash in operating activities of $20.0 million, primarily resulting from our net loss of $20.9 million, partially offset by the non-cash charge related to stock compensation expense of $2.7 million.
Changes in accounts payable and accrued expenses in all periods were generally due to growth in our business, the advancement of our product candidates and the timing of vendor invoicing and payments.
Investing activities
During the three months ended March 31, 2024, we had cash used in investing activities of $13.7 million primarily from the sales and maturities of investments, netted against our purchase of investments.
During the three months ended March 31, 2023, we had cash provided by investing activities of $24.8 million primarily from the sales and maturities of investments.
Financing activities
During the three months ended March 31, 2024, we had cash provided by financing activities of $4.1 million, consisting of proceeds from exercise of stock options and participation in the employee stock purchase plan as well as the sale of shares of our common stock in March 2024 pursuant to the ATM Program.
During the three months ended March 31, 2023, we had cash provided by financing activities of $0.1 million consisting of proceeds from the participation in the employee stock purchase plan.
Funding requirements
We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance clinical trials of our product candidates. In addition, we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses. The timing and amount of our operating expenditures will depend largely on our ability to:
•advance BDTX-1535 and BDTX-4933 through clinical trials;
•manufacture, or have manufactured on our behalf, our drug material and develop processes for late stage and commercial manufacturing;
•seek regulatory approvals for any product candidates that successfully complete clinical trials;
29
•establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval and intend to commercialize on our own;
•hire additional clinical, quality control and scientific personnel; and
•obtain, maintain, expand, enforce and protect our intellectual property portfolio.
As of March 31, 2024, we had cash, cash equivalents and investments of $115.2 million. We believe that our existing cash, cash equivalents and investments will enable us to fund our operating expenses and capital expenditure requirements into the third quarter of 2025. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We anticipate that we will require additional capital as we seek regulatory approval of our product candidates and if we choose to pursue in-licenses or acquisitions of other product candidates. If we receive regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize.
Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to further reduce or terminate our operations. Our future funding requirements will depend on and could increase significantly as a result of many factors, including:
•the scope, progress, results and costs of developing our product candidates, and conducting clinical trials;
•the costs, timing and outcome of regulatory review of our product candidates;
•the costs, timing and ability to manufacture our product candidates to supply our clinical development efforts and our clinical trials;
•the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;
•subject to receipt of regulatory approval, the costs of commercialization activities for our product candidates, to the extent such costs are not the responsibility of any future collaborators, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities;
•the ability to receive additional non-dilutive funding;
•the revenue, if any, received from commercial sale of our product candidates, should any of our product candidates receive marketing approval;
•the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining, expanding and enforcing our intellectual property rights and defending intellectual property-related claims;
•our ability to establish and maintain collaborations on favorable terms, if at all;
•the extent to which we acquire or in-license other product candidates and technologies; and
•the costs of operating as a public company.
30
As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time, if ever, as we can generate substantial product revenue from product sales, we expect to finance our operations through a combination of public or private equity offerings, debt financings, collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties or through other sources of financing. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. However, the trading prices for our common stock and for other biopharmaceutical companies have been highly volatile. As a result, we may face difficulties raising capital through sales of our common stock, and such sales may be on unfavorable terms. Similarly, adverse macroeconomic conditions and market volatility resulting from global economic developments, political unrest, high inflation, global health crises, or other factors could materially and adversely affect our ability to consummate an equity or debt financing on favorable terms or at all. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all.
To the extent that we raise additional capital through the sale of private or public equity or convertible debt securities, the ownership interest of our stockholders may be materially diluted, and the terms of such securities could include liquidation or other preferences and anti-dilution protections that could adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business. In addition, debt financing may involve significant cash payment obligations and specific financial ratios that may restrict our ability to operate our business would result in fixed payment obligations.
If we raise additional funds through collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves, obtain capital through arrangements with collaborators on terms unfavorable to us or pursue merger or acquisition strategies, all of which could adversely affect the holdings or the rights of our stockholders.
Contractual obligations and commitments
The following summarizes our contractual obligations as of March 31, 2024:

Payments Due by Period

Less than 1 Year1 to 3 Years3 to 5 YearsMore than 5 Years

Total
(in thousands)
Property leases - commenced
$4,388 $9,138 $9,663 $6,140 $29,329 
Total
$4,388 $9,138 $9,663 $6,140 

$29,329 
Property leases – commenced
The amounts reported for property leases represent future minimum lease payments under non-cancelable operating leases in effect as of March 31, 2024. The minimum lease payments do not include common area maintenance charges or real estate taxes.
31
Other contractual obligations
The contractual obligations table does not include any potential future milestone payments or royalty payments we may be required to make under our existing license agreements due to the uncertainty of the occurrence of the events requiring payment under those agreements.
Critical accounting policies and significant judgments and use of estimates
Our condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States (GAAP). The preparation of our condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.
Our critical accounting policies are described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations— Critical Accounting Policies and Use of Estimates” in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on March 12, 2024. During the three months ended March 31, 2024, there were no material changes to our critical accounting policies from those previously disclosed.
Recently issued accounting pronouncements
A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report.
Emerging growth company and smaller reporting company status
The Jumpstart Our Business Startups Act of 2012 (the JOBS Act) permits an “emerging growth company” such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected to not “opt out” of this provision and, as a result, we will adopt new or revised accounting standards at the time private companies adopt the new or revised accounting standard and will do so until such time that we either (i) irrevocably elect to “opt out” of such extended transition period or (ii) no longer qualify as an emerging growth company.
We are also a “smaller reporting company” meaning that the market value of our stock held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.
Item 3. Quantitative and Qualitative Disclosure About Market Risk
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.
32
Item 4. Controls and Procedures
Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) as of the end of the period covered by this Quarterly Report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2024.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the period covered by this Quarterly Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
33
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
The information required with respect to this item can be found under “Legal Proceedings” in Note 11 to our condensed financial statements included elsewhere in this Quarterly Report on Form 10-Q and is incorporated by reference into this Item 1. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business, the resolution of which we do not anticipate would have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.
Item 1A. Risk Factors
Our business faces significant risks and uncertainties. Certain important factors may have a material adverse effect on our business prospects, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to carefully consider the discussion of risk factors in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, which could materially affect our business, financial condition or future results, in addition to other information contained in or incorporated by reference into this Quarterly Report on Form 10-Q and our other public filings with the Securities and Exchange Commission, or the SEC. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business, prospects, financial condition and results of operations. Certain statements in this Quarterly Report are forward-looking statements. Please also see the section entitled “Special Note Regarding Forward-Looking Statements.”
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Recent Sales of Unregistered Equity Securities
None.
Use of Proceeds from IPO of Common Stock
On February 3, 2020, we completed the IPO of our common stock pursuant to which we issued and sold 12,174,263 shares of our common stock, including the exercise in full by the underwriters of their option to purchase up to 1,587,947 additional shares of common stock, at a public offering price of $19.00 per share.
The offer and sale of all of the shares of our common stock in our IPO were registered under the Securities Act pursuant to a registration statement on Form S-1, as amended (File No. 333-235789), which was declared effective by the SEC on January 29, 2020. J.P. Morgan Securities LLC, Jefferies LLC, Cowen and Company, LLC and Canaccord Genuity LLC acted as joint book-running managers of the offering and as representatives of the underwriters.
We received aggregate gross proceeds from our IPO of $231.3 million, or aggregate net proceeds of $212.1 million after deducting underwriting discounts and commissions and other offering costs. None of the underwriting discounts and commissions or offering expenses were incurred or paid, directly or indirectly, to any of our directors or officers or their associates or to persons owning 10% or more of our common stock or to any of our affiliates.

There has been no material change in our planned use of the net proceeds from the IPO as described in our final prospectus, filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act on January 30, 2020.
Item 3. Defaults Upon Senior Securities
None.
34
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
10b5-1 Plans
From time to time, our officers (as defined in Rule 16a–1(f)) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the three months ended March 31, 2024, our officers and directors took the following actions with respect to 10b5-1 trading arrangements:
On March 28, 2024, Fang Ni, our Chief Business Officer and Chief Financial Officer, entered into a trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Ni 10b5-1 Plan). The Ni 10b5-1 Plan is scheduled to commence on June 29, 2024, and will run through June 29, 2025. The aggregate maximum number of shares of common stock that may be sold pursuant to the Ni 10b5-1 Plan is up to 40,470 shares.
On March 27, 2024, Brent Hatzis-Schoch, our Chief Operating Officer and General Counsel, entered into a trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Hatzis-Schoch 10b5-1 Plan). The Hatzis-Schoch 10b5-1 Plan is scheduled to commence on July 1, 2024, and will run through July 1, 2025. The aggregate maximum number of shares of common stock that may be sold pursuant to the Hatzis-Schoch 10b5-1 Plan is up to 72,400 shares.
35

Item 6. Exhibits
The exhibits listed on the Exhibit Index immediately preceding such exhibits, which is incorporated herein by reference, are filed or furnished as part of this Quarterly Report.
Exhibit
No.

Exhibit Index
31.1*
31.2*
32.1*+
101.INS

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH

Inline XBRL Taxonomy Extension Schema Document.
101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.LAB

Inline XBRL Taxonomy Extension Labels Linkbase Document.
101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document.
101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document.
104Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.)
*

Filed herewith.
+

This certification will not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent specifically incorporated by reference into such filing.

36
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Black Diamond Therapeutics, Inc.



Date: May 9, 2024By:
/s/ Mark A. Velleca


Mark A. Velleca
President and Chief Executive Officer
(Principal Executive Officer)

Black Diamond Therapeutics, Inc.



Date: May 9, 2024By:
/s/ Fang Ni


Fang Ni
Chief Business Officer and Chief Financial Officer
(Principal Financial Officer)

37
 EX-31.1 2 exhibit311_q12024.htm EX-31.1 Document

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO RULE 13a-14(a) OR 15d-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002

I, Mark A. Velleca, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2024 of Black Diamond Therapeutics, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and



5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 9, 2024
           By: /s/ Mark A. Velleca
  
Mark A. Velleca
President, Chief Executive Officer
and Director
(Principal Executive Officer)








 EX-31.2 3 exhibit312_q12024.htm EX-31.2 Document

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO RULE 13a-14(a) OR 15d-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002

I, Fang Ni, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2024 of Black Diamond Therapeutics, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and



5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 9, 2024
By:/s/ Fang Ni
  
Fang Ni
Chief Business Officer and Chief Financial Officer
(Principal Financial Officer)








 EX-32.1 4 exhibit321_q12024.htm EX-32.1 Document

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Mark A. Velleca, the Principal Executive Officer, and Fang Ni, the Principal Financial Officer, of Black Diamond Therapeutics, Inc. (the “Company”), hereby certify, that, to their knowledge:

(1)the Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 9, 2024
By:/s/ Mark A. Velleca
  
Mark A. Velleca
President, Chief Executive Officer
and Director
(Principal Executive Officer)






Date: May 9, 2024
By:/s/ Fang Ni
  
Fang Ni
Chief Business Officer and Chief Financial Officer
(Principal Financial Officer)








 EX-101.SCH 5 bdtx-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - EQUITY METHOD INVESTMENT link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - NET LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - BENEFIT PLANS link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - NET LOSS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - INVESTMENTS - Schedule of Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - INVESTMENTS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - EQUITY METHOD INVESTMENT (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - NET LOSS PER SHARE - Computation of Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - LEASES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - LEASES - Summary of Lease Cost and Other Operating Lease Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - BENEFIT PLANS (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 bdtx-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 bdtx-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 bdtx-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Pay vs Performance Disclosure [Line Items] Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Accrued Liabilities, Current Research and development Research and Development Expense Changes in current assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Research and development asset acquired other than through business combination, written-off Research and Development Asset Acquired Other than Through Business Combination, Writeoff Investment, Name [Domain] Investment, Name [Domain] Units outstanding (in shares) Unvested restricted common stock, beginning balance (in shares) Unvested restricted common stock, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number (Accretion) amortization on investments Investment Income, Net, Amortization of Discount and Premium ATM Program At Market Equity Program [Member] At Market Equity Program Statement of Stockholders' Equity [Abstract] Investments, Debt and Equity Securities [Abstract] Employer contribution amount Defined Contribution Plan, Employer Discretionary Contribution Amount Equity Method Investments and Joint Ventures [Abstract] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Unvested performance restricted stock units Performance Shares [Member] Sale of stock, authorized consideration Sale of Stock, Authorized Consideration Sale of Stock, Authorized Consideration Accounts payable Accounts Payable, Current Options exercisable, remaining life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Restatement Determination Date: Restatement Determination Date [Axis] Investment, Name [Axis] Investment, Name [Axis] Purchases of investments Payments to Acquire Investments Total other income (expense), net Nonoperating Income (Expense) Commitments and contingencies (Note 11) Commitments and Contingencies Lessee, Operating Lease, Liability, to be Paid [Abstract] Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Insider Trading Policies and Procedures [Line Items] Options exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Schedule of Restricted Stock Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Proceeds from equity financing Proceeds from Issuance or Sale of Equity Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Area leased (square feet) Lessee, Operating Lease, Area Lessee, Operating Lease, Area Options vested or expected to vest, intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Proceeds from issuance of common stock, net of issuance costs Proceeds from Issuance of Common Stock NATURE OF BUSINESS AND BASIS OF PRESENTATION Business Description and Basis of Presentation [Text Block] Vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Current liabilities: Liabilities, Current [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued or outstanding at March 31, 2024 and December 31, 2023 Preferred Stock, Value, Issued Subsequent Event Type [Domain] Subsequent Event Type [Domain] Weighted average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Net loss per share, diluted (in dollars per share) Net loss per share, diluted (in dollars per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Options vested or expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Exercise of common stock options Stock Issued During Period, Value, Stock Options Exercised Trading Symbol(s) Trading Symbol Letter of credit outstanding Letters of Credit Outstanding, Amount Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Investments: Investments, Fair Value Disclosure Net loss Net loss Net loss Net Income (Loss) Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name LEASES Lessee, Operating Leases [Text Block] Noncash rent expense Rent Expense Rent Expense Corporate bonds Corporate bonds Corporate Bond Securities [Member] 2020 Stock Option Plan 2020 Stock Option Plan [Member] 2020 Stock Option Plan Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] Entity Ex Transition Period Entity Ex Transition Period Shares issuable under employee stock purchase plan Employee Stock [Member] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] INVESTMENTS Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Stockholders' equity: Equity, Attributable to Parent [Abstract] Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Exercise of common stock options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Schedule of Computation of Net Loss per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Executive Category: Executive Category [Axis] Number of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Level 1 Fair Value, Inputs, Level 1 [Member] Shelf Registration Statement Shelf Registration Statement [Member] Shelf Registration Statement Name Measure Name Name Forgone Recovery, Individual Name Schedule of Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Increase of authorized shares, percent of common stock outstanding Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding Measurement Frequency [Axis] Measurement Frequency [Axis] Warrants to purchase common stock Warrant [Member] Non-current operating lease liabilities Operating Lease, Liability, Noncurrent Restricted stock units Restricted Stock Units (RSUs) [Member] Accounts payable Increase (Decrease) in Accounts Payable, Trade Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Depreciation expense Depreciation Retirement Benefits [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Schedule of Future Minimum Lease Payments Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Number of shares sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Payables and Accruals [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Accrued Expenses Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Schedule of Lease Cost and Other Operating Lease Information Lease, Cost [Table Text Block] Research and development Research and Development Expense [Member] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Antidilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Units granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Plan Name [Domain] Plan Name [Domain] Document Quarterly Report Document Quarterly Report Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] General and administrative General and Administrative Expense [Member] Property and equipment Property, Plant and Equipment, Gross Options outstanding, remaining life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Trading Arrangement: Trading Arrangement [Axis] Less: interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Use of estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Entity File Number Entity File Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Current portion of operating lease liability Operating Lease, Liability, Current Issuance of common stock related to ESPP (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Proceeds from sales and maturities of investments Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Entity Shell Company Entity Shell Company 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Recently issued accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Cash, cash equivalents and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Stock price (in dollars per share) Sale of Stock, Price Per Share Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Variable lease cost Variable Lease, Cost Operating lease cost Operating Lease, Cost Common stock, shares issued (in shares) Common Stock, Shares, Issued Units vested (in shares) Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Name of each exchange on which registered Security Exchange Name Total Assets, Fair Value Disclosure Sale of stock, net of offering costs Sale of Stock, Consideration Received on Transaction Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Stock options Options to purchase common stock Employee Stock Option [Member] Employer contribution, matching contribution percentage Defined Contribution Plan, Employer Matching Contribution, Percent of Match Unrecognized compensation cost, recognition period (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Tabular List, Table Tabular List [Table Text Block] Short-term lease cost Short-Term Lease, Cost Entity Address, Address Line One Entity Address, Address Line One Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Subsequent Event [Table] Subsequent Event [Table] STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Principles of consolidation and unaudited interim financial information Basis of Accounting, Policy [Policy Text Block] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Four Lessee, Operating Lease, Liability, Payments, Due after Year Four Subsequent Event Subsequent Event [Member] Maximum employee subscription rate Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Restricted cash Restricted cash, end of period Restricted Cash, Noncurrent Contracted research services Accrued Contract Research Service Fees, Current Accrued Contract Research Service Fees, Current Issuance of common stock, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues Canceled or forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of each class Title of 12(b) Security Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] 2020 ESPP 2020 Employee Stock Purchase Plan [Member] 2020 Employee Stock Purchase Plan Cash equivalents: Cash and Cash Equivalents, Fair Value Disclosure Sublease income Sublease Income Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Unvested restricted common stock, beginning balance (in dollars per share) Unvested restricted common stock, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Loss on sale of equipment Gain (Loss) on Sale of Equipment Gain (Loss) on Sale of Equipment Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Equity method investment Equity Method Investments Total lease cost Lease, Cost Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Total Shareholder Return Amount Total Shareholder Return Amount Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Leases [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Non-current operating lease liabilities Increase (Decrease) in Operating Lease Liabilities Increase (Decrease) in Operating Lease Liabilities Cash paid for amounts included in the measurement of lease liability Operating Lease, Payments Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Other income (expense): Other Income and Expenses [Abstract] PEO PEO [Member] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Sale of Stock [Axis] Sale of Stock [Axis] Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Total lease liability Operating Lease, Liability Total liabilities Liabilities Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Accumulated other comprehensive income (loss) AOCI Attributable to Parent [Member] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Gain on sale of IP Gain (Loss) on Disposition of Intangible Assets Measurement Frequency [Domain] Measurement Frequency [Domain] PROPERTY AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] All Executive Categories All Executive Categories [Member] Principal office, lease two Operating Lease, Principal Office, Two [Member] Operating Lease, Principal Office, Two Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Plan Name [Axis] Plan Name [Axis] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Earnings Per Share [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Common stock; $0.0001 par value; 500,000,000 shares authorized at March 31, 2024 and December 31, 2023; 52,527,626 shares issued and outstanding at March 31, 2024 and 51,645,557 shares issued and outstanding at December 31, 2023 Common Stock, Value, Issued General and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Professional and consulting fees Accrued Professional Fees, Current Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Total current assets Assets, Current All Individuals All Individuals [Member] Other income (expense) Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date PEO Name PEO Name Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Options exercisable, intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value EQUITY METHOD INVESTMENT Equity Method Investments and Joint Ventures Disclosure [Text Block] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Investments Debt Securities, Available-for-Sale, Current Furniture and fixtures Furniture and Fixtures [Member] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Lease Contractual Term [Domain] Lease Contractual Term [Domain] Statement of Financial Position [Abstract] Total stockholders' equity Beginning balance Ending balance Equity, Attributable to Parent Unvested restricted stock Restricted Stock [Member] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Subsequent Events [Abstract] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Level 2 Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Title Trading Arrangement, Individual Title Outstanding, beginning balance (in dollars per share) Outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Launchpad Therapeutics, Inc. Launchpad Therapeutics, Inc. [Member] Launchpad Therapeutics, Inc. Common stock Common Stock [Member] Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code NET LOSS PER SHARE Earnings Per Share [Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Equity method investment, ownership percentage Equity Method Investment, Ownership Percentage Document Fiscal Year Focus Document Fiscal Year Focus Lease term (in years) Lessee, Operating Lease, Term of Contract Property and equipment, net Total Property and Equipment, net Property, Plant and Equipment, Net Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Unrealized gain (loss) on investments, net Unrealized gain (loss) on investments OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax Accumulated deficit Retained Earnings [Member] Schedule of Stock-Based Compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and stockholders' equity Liabilities and Equity Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net loss per share, basic (in dollars per share) Net loss per share, basic (in dollars per share) Earnings Per Share, Basic Right-of-use assets Operating Lease, Right-of-Use Asset Unrecognized compensation cost, options Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Issuance of common stock related to ESPP Stock Issued During Period, Value, Employee Stock Purchase Plan Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Sale of Stock [Domain] Sale of Stock [Domain] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] 2024 (excluding the three months ended March 31, 2024) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Options vested or expected to vest, remaining life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Principles of consolidation Consolidation, Policy [Policy Text Block] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Follow-on Offering Follow-on Offering [Member] Follow-on Offering Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Termination Date Trading Arrangement Termination Date Common stock, shares authorized (in shares) Common Stock, Shares Authorized Fair Value Debt Securities, Available-for-Sale ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Property, Plant and Equipment [Abstract] Adjustment to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] All Trading Arrangements All Trading Arrangements [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Fair value of units vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Additional paid-in capital Additional Paid in Capital Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Statement of Comprehensive Income [Abstract] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Cancelled or forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Units forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Number of leases Lessee, Operating Lease, Number Of Contracts Lessee, Operating Lease, Number Of Contracts Employer contribution, percent of each participant's salary Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Insider Trading Arrangements [Line Items] Options outstanding, intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Award purchase period (in months) Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period Impairment of fair value assets Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not Previously Recorded Stock-based compensation (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Brent Hatzis-Schoch [Member] Brent Hatzis-Schoch Adjustment to Compensation, Amount Adjustment to Compensation Amount Lease Contractual Term [Axis] Lease Contractual Term [Axis] Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Adoption Date Trading Arrangement Adoption Date Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Options exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Entity Central Index Key Entity Central Index Key Fang Ni [Member] Fang Ni SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] Stock-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Payroll and related expenses Employee-related Liabilities, Current FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Name Trading Arrangement, Individual Name Issuance of common stock, net of issuance costs Sale of stock, gross Stock Issued During Period, Value, New Issues Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Weighted-average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Amendment Flag Amendment Flag Other Operating Lease Information Lease, Other Information [Abstract] Lease, Other Information [Abstract] Money market funds Money Market Funds [Member] Performance restricted stock units Performance Restricted Stock Units [Member] Performance Restricted Stock Units Employee Stock Purchase Plan and Other Other Award Type [Member] Other Award Type Cash and cash equivalents Cash and cash equivalents, end of period Cash and Cash Equivalents, at Carrying Value Surrender of shares for taxes (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Shares issued under share-based compensation plan Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Assets: Assets, Fair Value Disclosure [Abstract] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Leasehold improvements Leasehold Improvements [Member] Weighted average common shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Number of additional shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Operating expenses: Operating Expenses [Abstract] Company Selected Measure Amount Company Selected Measure Amount Additional paid-in capital Additional Paid-in Capital [Member] Lease Cost Lease, Cost [Abstract] Expired (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Loss recognized from equity method investment Income (Loss) from Equity Method Investments Cover [Abstract] Commercial paper Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Interest income Investment Income, Nonoperating SUBSEQUENT EVENTS Subsequent Events [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Recurring Fair Value, Recurring [Member] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Total lease payments Lessee, Operating Lease, Liability, to be Paid BENEFIT PLANS Compensation and Employee Benefit Plans [Text Block] Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Total operating expenses Operating Expenses Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Non-PEO NEO Non-PEO NEO [Member] Lease term, optional extension (in years) Lessee, Operating Lease, Renewal Term Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Maximum percent of fair market value of common stock Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Weighted average common shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Loss from operations Operating Income (Loss) Maximum employee subscription amount Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount Comprehensive loss: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Common shares received from equity method investment (in shares) Equity Method Investment, Shares Received in Noncash Exchange Equity Method Investment, Shares Received in Noncash Exchange Proceeds from exercise of common stock options and ESPP Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Options vested or expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Operating Lease, Office and Laboratory Space, NY Operating Lease, Office and Laboratory Space, NY [Member] Operating Lease, Office and Laboratory Space, NY Weighted Average Remaining Life and Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Schedule of Marketable Securities Debt Securities, Available-for-Sale [Table Text Block] EX-101.PRE 9 bdtx-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover Page - shares
 3 Months Ended
Mar. 31, 2024
May 06, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2024  
Document Transition Report false  
Entity File Number 001-38501  
Entity Registrant Name BLACK DIAMOND THERAPEUTICS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 81-4254660  
Entity Address, Address Line One One Main Street, 14th Floor  
Entity Address, City or Town Cambridge  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02142  
City Area Code (617)  
Local Phone Number 252-0848  
Title of each class Common stock, par value $0.0001  
Trading Symbol(s) BDTX  
Name of each exchange on which registered NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   56,252,794
Amendment Flag false  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2024  
Entity Central Index Key 0001701541  
Current Fiscal Year End Date --12-31  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 25,422 $ 56,221
Investments 89,777 75,179
Prepaid expenses and other current assets 3,607 2,634
Total current assets 118,806 134,034
Property and equipment, net 1,644 1,730
Restricted cash 819 823
Right-of-use assets 21,252 21,980
Total assets 142,521 158,567
Current liabilities:    
Accounts payable 1,176 2,324
Accrued expenses and other current liabilities 15,678 17,322
Total current liabilities 16,854 19,646
Non-current operating lease liabilities 21,361 22,185
Total liabilities 38,215 41,831
Commitments and contingencies (Note 11)
Stockholders' equity:    
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued or outstanding at March 31, 2024 and December 31, 2023 0 0
Common stock; $0.0001 par value; 500,000,000 shares authorized at March 31, 2024 and December 31, 2023; 52,527,626 shares issued and outstanding at March 31, 2024 and 51,645,557 shares issued and outstanding at December 31, 2023 7 7
Additional paid-in capital 540,050 534,187
Accumulated other comprehensive loss (95) (27)
Accumulated deficit (435,656) (417,431)
Total stockholders' equity 104,306 116,736
Total liabilities and stockholders' equity $ 142,521 $ 158,567
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Mar. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 500,000,000 500,000,000
Common stock, shares issued (in shares) 52,527,626 51,645,557
Common stock, shares outstanding (in shares) 52,527,626 51,645,557
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:    
Research and development $ 13,545 $ 14,753
General and administrative 6,701 6,808
Total operating expenses 20,246 21,561
Loss from operations (20,246) (21,561)
Other income (expense):    
Interest income 637 622
Other income (expense) 1,384 64
Total other income (expense), net 2,021 686
Net loss $ (18,225) $ (20,875)
Net loss per share, basic (in dollars per share) $ (0.35) $ (0.57)
Net loss per share, diluted (in dollars per share) $ (0.35) $ (0.57)
Weighted average common shares outstanding, basic (in shares) 51,808,849 36,483,878
Weighted average common shares outstanding, diluted (in shares) 51,808,849 36,483,878
Comprehensive loss:    
Net loss $ (18,225) $ (20,875)
Other comprehensive income (loss):    
Unrealized gain (loss) on investments, net (68) 648
Comprehensive loss $ (18,293) $ (20,227)
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash flows from operating activities:    
Net loss $ (18,225) $ (20,875)
Adjustment to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 1,713 2,671
Depreciation expense 86 122
(Accretion) amortization on investments (932) 109
Noncash rent expense 728 690
Loss on sale of equipment 0 37
Changes in current assets and liabilities:    
Prepaid expenses and other current assets (973) 383
Accounts payable (1,128) 1,169
Accrued expenses and other current liabilities (1,644) (3,583)
Non-current operating lease liabilities (824) (754)
Net cash used in operating activities (21,199) (20,031)
Cash flows from investing activities:    
Proceeds from sales and maturities of investments 38,500 24,806
Purchases of investments (52,234) 0
Net cash (used in) provided by investing activities (13,734) 24,806
Cash flows from financing activities:    
Proceeds from exercise of common stock options and ESPP 150 51
Proceeds from issuance of common stock, net of issuance costs 3,980 0
Net cash provided by financing activities 4,130 51
Net increase (decrease) in cash and cash equivalents (30,803) 4,826
Cash, cash equivalents and restricted cash, beginning of period 57,044 35,483
Cash, cash equivalents and restricted cash, end of period 26,241 40,309
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents    
Cash and cash equivalents, end of period 25,422 39,141
Restricted cash, end of period 819 1,168
Cash, cash equivalents and restricted cash, end of period $ 26,241 $ 40,309
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common stock
Additional paid-in capital
Accumulated other comprehensive income (loss)
Accumulated deficit
Beginning balance (in shares) at Dec. 31, 2022   36,434,297      
Beginning balance at Dec. 31, 2022 $ 115,695 $ 5 $ 452,503 $ (1,824) $ (334,989)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Vesting of restricted stock units (in shares)   23,575      
Surrender of shares for taxes (in shares)   (3,903)      
Issuance of common stock related to ESPP (in shares)   33,202      
Issuance of common stock related to ESPP 51   51    
Stock-based compensation (in shares)   24,776      
Stock-based compensation 2,671   2,671    
Unrealized gain (loss) on investments 648     648  
Net loss (20,875)       (20,875)
Ending balance (in shares) at Mar. 31, 2023   36,511,947      
Ending balance at Mar. 31, 2023 $ 98,190 $ 5 455,225 (1,176) (355,864)
Beginning balance (in shares) at Dec. 31, 2023 51,645,557 51,645,557      
Beginning balance at Dec. 31, 2023 $ 116,736 $ 7 534,187 (27) (417,431)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock, net of issuance costs (in shares)   800,000      
Issuance of common stock, net of issuance costs $ 4,000   4,000    
Exercise of common stock options (in shares) 47,741 47,741      
Exercise of common stock options $ 86   86    
Vesting of restricted stock units (in shares)   1,250      
Issuance of common stock related to ESPP (in shares)   26,659      
Issuance of common stock related to ESPP 64   64    
Stock-based compensation (in shares)   6,419      
Stock-based compensation 1,713   1,713    
Unrealized gain (loss) on investments (68)     (68)  
Net loss $ (18,225)       (18,225)
Ending balance (in shares) at Mar. 31, 2024 52,527,626 52,527,626      
Ending balance at Mar. 31, 2024 $ 104,306 $ 7 $ 540,050 $ (95) $ (435,656)
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NATURE OF BUSINESS AND BASIS OF PRESENTATION
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NATURE OF BUSINESS AND BASIS OF PRESENTATION NATURE OF BUSINESS AND BASIS OF PRESENTATION
Black Diamond Therapeutics, Inc. (the Company) is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing and incurring research and development costs related to the development and advancement of its product candidates identified by its Mutation-Allostery-Pharmacology (MAP) drug discovery engine.
The Company is subject to risks and uncertainties common to clinical-stage companies in the biotechnology industry. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.
On November 14, 2022, the Company filed a shelf registration statement on Form S-3 (the Shelf Registration Statement), with the Securities and Exchange Commission (the SEC), which covers the offering, issuance and sale of the Company’s common stock, preferred stock, debt securities, warrants and/or units of any combination thereof up to a maximum offering price of $500 million. The Company simultaneously entered into an Open Market Sale AgreementSM with Jefferies LLC (Jefferies), as sales agent, to provide for the issuance and sale by the Company of up to $150 million of its common stock from time to time through Jefferies (the ATM Program). The Shelf Registration Statement became effective on November 22, 2022. As of March 31, 2024, the Company sold 800,000 shares of its common stock pursuant to the ATM Program, resulting in gross proceeds to the Company of approximately $4.0 million ($3.9 million net of offering costs).
On July 5, 2023, the Company completed an underwritten public offering (the Follow-on Offering) of 15,000,000 shares of the Company’s common stock at a price to the public of $5.00 per share. The aggregate net proceeds from the Follow-on Offering totaled approximately $71.9 million, after deducting underwriting discounts and commissions.
The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. Historically, the Company has funded its operations primarily with proceeds from the sale of common stock and preferred stock. The Company has had recurring losses and negative cash flows from operations in all periods since inception and had an accumulated deficit of $435.7 million as of March 31, 2024. The Company expects to continue to generate operating losses for the foreseeable future.
As of May 9, 2024, the issuance date of the condensed consolidated financial statements, the Company expects that its cash, cash equivalents and investments will be sufficient to fund its currently planned operations for at least the next 12 months from the filing date of these condensed consolidated financial statements.
The Company will seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, or reduce headcount and general and administrative costs, which could adversely affect its business prospects. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The following is a summary of significant accounting policies followed in the preparation of these condensed consolidated financial statements.
Principles of consolidation
The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics Security Corporation and Black Diamond Therapeutics (Canada), Inc., after elimination of all significant intercompany accounts and transactions. On October 10, 2023, Black Diamond Therapeutics (Canada), Inc. was dissolved by way of voluntary dissolution.
Unaudited interim financial information
The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. In the opinion of the Company’s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.
Use of estimates
The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
The Company continues to monitor the impact of global economic developments, political unrest, high inflation, disruptions in capital markets, changes in international trade relationships and military conflicts, and health crises, on all aspects of its business, and has considered the impact of these factors on estimates within its financial statements. The extent to which future developments may impact the Company’s business, results of operations or financial condition are uncertain and cannot be predicted with confidence and there may be changes to estimates in future periods. As of the date of issuance of these condensed consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of these factors and is not aware of any specific related event or circumstance that would require it to update its estimates.
Recently issued accounting pronouncements
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09). ASU 2023-09 requires that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate). The standard is effective for annual and interim periods beginning after December 15, 2024. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The adoption is not expected to have a material impact on the Company’s consolidated financial statements.
In November 2023, the FASB issued ASU 2023-07, Improvements to Reportable Segment Disclosures (Topic 280) (ASU 2023-07) which requires enhanced disclosure of (1) significant segment expenses that are regularly provided to the chief operating decision maker (CODM) and included within each reported measure of segment profit or loss, (2) the amount and description of the composition of other segment items which reconcile to segment profit or loss, and (3) the title and position of the entity’s CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and allocating resources. The amendments also expand the interim segment disclosure requirements. This new guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this ASU apply retrospectively to all prior periods presented in the financial statements. The Company is in the process of assessing the impact on its financial statements from the adoption of the new guidance and the period in which the new guidance will be adopted.
In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements - Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative (ASU 2023-06). The standard is effective for annual and interim periods beginning after December 15, 2024. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The adoption is not expected to have a material impact on the Company’s consolidated financial statements.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FAIR VALUE MEASUREMENTS
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:

Fair value measurements at March 31, 2024 using:

Level 1

Level 2Level 3Total
Assets:





Cash equivalents:
Money market funds$20,498 $— $— $20,498 
Investments:
Commercial paper— 82,830 — 82,830 
Corporate bonds— 6,947 — 6,947 
Total$20,498 $89,777 $— $110,275 

Fair value measurements at December 31, 2023 using:

Level 1

Level 2Level 3Total
Assets:





Cash equivalents:
Money market funds$30,803 $— $— $30,803 
Investments:
Commercial paper— 44,871 — 44,871 
Corporate bonds— 30,308 — 30,308 
Total$30,803 $75,179 $— $105,982 
When developing fair value estimates, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. When available, the Company uses quoted market prices to measure fair value. The valuation technique used to measure fair value for the Company's Level 1 and Level 2 assets is a market approach, using prices and other relevant information generated by market transactions involving identical or comparable assets. If market prices are not available, the fair value measurement is based on models that use primarily market-based parameters including yield curves, volatilities, credit ratings and currency rates. In certain cases where market rate assumptions are not available, the Company is required to make judgments about assumptions market participants would use to estimate the fair value of a financial instrument.
There were no transfers in or out of Level 3 categories in the periods presented.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVESTMENTS
 3 Months Ended
Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]  
INVESTMENTS INVESTMENTS
As of March 31, 2024, investments were comprised of the following:
Amortized Cost

Unrealized GainsUnrealized LossesFair Value
Commercial paper$82,921 $— $(91)$82,830 
Corporate bonds6,951 — (4)6,947 
Total$89,872 $— $(95)$89,777 
As of December 31, 2023, investments were comprised of the following:
Amortized Cost

Unrealized GainsUnrealized LossesFair Value
Commercial paper$44,880 $4 $(13)$44,871 
Corporate bonds30,326 — (18)30,308 
Total$75,206 $4 $(31)$75,179 
As of March 31, 2024, all marketable securities held by the Company had remaining contractual maturities of one year or less.
As of December 31, 2023, all marketable securities held by the Company had remaining contractual maturities of one year or less.
As of March 31, 2024, the Company reviewed its investment portfolio to assess the unrealized losses on its available-for-sale investments. The Company evaluated whether it intended to sell the security and whether it was more likely than not that the Company would be required to sell the security before recovering its amortized cost basis. The Company also determined no portion of the unrealized losses relate to a credit loss. There have been no impairments of the Company’s assets measured and carried at fair value during the three months ended March 31, 2024 and the year ended December 31, 2023.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
PROPERTY AND EQUIPMENT
 3 Months Ended
Mar. 31, 2024
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT PROPERTY AND EQUIPMENT
Property and equipment, net consisted of the following:

March 31,
2024

December 31,
2023
Furniture and fixtures$17 $17 
Leasehold improvements2,512 2,512 
Property and equipment2,529 2,529 
Less: accumulated depreciation(885)(799)
Total Property and Equipment, net$1,644 $1,730 

Depreciation expense for the three months ended March 31, 2024 and 2023 was $86 and $122, respectively.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
EQUITY METHOD INVESTMENT
 3 Months Ended
Mar. 31, 2024
Equity Method Investments and Joint Ventures [Abstract]  
EQUITY METHOD INVESTMENT EQUITY METHOD INVESTMENT
In December 2022, the Company received 9,000,000 shares of common stock in a newly formed antibody-focused precision oncology company, Launchpad Therapeutics, Inc. (Launchpad), in exchange for contributing early discovery-stage antibody programs and granting Launchpad a license to use its MAP drug discovery engine to discover, develop and commercialize large molecule therapeutics. As of the transaction date and as of March 31, 2024, the Company has a 39.1% voting interest in Launchpad and one seat on Launchpad’s Board of Directors which provide the Company with significant influence over Launchpad. The remaining voting interest in Launchpad is held by Versant Ventures and New Enterprise Associates (NEA), who are shareholders of the Company.
The Company accounted for the transaction under the equity method and recorded the carrying value of the Company’s investment in Launchpad common shares of $2,250 in equity method investments in the consolidated balance sheets. The contributed in process research and development (IPR&D) had zero basis on the Company’s books prior to the transaction, therefore the Company recognized a gain on sale of IPR&D of $2,232 in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2022. The Company also recognized a loss from investments in equity method investee of $1,540 in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2022, associated with the Company’s proportionate share of Launchpad’s losses. The assets contributed by the Company were principally IPR&D and were not deemed a business by Launchpad, therefore the Company determined its remaining basis difference of $710 was substantially related to IPR&D and immediately expensed it. As of December 31, 2022, the carrying value of the investment in Launchpad was reduced to zero. Since the Company has no obligation to provide financing support to Launchpad, the Company is not required to record further losses exceeding the carrying value of the investment. The Company also determined that its investment in Launchpad is not material or significant to its operations or financial position. As of March 31, 2024, the carrying value of the investment in Launchpad was zero.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
 3 Months Ended
Mar. 31, 2024
Payables and Accruals [Abstract]  
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued expenses and other current liabilities consisted of the following:

March 31,
2024

December 31,
2023
Contracted research services$8,984 $8,071 
Payroll and related expenses2,510 5,175 
Professional and consulting fees1,000 963 
Current portion of operating lease liability3,184 3,113 
Total accrued expenses and other current liabilities$15,678 $17,322 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCK-BASED COMPENSATION
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION
2020 Stock Option and Incentive Plan
The 2020 Stock Option and Incentive Plan (the 2020 Plan) was approved by the Company’s board of directors on December 5, 2019, and the Company’s stockholders on January 14, 2020 and became effective on the date immediately prior to the date on which the registration statement for the Company’s initial public offering (IPO) was declared effective. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company’s officers, employees, directors and consultants. The 2020 Plan provides for an annual increase, to be added on the first day of each fiscal year, by up to 4% of the Company’s outstanding shares of common stock as of the last day of the prior year. On January 1, 2024, 2,065,822 shares of common stock, representing 4% of the Company’s outstanding shares of common stock as of December 31, 2023, were added to the 2020 Plan.
2020 Employee Stock Purchase Plan
The 2020 Employee Stock Purchase Plan (the 2020 ESPP) was approved by the Company’s board of directors on December 5, 2019, and the Company’s stockholders on January 14, 2020, and became effective on the date immediately prior to the date on which the registration statement for the Company’s IPO was declared effective. The 2020 ESPP provides for an annual increase, to be added on the first day of each fiscal year, by up to 1% of the number of shares of the Company’s common stock outstanding on the immediately preceding December 31. The number of authorized shares reserved for issuance under the 2020 ESPP was increased by 326,364 shares effective as of January 1, 2024.
Stock-based compensation expense
The Company recorded stock-based compensation expense in the following award type categories included within the condensed consolidated statements of operations and comprehensive loss:
Three Months Ended
March 31,

20242023
Stock options$1,623 $2,455 
Restricted stock units16 112 
Employee Stock Purchase Plan and Other74 104 

$1,713 $2,671 
For the three months ended March 31, 2024, the Company issued 6,419 shares of common stock under its 2020 Plan in accordance with its policy where non-employee directors may elect to receive their compensation in the form of common stock in lieu of cash.
The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:
Three Months Ended
March 31,

2024

2023
Research and development$635 

$949 
General and administrative1,078 

1,722 

$1,713 

$2,671 
Options
The following table summarizes the stock option activity under the Company’s equity awards plans:

Options

Weighted
Average
Exercise
Price

Weighted
Average
Remaining
Life
(in Years)

Intrinsic
Value
(in thousands)
Outstanding December 31, 20238,135,711 $7.85 8.0$1,146 
Granted2,895,550 $4.85 
Exercised(47,741)$1.78 
Cancelled or forfeited(16,500)$1.82 
Expired(300)$7.73 
Outstanding March 31, 202410,966,720 $7.09 8.3$11,996 
Options vested or expected to vest at March 31, 202410,966,720 $7.09 8.3$11,996 
Options exercisable at March 31, 20244,242,313 $11.65 6.7$3,488 
For the three months ended March 31, 2024, total unrecognized compensation cost related to the unvested stock-options was $18,345, which is expected to be recognized over a weighted average period of 3.1 years.
Restricted stock units
The fair values of restricted stock units are based on the market value of the Company’s stock on the date of the grant. Under terms of the time-based restricted stock agreements covering the common stock, shares of restricted common stock are subject to a vesting schedule. The following table summarizes time-based restricted stock activity since January 1, 2024:

Number of
shares
Weighted
average
grant date
fair value
Unvested restricted common stock as of December 31, 202320,799 $2.41 
Vested(1,250)$3.79 
Unvested restricted common stock as of March 31, 202419,549 $2.32 
The total fair value of time-based restricted stock units vested during the three months ended March 31, 2024 was $5.
For the three months ended March 31, 2024, total unrecognized compensation cost related to the time-based unvested restricted stock units was $6, which is expected to be recognized over a weighted average period of 0.1 years.
The Company had 19,000 performance restricted stock units outstanding at the year ended December 31, 2023. For the three months ended March 31, 2024, the Company granted no performance restricted stock units to its employees, released no performance restricted stock units due to the achievement of certain financing milestones, and had no performance restricted stock units forfeited. As of March 31, 2024, the Company had 19,000 performance restricted stock units outstanding.

Recognition of stock-based compensation expense associated with performance restricted stock units commences when the performance conditions are considered probable of achievement, using management’s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones.
As of March 31, 2024, for performance-based restricted stock units that were outstanding, the achievement of the milestones that had not been met was considered not probable, and therefore no expense has been recognized related to these awards in the three months ended March 31, 2024.
Employee stock purchase plan
The 2020 ESPP enables eligible employees to purchase shares of the Company's common stock at the end of each six-month offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Eligible employees generally included all employees. Offering periods begin on the first trading day of January and July of each year and end on the last trading day in June and December of each year, except for the first offering period which began on the first trading day in March and ended on the last trading day in June. Share purchases are funded through payroll deductions of up to 10% of an employee’s eligible compensation for each payroll period, up to $25 each calendar year.
During the three months ended March 31, 2024 and 2023, there were 26,659 and 33,202 shares, respectively, issued under the 2020 ESPP.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NET LOSS PER SHARE
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
NET LOSS PER SHARE NET LOSS PER SHARE
Net loss per share
The following table summarizes the computation of basic and diluted net loss per share attributable to common shareholders of the Company (in thousands, except share and per share amounts):

Three Months Ended
March 31,

2024

2023
Net loss$(18,225)

$(20,875)
Weighted average common shares outstanding, basic and diluted51,808,849 

36,483,878 
Net loss per share, basic and diluted$(0.35)

$(0.57)

The Company’s potentially dilutive securities, which include options, unvested restricted stock and warrants to purchase common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:
Three Months Ended
March 31,

20242023
Options to purchase common stock10,966,720 7,710,285 
Unvested restricted stock19,549 86,290 
Shares issuable under employee stock purchase plan86,858 102,351 
Unvested performance restricted stock units19,000 229,859 
Warrants to purchase common stock10,757 10,757 

11,102,884 8,139,542 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LEASES
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
LEASES LEASES
The Company has historically entered into lease arrangements for its facilities. As of March 31, 2024, the Company had two operating leases with required future minimum payments. The Company determined the classification of these leases to be operating leases and recorded right-of-use assets and lease liabilities as of the effective dates. The Company’s leases generally do not include termination or purchase options.
Operating leases
In July 2020, the Company entered into a seven-year agreement with an option to extend for five additional years to lease two floors totaling approximately 25,578 square feet of office space for its principal office, which is located in Cambridge, MA. The lease on the first floor commenced on August 1, 2020 and the lease on the second floor commenced March 9, 2021. The Company recognized the respective lease balances on the condensed consolidated balance sheets when the lease of each floor commenced. Under the terms of the lease, the Company was required to issue a $1,168 letter of credit as security for the lease, which was reduced to $779 in August 2023 pursuant to the terms of the lease agreement. Additionally, on December 12, 2022, the Company entered into a sublease for one floor of its Cambridge, Massachusetts office space. The sublease terminates on August 31, 2028, which is also the date on which the Company's lease terminates. Sublease income is recognized on a straight-line basis over the term of the sublease agreement. The Company was not relieved of its primary obligation under the Cambridge office lease as a result of the sublease.
In December 2020, the Company entered into an eleven-year agreement to lease approximately 18,120 square feet of office and laboratory space in New York, NY. The Company has an option to extend the lease for five additional years. The lease commenced August 26, 2021 and the related lease balance was recognized on the condensed consolidated balance sheet.
The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating lease for the three months ended March 31, 2024 and 2023:
Three Months Ended March 31,
20242023
Lease Cost
Operating lease cost$1,054 $1,054 
Short-term lease cost17 17 
Variable lease cost237 256 
Sublease income(456)(135)
Total lease cost$852 $1,192 
Other Operating Lease InformationMarch 31, 2024March 31, 2023
Cash paid for amounts included in the measurement of lease liability$1,080 $1,051 
Weighted-average remaining lease term6.77.6
Weighted-average discount rate5.3 %5.3 %
The variable lease costs for the three months ended March 31, 2024 and 2023 include common area maintenance and other operating charges. As the Company’s leases do not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.
Future minimum lease payments under the Company’s operating leases as of March 31, 2024 were as follows:
As of March 31, 2024
2024 (excluding the three months ended March 31, 2024)
$3,279 
20254,477 
20264,599 
20274,724 
20283,926 
Thereafter8,324 
Total lease payments29,329 
Less: interest(4,784)
Total lease liability$24,545 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
COMMITMENTS AND CONTINGENCIES
 3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
The Company enters into contracts in the normal course of business with contract research organizations (CROs), contract manufacturing organizations (CMOs) and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of service providers, up to the date of cancellation.
License agreements
The Company is a party to license agreements, which include contingent payments. These payments will become payable if and when certain development, regulatory and commercial milestones are achieved. As of March 31, 2024, the satisfaction and timing of the contingent payments is uncertain and not reasonably estimable.
Indemnification agreements
In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of March 31, 2024 or December 31, 2023.
Legal proceedings
The Company is not currently party to and is not aware of any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BENEFIT PLANS
 3 Months Ended
Mar. 31, 2024
Retirement Benefits [Abstract]  
BENEFIT PLANS BENEFIT PLANS
The Company has a tax-qualified 401(k) and Profit Sharing defined contribution plan (the 401(k) Plan). Under the 401(k) Plan, the Company provides an employer safe harbor matching contribution equal to 100% of a participant’s eligible contributions of up to 6% of eligible compensation, subject to limits established by the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the Code). All matching contributions are fully vested when made. During the three months ended March 31, 2024 and 2023, the Company contributed $348 and $376, respectively, to the 401(k) Plan.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUBSEQUENT EVENTS
 3 Months Ended
Mar. 31, 2024
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS SUBSEQUENT EVENTS
In April 2024, the Company sold 1,000,000 shares of its common stock pursuant to the ATM Program, resulting in gross proceeds to the Company of approximately $5.4 million ($5.3 million net of offering costs).
In May 2024, the Company sold 2,690,853 shares of its common stock pursuant to the ATM Program, resulting in gross proceeds to the Company of approximately $15.6 million ($15.3 million net of offering costs).
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Pay vs Performance Disclosure    
Net loss $ (18,225) $ (20,875)
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2024
shares
Trading Arrangements, by Individual  
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Fang Ni [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
On March 28, 2024, Fang Ni, our Chief Business Officer and Chief Financial Officer, entered into a trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Ni 10b5-1 Plan). The Ni 10b5-1 Plan is scheduled to commence on June 29, 2024, and will run through June 29, 2025. The aggregate maximum number of shares of common stock that may be sold pursuant to the Ni 10b5-1 Plan is up to 40,470 shares.
Name Fang Ni
Title Chief Business Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date March 28, 2024
Arrangement Duration 365 days
Aggregate Available 40,470
Brent Hatzis-Schoch [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
On March 27, 2024, Brent Hatzis-Schoch, our Chief Operating Officer and General Counsel, entered into a trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Hatzis-Schoch 10b5-1 Plan). The Hatzis-Schoch 10b5-1 Plan is scheduled to commence on July 1, 2024, and will run through July 1, 2025. The aggregate maximum number of shares of common stock that may be sold pursuant to the Hatzis-Schoch 10b5-1 Plan is up to 72,400 shares.
Name Brent Hatzis-Schoch
Title Chief Operating Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date March 27, 2024
Arrangement Duration 365 days
Aggregate Available 72,400
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Principles of consolidation and unaudited interim financial information
Black Diamond Therapeutics, Inc. (the Company) is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing and incurring research and development costs related to the development and advancement of its product candidates identified by its Mutation-Allostery-Pharmacology (MAP) drug discovery engine.
The Company is subject to risks and uncertainties common to clinical-stage companies in the biotechnology industry. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.
Principles of consolidation
The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics Security Corporation and Black Diamond Therapeutics (Canada), Inc., after elimination of all significant intercompany accounts and transactions. On October 10, 2023, Black Diamond Therapeutics (Canada), Inc. was dissolved by way of voluntary dissolution.
Unaudited interim financial information
The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. In the opinion of the Company’s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.
Principles of consolidation
Principles of consolidation
The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics Security Corporation and Black Diamond Therapeutics (Canada), Inc., after elimination of all significant intercompany accounts and transactions. On October 10, 2023, Black Diamond Therapeutics (Canada), Inc. was dissolved by way of voluntary dissolution.
Use of estimates
Use of estimates
The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
Recently issued accounting pronouncements
Recently issued accounting pronouncements
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09). ASU 2023-09 requires that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate). The standard is effective for annual and interim periods beginning after December 15, 2024. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The adoption is not expected to have a material impact on the Company’s consolidated financial statements.
In November 2023, the FASB issued ASU 2023-07, Improvements to Reportable Segment Disclosures (Topic 280) (ASU 2023-07) which requires enhanced disclosure of (1) significant segment expenses that are regularly provided to the chief operating decision maker (CODM) and included within each reported measure of segment profit or loss, (2) the amount and description of the composition of other segment items which reconcile to segment profit or loss, and (3) the title and position of the entity’s CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and allocating resources. The amendments also expand the interim segment disclosure requirements. This new guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this ASU apply retrospectively to all prior periods presented in the financial statements. The Company is in the process of assessing the impact on its financial statements from the adoption of the new guidance and the period in which the new guidance will be adopted.
In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements - Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative (ASU 2023-06). The standard is effective for annual and interim periods beginning after December 15, 2024. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The adoption is not expected to have a material impact on the Company’s consolidated financial statements.
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FAIR VALUE MEASUREMENTS (Tables)
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:

Fair value measurements at March 31, 2024 using:

Level 1

Level 2Level 3Total
Assets:





Cash equivalents:
Money market funds$20,498 $— $— $20,498 
Investments:
Commercial paper— 82,830 — 82,830 
Corporate bonds— 6,947 — 6,947 
Total$20,498 $89,777 $— $110,275 

Fair value measurements at December 31, 2023 using:

Level 1

Level 2Level 3Total
Assets:





Cash equivalents:
Money market funds$30,803 $— $— $30,803 
Investments:
Commercial paper— 44,871 — 44,871 
Corporate bonds— 30,308 — 30,308 
Total$30,803 $75,179 $— $105,982 
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVESTMENTS (Tables)
 3 Months Ended
Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]  
Schedule of Marketable Securities
As of March 31, 2024, investments were comprised of the following:
Amortized Cost

Unrealized GainsUnrealized LossesFair Value
Commercial paper$82,921 $— $(91)$82,830 
Corporate bonds6,951 — (4)6,947 
Total$89,872 $— $(95)$89,777 
As of December 31, 2023, investments were comprised of the following:
Amortized Cost

Unrealized GainsUnrealized LossesFair Value
Commercial paper$44,880 $4 $(13)$44,871 
Corporate bonds30,326 — (18)30,308 
Total$75,206 $4 $(31)$75,179 
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
PROPERTY AND EQUIPMENT (Tables)
 3 Months Ended
Mar. 31, 2024
Property, Plant and Equipment [Abstract]  
Schedule of Property, Plant and Equipment
Property and equipment, net consisted of the following:

March 31,
2024

December 31,
2023
Furniture and fixtures$17 $17 
Leasehold improvements2,512 2,512 
Property and equipment2,529 2,529 
Less: accumulated depreciation(885)(799)
Total Property and Equipment, net$1,644 $1,730 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)
 3 Months Ended
Mar. 31, 2024
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses
Accrued expenses and other current liabilities consisted of the following:

March 31,
2024

December 31,
2023
Contracted research services$8,984 $8,071 
Payroll and related expenses2,510 5,175 
Professional and consulting fees1,000 963 
Current portion of operating lease liability3,184 3,113 
Total accrued expenses and other current liabilities$15,678 $17,322 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCK-BASED COMPENSATION (Tables)
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-Based Compensation
The Company recorded stock-based compensation expense in the following award type categories included within the condensed consolidated statements of operations and comprehensive loss:
Three Months Ended
March 31,

20242023
Stock options$1,623 $2,455 
Restricted stock units16 112 
Employee Stock Purchase Plan and Other74 104 

$1,713 $2,671 
The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:
Three Months Ended
March 31,

2024

2023
Research and development$635 

$949 
General and administrative1,078 

1,722 

$1,713 

$2,671 
Schedule of Stock Option Activity
The following table summarizes the stock option activity under the Company’s equity awards plans:

Options

Weighted
Average
Exercise
Price

Weighted
Average
Remaining
Life
(in Years)

Intrinsic
Value
(in thousands)
Outstanding December 31, 20238,135,711 $7.85 8.0$1,146 
Granted2,895,550 $4.85 
Exercised(47,741)$1.78 
Cancelled or forfeited(16,500)$1.82 
Expired(300)$7.73 
Outstanding March 31, 202410,966,720 $7.09 8.3$11,996 
Options vested or expected to vest at March 31, 202410,966,720 $7.09 8.3$11,996 
Options exercisable at March 31, 20244,242,313 $11.65 6.7$3,488 
Schedule of Restricted Stock Activity The following table summarizes time-based restricted stock activity since January 1, 2024:

Number of
shares
Weighted
average
grant date
fair value
Unvested restricted common stock as of December 31, 202320,799 $2.41 
Vested(1,250)$3.79 
Unvested restricted common stock as of March 31, 202419,549 $2.32 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NET LOSS PER SHARE (Tables)
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Computation of Net Loss per Share
The following table summarizes the computation of basic and diluted net loss per share attributable to common shareholders of the Company (in thousands, except share and per share amounts):

Three Months Ended
March 31,

2024

2023
Net loss$(18,225)

$(20,875)
Weighted average common shares outstanding, basic and diluted51,808,849 

36,483,878 
Net loss per share, basic and diluted$(0.35)

$(0.57)
Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:
Three Months Ended
March 31,

20242023
Options to purchase common stock10,966,720 7,710,285 
Unvested restricted stock19,549 86,290 
Shares issuable under employee stock purchase plan86,858 102,351 
Unvested performance restricted stock units19,000 229,859 
Warrants to purchase common stock10,757 10,757 

11,102,884 8,139,542 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LEASES (Tables)
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Schedule of Lease Cost and Other Operating Lease Information
The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating lease for the three months ended March 31, 2024 and 2023:
Three Months Ended March 31,
20242023
Lease Cost
Operating lease cost$1,054 $1,054 
Short-term lease cost17 17 
Variable lease cost237 256 
Sublease income(456)(135)
Total lease cost$852 $1,192 
Other Operating Lease InformationMarch 31, 2024March 31, 2023
Cash paid for amounts included in the measurement of lease liability$1,080 $1,051 
Weighted-average remaining lease term6.77.6
Weighted-average discount rate5.3 %5.3 %
Schedule of Future Minimum Lease Payments
Future minimum lease payments under the Company’s operating leases as of March 31, 2024 were as follows:
As of March 31, 2024
2024 (excluding the three months ended March 31, 2024)
$3,279 
20254,477 
20264,599 
20274,724 
20283,926 
Thereafter8,324 
Total lease payments29,329 
Less: interest(4,784)
Total lease liability$24,545 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Jul. 05, 2023
Nov. 14, 2022
Mar. 31, 2024
Dec. 31, 2023
Subsidiary, Sale of Stock [Line Items]        
Sale of stock, gross     $ 4,000  
Accumulated deficit     $ 435,656 $ 417,431
Shelf Registration Statement        
Subsidiary, Sale of Stock [Line Items]        
Sale of stock, authorized consideration   $ 500,000    
ATM Program        
Subsidiary, Sale of Stock [Line Items]        
Sale of stock, authorized consideration   $ 150,000    
Number of shares sold (in shares)     800,000  
Sale of stock, gross     $ 4,000  
Sale of stock, net of offering costs     $ 3,900  
Follow-on Offering        
Subsidiary, Sale of Stock [Line Items]        
Number of shares sold (in shares) 15,000,000      
Stock price (in dollars per share) $ 5.00      
Proceeds from equity financing $ 71,900      
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - Recurring - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Assets:    
Total $ 110,275 $ 105,982
Money market funds    
Assets:    
Cash equivalents: 20,498 30,803
Commercial paper    
Assets:    
Investments: 82,830 44,871
Corporate bonds    
Assets:    
Investments: 6,947 30,308
Level 1    
Assets:    
Total 20,498 30,803
Level 1 | Money market funds    
Assets:    
Cash equivalents: 20,498 30,803
Level 1 | Commercial paper    
Assets:    
Investments: 0 0
Level 1 | Corporate bonds    
Assets:    
Investments: 0 0
Level 2    
Assets:    
Total 89,777 75,179
Level 2 | Money market funds    
Assets:    
Cash equivalents: 0 0
Level 2 | Commercial paper    
Assets:    
Investments: 82,830 44,871
Level 2 | Corporate bonds    
Assets:    
Investments: 6,947 30,308
Level 3    
Assets:    
Total 0 0
Level 3 | Money market funds    
Assets:    
Cash equivalents: 0 0
Level 3 | Commercial paper    
Assets:    
Investments: 0 0
Level 3 | Corporate bonds    
Assets:    
Investments: $ 0 $ 0
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVESTMENTS - Schedule of Marketable Securities (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost $ 89,872 $ 75,206
Unrealized Gains 0 4
Unrealized Losses (95) (31)
Fair Value 89,777 75,179
Commercial paper    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 82,921 44,880
Unrealized Gains 0 4
Unrealized Losses (91) (13)
Fair Value 82,830 44,871
Corporate bonds    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 6,951 30,326
Unrealized Gains 0 0
Unrealized Losses (4) (18)
Fair Value $ 6,947 $ 30,308
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVESTMENTS - Additional Information (Details) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]    
Impairment of fair value assets $ 0 $ 0
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
PROPERTY AND EQUIPMENT (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Property, Plant and Equipment [Line Items]      
Property and equipment $ 2,529   $ 2,529
Less: accumulated depreciation (885)   (799)
Total Property and Equipment, net 1,644   1,730
Depreciation expense 86 $ 122  
Furniture and fixtures      
Property, Plant and Equipment [Line Items]      
Property and equipment 17   17
Leasehold improvements      
Property, Plant and Equipment [Line Items]      
Property and equipment $ 2,512   $ 2,512
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
EQUITY METHOD INVESTMENT (Details) - USD ($)
 12 Months Ended
Dec. 31, 2022
Mar. 31, 2024
Dec. 01, 2022
Schedule of Equity Method Investments [Line Items]      
Gain on sale of IP $ 2,232,000    
Research and development asset acquired other than through business combination, written-off $ 710,000    
Launchpad Therapeutics, Inc.      
Schedule of Equity Method Investments [Line Items]      
Common shares received from equity method investment (in shares) 9,000,000    
Equity method investment, ownership percentage   39.10%  
Equity method investment $ 0 $ 0 $ 2,250,000
Loss recognized from equity method investment $ 1,540,000    
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Payables and Accruals [Abstract]    
Contracted research services $ 8,984 $ 8,071
Payroll and related expenses 2,510 5,175
Professional and consulting fees 1,000 963
Current portion of operating lease liability $ 3,184 $ 3,113
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Total accrued expenses and other current liabilities Total accrued expenses and other current liabilities
Total accrued expenses and other current liabilities $ 15,678 $ 17,322
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)
 3 Months Ended
Jan. 01, 2024
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Jan. 14, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Unrecognized compensation cost, options   $ 18,345,000      
Stock-based compensation expense   $ 1,713,000 $ 2,671,000    
2020 Stock Option Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Increase of authorized shares, percent of common stock outstanding 4.00%       4.00%
Number of additional shares authorized (in shares) 2,065,822        
2020 ESPP          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Increase of authorized shares, percent of common stock outstanding         1.00%
Number of additional shares authorized (in shares) 326,364        
Stock options          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Unrecognized compensation cost, recognition period (in years)   3 years 1 month 6 days      
Stock-based compensation expense   $ 1,623,000 2,455,000    
Stock options | 2020 Stock Option Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Shares issued under share-based compensation plan   6,419      
Restricted stock units          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Unrecognized compensation cost, recognition period (in years)   1 month 6 days      
Fair value of units vested   $ 5,000      
Unrecognized compensation cost   6,000      
Stock-based compensation expense   $ 16,000 $ 112,000    
Unvested performance restricted stock units          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Units outstanding (in shares)       19,000  
Units vested (in shares)   0      
Performance restricted stock units          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Units outstanding (in shares)   19,000      
Units granted (in shares)   0      
Units forfeited (in shares)   0      
Stock-based compensation expense   $ 0      
Shares issuable under employee stock purchase plan | 2020 ESPP          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Shares issued under share-based compensation plan   26,659 33,202    
Award purchase period (in months)   6 months      
Maximum percent of fair market value of common stock   85.00%      
Maximum employee subscription rate   10.00%      
Maximum employee subscription amount   $ 25,000      
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Stock-based compensation expense $ 1,713 $ 2,671
Research and development    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Stock-based compensation expense 635 949
General and administrative    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Stock-based compensation expense 1,078 1,722
Stock options    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Stock-based compensation expense 1,623 2,455
Restricted stock units    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Stock-based compensation expense 16 112
Employee Stock Purchase Plan and Other    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Stock-based compensation expense $ 74 $ 104
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Options    
Outstanding, beginning balance (in shares) 8,135,711  
Granted (in shares) 2,895,550  
Exercised (in shares) (47,741)  
Canceled or forfeited (in shares) (16,500)  
Expired (in shares) (300)  
Outstanding, ending balance (in shares) 10,966,720 8,135,711
Options vested or expected to vest (in shares) 10,966,720  
Options exercisable (in shares) 4,242,313  
Weighted Average Exercise Price    
Outstanding, beginning balance (in dollars per share) $ 7.85  
Granted (in dollars per share) 4.85  
Exercised (in dollars per share) 1.78  
Cancelled or forfeited (in dollars per share) 1.82  
Expired (in dollars per share) 7.73  
Outstanding, ending balance (in dollars per share) 7.09 $ 7.85
Options vested or expected to vest (in dollars per share) 7.09  
Options exercisable (in dollars per share) $ 11.65  
Weighted Average Remaining Life and Intrinsic Value    
Options outstanding, remaining life (in years) 8 years 3 months 18 days 8 years
Options vested or expected to vest, remaining life (in years) 8 years 3 months 18 days  
Options exercisable, remaining life (in years) 6 years 8 months 12 days  
Options outstanding, intrinsic value $ 11,996 $ 1,146
Options vested or expected to vest, intrinsic value 11,996  
Options exercisable, intrinsic value $ 3,488  
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details) - Unvested restricted stock
 3 Months Ended
Mar. 31, 2024
$ / shares
shares
Number of shares  
Unvested restricted common stock, beginning balance (in shares) | shares 20,799
Vested (in shares) | shares (1,250)
Unvested restricted common stock, ending balance (in shares) | shares 19,549
Weighted average grant date fair value  
Unvested restricted common stock, beginning balance (in dollars per share) | $ / shares $ 2.41
Vested (in dollars per share) | $ / shares 3.79
Unvested restricted common stock, ending balance (in dollars per share) | $ / shares $ 2.32
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NET LOSS PER SHARE - Computation of Net Loss per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Earnings Per Share [Abstract]    
Net loss $ (18,225) $ (20,875)
Weighted average common shares outstanding, basic (in shares) 51,808,849 36,483,878
Weighted average common shares outstanding, diluted (in shares) 51,808,849 36,483,878
Net loss per share, basic (in dollars per share) $ (0.35) $ (0.57)
Net loss per share, diluted (in dollars per share) $ (0.35) $ (0.57)
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details) - shares
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares) 11,102,884 8,139,542
Options to purchase common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares) 10,966,720 7,710,285
Unvested restricted stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares) 19,549 86,290
Shares issuable under employee stock purchase plan    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares) 86,858 102,351
Unvested performance restricted stock units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares) 19,000 229,859
Warrants to purchase common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares) 10,757 10,757
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LEASES - Narrative (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
contract
Aug. 31, 2023
USD ($)
Dec. 31, 2020
ft²
Jul. 31, 2020
USD ($)
ft²
Lessee, Lease, Description [Line Items]        
Number of leases | contract 2      
Principal office, lease two        
Lessee, Lease, Description [Line Items]        
Lease term (in years)       7 years
Lease term, optional extension (in years)       5 years
Area leased (square feet)       25,578
Letter of credit outstanding | $   $ 779   $ 1,168
Operating Lease, Office and Laboratory Space, NY        
Lessee, Lease, Description [Line Items]        
Lease term (in years)     11 years  
Lease term, optional extension (in years)     5 years  
Area leased (square feet)     18,120  
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LEASES - Summary of Lease Cost and Other Operating Lease Information (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Lease Cost    
Operating lease cost $ 1,054 $ 1,054
Short-term lease cost 17 17
Variable lease cost 237 256
Sublease income (456) (135)
Total lease cost 852 1,192
Other Operating Lease Information    
Cash paid for amounts included in the measurement of lease liability $ 1,080 $ 1,051
Weighted-average remaining lease term (in years) 6 years 8 months 12 days 7 years 7 months 6 days
Weighted-average discount rate 5.30% 5.30%
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LEASES - Schedule of Future Minimum Lease Payments (Details)
$ in Thousands
Mar. 31, 2024
USD ($)
Lessee, Operating Lease, Liability, to be Paid [Abstract]  
2024 (excluding the three months ended March 31, 2024) $ 3,279
2025 4,477
2026 4,599
2027 4,724
2028 3,926
Thereafter 8,324
Total lease payments 29,329
Less: interest (4,784)
Total lease liability $ 24,545
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
BENEFIT PLANS (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Retirement Benefits [Abstract]    
Employer contribution, matching contribution percentage 100.00%  
Employer contribution, percent of each participant's salary 6.00%  
Employer contribution amount $ 348 $ 376
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUBSEQUENT EVENTS (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
May 09, 2024
Apr. 30, 2024
Mar. 31, 2024
Subsequent Event [Line Items]      
Issuance of common stock, net of issuance costs     $ 4,000
ATM Program      
Subsequent Event [Line Items]      
Number of shares sold (in shares)     800,000
Issuance of common stock, net of issuance costs     $ 4,000
Sale of stock, net of offering costs     $ 3,900
ATM Program | Subsequent Event      
Subsequent Event [Line Items]      
Number of shares sold (in shares) 2,690,853 1,000,000  
Issuance of common stock, net of issuance costs $ 15,600 $ 5,400  
Sale of stock, net of offering costs $ 15,300 $ 5,300  
EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( *\YJ5@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "O.:E8-,BB,^X K @ $0 &1O8U!R;W!S+V-O&ULS9)1 M2\,P$,>_BN2]O:15P=#E9<,G!<&!XEM(;EM8DX;DI-VWMZU;A^@'\#%W__SN M=W"-B=)T"5]2%S&1PWPS^#9D:>**'8BB!,CF@%[GHC9' MO4>H.+\'CZ2M)@T3L(@+D:G&&FD2:NK2&6_-@H^?J9UAU@"VZ#%0!E$*8&J: M&$]#V\ 5,,$(D\_?!;0+<:[^B9T[P,[)(;LEU?=]V==S;MQ!P/OST^N\;N%" M)AT,CK^RDW2*N&*7R6_U>K-]9*KBU6W![PK^L!5"BEH*\3&Y_O"["OO.NIW[ MQ\870=7 K[M07U!+ P04 " "O.:E8F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M *\YJ5BSODM[!@8 ,X? 8 >&PO=V]R:W-H965T&UL MM9EO<^(V$,:_BH9V.NU,"+8,A+L29L!)>LQ=Q'J_Y6R*]IP+DB+W&4I+>-0*G5VU8K]0(>L_1: MK'@"=Q9"QDS!J5RVTI7DS,^"XJA%+:O;BEF8- ;][-I$#OIBK:(PX1-)TG4< M,[D;\4AL;QMVXW#A.5P&2E]H#?HKMN13KCZO)A+.6H6*'\8\24.1$,D7MXVA M_=9U'!V0/?%[R+?IT3'1*',AONJ3L7_;L'2+>,0]I248_&RXRZ-(*T$[_MV+ M-HK_J0./CP_J#QD\P,Q9RET1_1'Z*KAM]!K$YPNVCM2SV+[C>Z".UO-$E&9_ MR39_MMUN$&^=*A'O@Z$%<9CDO^QEWQ%' 0!J#J#[ /HJP#X5X.P#LIYKY2W+ ML.Z88H.^%%LB]=.@I@^ROLFB@29,=!JG2L+=$.+4P!4;+LD$,D::) V8Y&F_ MI4!8WVYY>Y%1+D)/B#CD420J2,E]XG/_V_@6-*AH%3VT:D11P4ZY\!VQNJ;H;UKC%'WD9'(.VD=_#^>IDC#L_C%U4*[0-BOHN?@V73&/ MWS9@LJ5<;GAC\-,/=M?ZU43WG<2^@6T7L&U,?7 GO#5,4T5FNQ4WD>+AMM7\ M9$)"HVHB=0JD3C6D3VLF%9?1CCSSE9#*A(=+*;DV=8J+1M7$ZQ9XW6IX$RY# MX>M)2.!=8$P>KE1,NY/S#HVOR7E3<-Y4')F2P6U,%[IDO M0_T:A30^L=@X1G&=T8>A^Y[/'Y_NR.S=_?-PAEW$CX_J,9,]NMFFGW>U:1EXTN"XO+7EI%=ZA[X-Z M>G4X(!_@.?(Q,><5EX0H\@@V' :*!'-W1>RV"LA#)(2I]UQ.=FX MYN/0"'H)TV27KLG&O[+1 M.H15\&DP7.#GKGWSBQ'L$H;)+AV3C=N<#\*#C$T"D6".XHP([="FU6OWC'R7 M\$MV:9ALW.W,0@5>22P(9UY O(BEYM4KKN**.(9/$ZRUO:]79,4DV;!HS/JLM9^B1:R2>-$\A@7L#3*U5V M #=RXHJG."]AAVAIAV@E.Z17=QD $1/Q%A=O-()T4I.Z#[F5C)"XVLD:"QY7E[(T113W,X?! M&G 8K%@.:Y:0\+BZ>*4GHI6J2'M3,\U-S32K[)./:P4>/M'>P4C\G5S-OA]R MM4ZFIK>3-H-.%\SDS9MVO[4Q,9;^A^+>91CSQ,]J@0\1,Z/@ J>3=PGWXY3N MQSE3S3G4.!_"-+/N>4GW 2X;WZ=GY#X9S2L>5)>Q-#L.;DU>,W[AX+A/$^)B MIPK5>%A=QM+H.)6,C@N8$A#'B<]?R'MN?,^&PO M=V]R:W-H965T&ULK5AM;]LV$/XKA%=L+6#'(B5*\Y#+)ZF^ZXQS M@WX4>:EO)YDQV^OY7"<9+YB^DEM>PIN-5 4S<*L>YWJK.$MKIR*?$\\+YP43 MY62UK)_=J=525B87);]32%=%P=3S!Y[+I]L)GKP\^"(>,V,?S%?++7OD]]Q\ MV]XIN)LW45)1\%(+62+%-[>3]_AZ3:AUJ"W^$OQ)'UTCF\J#E-_MS:?T=N)9 M1#SGB;$A&/SL^)KGN8T$./XY!)TTW[2.Q]"O S MJ[4L4Q@4GB*XTC(7*3-P\X'EK$PXNK>!-7K[K615*N#-.S1#W^X_HK=OWJ$W M2)3H:R8KS>-.[^ MJ?LR*N]9;EO#;"2PIS=6. M3U:__H)#[\:5W2L%.\G5;W+UQZ*OUDQG"$8-)?:"_U.)'>V=Z],UX$451!UG? M*J(X6KB1T089'45VI_B6B13Q'UN[?G1=36DRKF#9'D\D%V[:0^2'7A=VWXB$ M?N!&'3:HPU'47Z5A^04 P]ZW,8YC+^Q =)CY@3<$,FI 1F=*"RRES'-=4CLW MMW8"3%')C0MKU <1!D$'J<,H\CTWSKC!&8_B_ )34XG$]DN[C%S8XOX$Q8L. M-(>-[6"X[&M,P&@!XQ(SX(C[(!7L0N3""NTGA$.:56.&UHITFW7(@ M'J6=U?LDD15T6[1ES^PAY\Z$B:,[1-W>X+ B/AEH#;@E+CS.7 !057RT[QX- MF!.^[Y@P811W\3O,(O^(]DX3:!D-CU/::0L^A[7/73B,:;>[N]U>LP(SBF \A;GL.7$-TYC'W^ M\F.":1=CWRS L3\@;7!+W.RUF"QM?7F9 %[T]K,T?+^R,7[G MA#\:WMTJD+/G_/] IR5H&13'HSWVWLCD>R;SE"O]6\WUYMG=9$>I^*>;["M% M.\VZ96<\3L^@'3<<5E6*M,U_BMYX5Y[G86BZ"H$0K_@-PMX4'MD_I#.F;*.K M3":5^!?4JR/::7+50]B6!7Q(L'KDY>^3>HE"]QA-:V@4J%8%NO#3C9 M1?W3(9VCU-<*7G!H&=$II=#[&Y4- ^G*HN[$8-3D=@E8LD5%=LGJ?IL*>RT#3M=NB MF2A!$V\%-&$G2-Q#0 //H]W)XK+SH?<.P3W:ZI^5.551Y?59QT$\R +6>F8/ MJ'9 ;E([&8/T14+EQ$9@MP*'W)6^#204[X1B7#NADA?MLP"GX:TJ\^< MAC@*AGB-M J'7*)PM*.U.P$[M(L7^+V]ILL.AY$_(')(*W+(N,CI285Z 5X, MG_;./9S;%)>=:YLR/SK+LP>IT#T>1:E!=&W T;N*(([:GTWN;XS&S0GQZC]02P,$% @ KSFI6*:0/>\' P M<0H !@ !X;"]W;W)KYCV8)(+L>K8F6V@VZ_?=4(STJ9\=.,!_''/\3DW MU^2.-E+=ZPS D(><"SUV,F.*2]?5208YU1U9@,"=A50Y-3A52U<7"FA:@G+N M!I[7=W/*A!./RK6IBD=R93@3,%5$K_* M500<$F,I*/ZL80*<6R;4\7-+ZM1G6N#N^)']8VD>S4_>$I?H M#%?UR#6HR3*[R?;\Z^K\X(7SOU#5(5W_@@1>T&N!3_;#;R"IX=TFW,5,U.D( MZG0$)5_W!;Z90?M8I8;(!?G(!":!44ZF4K.RZKY?S;516'L_VJQ6W+UV;GLA M+W5!$Q@[>.,TJ#4X\;LW?M_[T&;\/Y$UTM"MT]#=QQY/\2Z!4E@(6(#)_04I MJ")KRE= SI@@J>2<*DT*4-6#/V_+1G5$5!YA_TW6L=?Q/,\?N>M=GP?#&@YZ MM8/>:0ZJ B5T93*IV&_U5/9%YCC?[ M'PH].J[0#X8UY ]J^8,3Y)]Y$_2F@0 '(2 8 >&PO=V]R:W-H965T&ULK5C;;N,V$/T50ET4"9!$HNY.;0,;;R\+=-L@V72?&8NVA)5$EZ3M MM%_?H21+LD2Q"9 76Y>9X3DE?2>([$O M"L+_N:,Y.RXL;)T>/&3;5*H']G*^(UOZ2.73[I[#G=U&2;*"EB)C)>)TL[ ^ MXMN56SE4%G]E]"AZUTA1>6;LN[KYG"PL1R&B.5U+%8+ WX&N:)ZK2(#C[R:H MU8ZI'/O7I^B_5.2!S#,1=,7R;UDBTX456RBA&[+/Y0,[_D8;0H&*MV:YJ'[1 ML;%U++3>"\F*QAD0%%E9_Y.79B)Z#A!'[^ V#N[0P9]P\!H'KR):(ZMH?2*2 M+.><'1%7UA!-751S4WD#FZQ4:7R4'-YFX">7*U8FD!2:(+@2+,\2(N'F4<(? M9$L*Q#;HSQWE1,VZ0*14E@4LF53E\D#1[TP(=/%4DGV2@>LEND9/CY_0Q8=+ M] %E)?J:LKT -S&W)0!6P]KK!MQ=#A+ZR4J4 _ \CDW-\&HBU;]\3V MSC4&_$+X#?+P%7(=U]?@6;W>W3/ \=K)]ZIXWD2\9E[++:(O.Y4%<:N;I#J( MKP^BZOQ6[,B:+BS(BJ#\0*WECS_@T/E)Q_"=@IWQ]5N^OBGZ\@$B$KY.JU64 MT ,TD9U:9#K2=:2PBJ1ZT6&)O< /YO:AST9CY4>!UUJ=P0Q:F($1YJ^TA+SD M%4J20-%E0JH\':@.:!TKZ$$((P]*)7U. 6JA7J*3:OM;$ M')3BL%]HK,(XG #L=H!=(^ _8%N80SEJ<;FC5GJ-8]<==ER=G>O$43 !KM-" M;)2>%AR"+H%$2CB]4ANT;(TN8!>1L#PGO/=2OQCJ(>(^..?&&W'0F@71!(5. MWK!9WW04DBS?JQW5&TCXKR.A-9LDT8D?-JO?MVKG"XC) =KUEB)8V 5LN"O ML!W<2R%!&4%Q^OFIW^KYC,4OP*!^L3\;4AI;>J$?>W$T(96XTTIL%LNWL.JG MS,1K+)=3O,:6_\.K$U<<&87K?"^N%I]6M+!1H]^J6N\5[9QSI]78*(OF-A:_ MLHUI[$QMK!-5/'O%3F)]EI:3."C0^DT%-DKUF_/S3M'.O[$Z\7;-XOU4%NXC@0?A6+6YU:J2RQG4#H4:26 M[>I.NEVA]O;NMTD,^#:)6=NAW7OZLQ,@$#NFE9"JXB3CR32%B^]R M3:D"KWE6R+O>6JG-[6 @DS7-B?S(-[303Y9\5!DKZ%P 6>8Y$3\?:,9?[GJPM[_QQ%9K96X,II,-6=%G MJKYMYD)?#0Y:4I;30C)> $&7=[U[>#O#U81*XF]&7^31&!A3%IQ_-Q=_I'>] MP""B&4V444'TSY;.:)8931K'CYW2WN&=9N+Q>*_]2$JI>+Z;K!'DK*A_R>O.$4<3 MM![W!+2;@-H3PHX)>#ST-ZL!^15^(6(CP##&X "%#KPS-X^'7O@X(.7<:4/=WG9.'!9 M.7 I> YT%@JB6+&JES%3C,I;E]MJM:%;K4GQ6[DA";WKZ1R65&QI;_KK+W 8 M_.:R^4+*3CP0'CP0^K1/O^J*E''I7!OUS&$UTY2=[;0/8X2BR6![#-\AAH)X MU(B= (L.P")O:.[3?W66F:4.%->%*>%%PC(*BAU@<]>,$Q/"TB2*7NIOCE]T MR?A=2-F)FX8'-PV]\7M6//G>-P4S!0G/-8M(4M5A^FK&U&5\K3$Z"A@<0=R* MJBV$AB/HCNGH ';D!?N):@\D["S D?7N>-B"9XM A-SHX@.ZV(ONZCY)!#78 MK@')N5#LOQJI_F/%EM:KT9DIL86F/\:H!=D6@L'8#7E\@#SV9Z]."K/^A4D3 MCT/'UJM'*&[!LV6&X\ -#P8-BP5>@'^:3-7^DT2GKF8L^J-D&^-&)Q<%%H2@ M!=(A@D<=((^H%OI98$V*%96F@"2EJ'Q)I*2:8S5K@HR1!7IBW:D)]DD3FS8*?B!!^$5B(XQ" <=F0J;(@6^IG65)>2>EU[M-2<^$,' M_F$8MO$[Q'#4Z>*&D*&7R$RQZ>^1-D2;4'WUV3+J3M MU L-+4,_+\\%3RA-=SXP3%+GCMXKEJ+R@6&6,PP-;?;%<118_&*+H3 .AAV1 M;'@:^HEZ7HID3>3;H-I,W(\0PE:ZV'(=?(T:OD9^OC[DRM4N6:[!1O MT[L_ ML/CI7( N$Y!-TWV(1Y8)#CF/NU'#Z.@,H[<29\D*HKERZYQZ?)[/G7ZQ21M&[>1Q"$4= M-1 UQ([\Q'YJ!).RU)&TC+BI]H(FM_8""9?N]$(VO>-Q;-EB2W4E5],!H/-[ M[2JYCE/*M32=L&U6#R&V8-M2G2%HB!^=(7Z-FQ5Z;V28_BJE]>BZZI>-.6;A M5 /3W6]U?>XH;,C![SB(@W:'Z) +8]15%)H^ /G[ %,4;BR@%7J=?4JPQ'QA M2RJI!5VQHC!1T6M*MPN,ITZ+;.:/1H'5D3G$[:R**&Y5%\MF3?U%\T'QM;;L!38\ALO]C:]Q[/K#MO M?_'NHGXA;:=^:CH)Y.\D9ET9]Y80VQT#BD+4_E#A$,-C&';4$=PT%]C?7#R] M>TUBNS^(8;O]=@CI_5K<@;;I(;"7G2^;7+MW#<\DET/,E5R#HW.%G(I5==PB M0;4#KK_%'^X>CG3NJX.,UOT'>#NK#V8:-?4YT1GNWU"J#CR/M7E$? MO=07BF^JTXL%5XKGU7!-24J%$=#/EYRK_85YP>$ ;/H_4$L#!!0 ( *\Y MJ5A? ?.7/P< * T 8 >&PO=V]R:W-H965T&ULO5M= M;]LV%/TKA%=L#5#7(O5E=XF!UI:P/FP(FJ9[&/:@2DPL5!8]D4[2_?I1LF*9 MI$Q;Z<7R$$OVO>=2]_"*Y*%T^/7_Q*;]?B?J+R?QRD]S3&RIN-]>5/)OL4;)\34N>LQ)5 M].YJ]!Z_BUVG=F@LON3TD1\/R,'C<7+R_F:\+I@A5_YIE878VF(Y31NV1;B$_L\3?: M7I!?XZ6LX,U_]-C:.B.4;KE@Z]99MF"=E[O/Y*E-Q($#=H\XD-:!G.O@M@ZN MYD#"(PY>Z^!I#EYPQ,%O'7P]PK&+#EJ'H,G]+EE-II>)2.:7%7M$56TMT>J# MAJ[&6R8X+^N>=2,J^6LN_<1\PO;\MDF^72^@*-T>W-$KU^=8%>H;Q$GU=LRY,RXY<3 M(=M81YJD;7L^[-I#CK3G,Q-)T>.VL+LMV'HM^RFO&]KCO;1[O\_D=%DT6F5C1"J5L+8M^55?C Y7ID><4O2X8YQ<] M\/'Y\+* \C07*LA$=H!]+R#[7D :5.\(Z@=ZGY=E7M[+*BV2,I7MDSG@JZ2B M_ (E BUI^A:Y^ TB#B%]K%KQZ]OC.[Y)4GHUDJG@M'J@H_G//^' ^;6/ZQV8 MWX#5M\:'N1MXKD=FX>7DX9!6R*@1)%@,!*:PZ>[9= >R>0Z#.\S@(.D8^\', M5U.^,,TTBZ5IX?G$=US5+#+-QGA*/-4J[K%R76\VG>WME!1Y^Q1YC:-[)$4? MRU2.PUSVS[>_9]:X%\H5S4Y2&'-@DNJCRM;Z?-X(&V92X'O8/;7Q_A5OBAA/O&W8ZX M?JA7%63("!(L!@)3F SV3 96)F^V547E#*:JN=P1AN1T&XGDB9YDT0H]E,7 M8''LSO2;WA(R9 0)%@.!*2R&>Q9#*XL?.=\VXY0D,3V8R.G1JAD"$C2+ 8"$PA=+HG= I":!^)4R/O/M;F(-;@0X?( MT_$BR'@Q$)C"RVS/R\Q^NZQ)&-W6]DB655X^R/EEHZ/T\H.-7 7>5*?'&GPP/9!H MT3D7$$.%5-GII ULUS;^H +5A/028"H-8^),]@L@4H6GPZ(RH- MG2:![:)$5&86?>GWI-JK$VXO4U;TH4-0BZ8J3#[&,T]7F$#C1J!H,12:RF@G MH6#K&EUG]"P6/4/.F4WQS-'+S333E\.MR2&#GN\3XNL#C6DWQEB?;<1]9J[O M3P/O2+_OI 9LUQH&2:O]23,% A\'\FK]4,_;N99+>Z,'=VM0/0$*326L4Q2P M75(XJ9[VDQ3TR*=!Z 8Z1::=P8TI)?BNAZ>AWK5[) <2ZAV[Q\C#H>?B(QV[ M6[/C\'^44#'HVAT4;0F*%H&BQ5!H:B?HUOGX90O]-ZB4TR[Y9?YLD#)^6E>U M1QO<"\RE_=2I__2"@XP:@:+%4&@JOYU>@.V"P4!^>SF=F?M!!@<+>SL&5ZRI M,9@Q(]"8,12:NH';Z0+$K@M$3[1*/IM%/3YBS,B1J 18R@T ME9Y.[B!VN>.E.TQVV,%E9@HA@8>-*@,504#18B@TE<9.!"$GGJL8L,M$3(D! MA]C5ZPKR:87E63$CT)@Q%)I*2:>W$/M#$B_>92+FDPSC0-]EL@0>QZ MQ?F[3%XO4Z9NX!.?A $Q5EOG6B[M+1[, ZAF 86F/J;<:1;N"XZC+[*B'KNQ_EATW&?DN7[@!UJ7GAR\JU&_NR.O M^#XO.2KHG?1TWH:R2U6[UV%V)X)MFMCPU&W\%GG1:"%Z<59+7.U4.%+?>_P M-NVEI+I2QFMKA%/9^6A^^.[RA/;SAK]JM?9;SX(\65K[2"_7Z?EH1@:I4B6! M)$C\6:GWJBQ)$,SXLY4YZE72P>WG3OI']AV^+*57[VWY-YV&XGST=B12EOY7K-N]LY%(&A]LU1Z&!94V\:_\VN+PGQPX:@\;L6CC:#6GTP*[R:1BG#05E$1Q^U3@7+F[G#U\^7XF[C^+RR^+Z M]FJQ$//;#^)ROKA>T.K]YZO%U>W#_.'Z[O9L&J"1SDV35OIEE'[T'>G'XL:: M4'AQ95*5[IZ?PM+>W*/.W,NC9P7>2#<1QX=C<30[.GE&WG'O_C'+._Z.O#N7 M2Z/_)8DA8_'>&F]+GZ>\,B$NV$Q\U$::1,M2++"HP,[@Q=_G2Q\< M^/6/IQ"*!IP\;0#EW#M?RT2=CVK2Y59J=/'S3X>O9[\^X]Y)[][)<]+_Y^C^ M_Z2+RU(FC^*#EI4%K@^%GH@&Z>#(4F%DI<1\;1R20IH<.C7 XD-0_L/X H1/TC2H_.3+VXE8:"#,,NBACBFX[6 !!Q%B M2^[Y!CDF3=",//XA'^BLRM"9\!P,=D.F*6,+OK3FULVF3!*)/2H4$ MC-,I?M>9AISEAC?=M+1[-2]+2[S=O+HO)'I,R^^7-_/[ Y&Z)A>I]HE%B#=" M&?!.[08"60)@_HD.Q_YK_^C9L(:X2[X'HCQHB*#0CKV$BORD+0@..;C4 #LI M3#1#FQ0-R&U8)Y@"G\02- '3O&\!!C&^2 M1'F?-110LJ14@'H<)V(!J\ M.VX51I$Q1,Z$=QPT8#*_KVM)45#*$*.D+E;"7J2"E. M0OQ.^[?CRXL] [C:R#35WZ:A)LPP!!*-15/;2!5J53J)!97S$ &T&Z4 !HJ2 MQU DJ9:RE7$KP;5",C@HNUHI0Z ]%<\NA;9)TV4Y%:R!., ]D'D]W<6Z4(:C M@;-NKUQ25#"WEJC8PNO<("7!:(HRC&E4"UJKW,N20+DSXA9!Y0I\>,)CQ]&N MV$R7U $1K R(\9HF@4X"KX;$=!Q!,V08O'J./:Y!>_^O+V['R@.QK$#\3Z% M2J4YBPG)JZ^Q])+V2GN>C*.\J_=TK-!(.*X7GH_;+%-4YP ),I83E@,"Y[J& ML(]^6RPP>":/8\"A(,%1 8X+J5H"G-XJZ)3.=9&>(CD:0VR <&X4MEJB\K)_ MU)<5UILZ]BH,L;IJJMY&Z"*28,>+T]D,LVY9XMANPGB<(&(IV_B22B)J)_4A M0Q*-N -+,0FX1S3\!?DXSYV*$5C<1% _*5:GN,6*E_TKT$.WX:@+E$83QF1E MR]B^]'R+XG*SPX;>OQ>'I[T/78IL0QO9%G1LGO%OX6R3;YO(H9T_W& ,M;F3 MU4%$XSGRH.XDU)%)!E]XB'L]A8F\1.&)F'.,;KA"=_/T+K$Q":?B[6PVGB$: M'K5DR/4=1^K&$2BA:Y);]HZI"R!@%%TD9^ZLY_1.E$I]MW\+.BZA8 5\071? MG$P&"%^^.)[\TK\9Q16RIPYWZP-.UT\-CIZR0\>[#O4]AJC"4\\:) Z@3-TL M2TR#O3C&_:-%$B![H/PHD00UC);@K=N]3M!] F%H!5%@ MC+',0=V<.B#YVF,66?.D=1",H8>\VT7QS>$ '$B>(660Q53DZ%"/ [WPL-%T M93OI:XQO;4K:@39"WMV5H#+KKT5^N!85$NQ;*L+7J5I2HK:] ]=HS;A!"!0W M-"M3.+D=DKYQ6ZC[>Q<&#D5]ENSB[H-??":3[O=NYNX*)=L>HAWM;&-="BL= M\0",Y4*S;# OHI5,Q&]()4SV";7J;X?0C%"*X^Y@(X6SDDZ7FUA9OHU15V9W MF0#K]JKJ;HTCA85,@4 WI&)&]*U?ACA!69U(7X@,%&CU;=E%PP1:'1:TA3D^ MCMG=B,UB2+ZD3R))4S5QQ$T5VJ'FM'IQ=,GFWRB5.R:K+[6*HDS>!M1 MICG**,\WG7&#*UT]Q5^,B8HF(X <&F)_5YDVXI?MLM27WK2]P- BM&$J\2K] M,1UWH]I;3*,-Q@I.!L'1_U_Y>K>I95,!LB/ M_7B'S60QUXRVYX#+*U;GNL)$*(3-<''R;>_?7L!UI91+VR+MU#Y)7<=(CJ7QY0D;65,W[@SFD'C<#C&'40V6 MW(Q9?X&N2N")-@,EZ]W?HXC[SX4,:+[+:]!$U]RHB7Q M'IOB2KNA^HH.P/%6]-W"4/"]K7AEZW;]W5M<'3N\'_<3UA/K1ME>L6%<.^=0V:-&/PRZY-TW,)/=764G MZSRG.@I+&0HF>R6-C$'LRQ77+IYD5)MOE,"Q:#@J/L_?>I^XU%(9'KX_;-6+ M+O6H%S)YMGF[.Q)UI:5KDW1JJT?2I9/I/7GJ4^%TZZ,P(I#SIV\:2P!S_#[< MK_9?U^?QH_*P/7Z:1^W/-?*@5!F.SB9O3D>1N-U+L#5_8E[:$&S%CQ12Y6@# M?L\L[IWM"RGH_\_AXM]02P,$% @ KSFI6)DQ/5.,"@ SQP !@ !X M;"]W;W)KE,EY;(YQ:G XF!Q_.CVD]+_B[5FO?^UM0)'-K M[^G#-#\=C,DA5:@LD 6)?Q[4A2H*,@0WOC4V!^V1M+'_=[+^B6-'+'/IU84M M_J'SL#H=O!^(7"UD782O=OUGU<3SANQEMO#\?[&.:X^/!B*K?;!ELQD>E-K$ M?^7W!H?>AO?C9S8<-AL.V>]X$'OY409Y=N+L6CA:#6OT!X?*N^&<-I2467#X M5F-?.)O=75U-OOY37'\2L^GG+]-/TXO)EULQN;BXOOMR._WR6=Q<_W5Z,;V< MG8P"SJ-=HZRQ?1YM'SYC^TA<61-67ER:7.6;^T?PLW7V,#E[?OBBP2OI]L71 MP5 ?&OR=P'AV+Y][: H[WC M[?:H@3[X2F;J=( .\FGT0F?2!'1<"V^5X(T[52ZT$0&6@%,EG>0.Q78\\DID M%@5C/%;A+X^MN0SXL-!&FDS+0OB !Z &\)&X<1H/JP+&8:#;0!;)5_*BK*1Y M)#]>85FLY(,2\;=,1%#":NP^/URM(Q=FU@U==S MKW,M': >BO-"9O?BHY8EHB8LG*Q4'73FQ4QEM=/A$>9<91O\R>0+>W8NI)&Y MW!V*J,G&W&=!3N' MQ8,Q-_C1BP%L.B/6THM<>V3T 3#,'_& R_'!%CB0:C-^6]-Q^TB"K',=LP+_ M=-FK &WBJ$OU\YJ2^2%'31YS <\5\O^THH9<1!B6@AT:BJIVOB;@@F53KJ9R M(KR<6M8%N]6>,[N\V!<7R@4,WPV_:?W"VF!L4!1Y5EA?@Y&$H254+ZUKV+DU ME)=JGBJU%TR'D'7"ECHP/LZ6'18\3A\/4,(#WP+' (PH5HH'NSYM391%G! !.;6O>0+@>AIB5-( M2A^X7JY__NG]X<&[7[R8&%/#1@Q5X 2#ZCIO;\@(XZW/"J)OJ&9*#ZJ3)54 M],U4.]I'/?,B6VG3D>*38TJ4_Y*=''+/R?Q7B(7H] YAHCUS$K;'G#>PHNT= M/>^MWV4,=:XHVP8.>4\-0]Y*L9#:=8 D;U!*4#V^C2AU$5*J;<[%X[&<*K^M MD@0LPR=02Q7%>U3GVK-75"!R"U6BGO5<\A MPDIZC+4J]EM8273H8@$IV<1/V<798*9$SEBOFHHIM)SK0@?=F'INB_I>43R@ MKIJ3TJWC<1+!W!>S'I\^[R/4+$G=MC)?V25->H9B3F3D%)6](&ZG'<$.TS!R M5-WPG3(L'9J6_,C5 ^1]Q6BV0:7('V11MWF%H,WN]TA'P_NU=!3?;8\RZ1O/ M@ZV+%#O!(\'2F"S8/N8;R&@H[@WF'B8)FBF>9ZE-D4UWK\*>KU1&N#$M\1<. MMX$'@G&!P6-=DU@=4*&%1@R>:B$2A;=&S@LE:D 8BSS3+JM+0(:CX?5EEPF@ M%9-%#H+GG'K [2%FHJ!K 2N3E31+%2NS;VG(SD3WN]C Z]UZM7$4FAATV)-0 M?#1]6J]TQF0&'+&H5!$@8M! :4MM6TJ:ARAGEVC:^G[Y4^=WE;69(%02JK.. M4&$NZY X -]G'.FRL'-*%)9B&F3]ZD"T) 4#9[(V< C\M0)$-+XBX0]I8+FZ MJ6I"2U8Z8'G,*BSTD&3BB>H#*R I>XAEG[9(WZ?+S\@I+4V8001I(K$_7H(CXTT)@J1Y](LKCO>1HRT]:89ZS8((G+4 MFC5,,[V(L0!Q73%Z&V2Y#^61P0I)/$!*+-N_H* C*X',2UA^:&Q"L>ZE1#OG?C< MZ9G;W>\;[\8R!UO5AJ&2[&*CBTMHKL:MY :.6F@F1*K@(?=JKP&B M\O08WQO51'UAO4Z/HO)+)F.[)71B&RH*Y;DSF2..XKEH\2).O?X!W.'4_EUA M4,Q1H!O"LI#="Y*57<=:HB5UQ%@]06$'_?HL$'PEI]'D">]VC7),66DP0\K8 M+*8$%6!KQZJ5&P#K\^9^6WA+'B:MGIHY&>V52U-+K5RA[E%KL:QU?#/PA",6 MV(MNH-ON;[/"T7 KF325\BI3()A+KM1^H[5[6M:^#VF&$?-(U.UT;8R+[6O)YI9@4>X_'FAK;"M49H\\8:P3/MWL3]%F&]'?;8:).[]A!USK3"+DXV\/ZJ? 7J5(E"9I<7 M;>OT#-Y%?4.AS !,T9F;XMJAX[3MT=[;_X^M/VAL;?NU8M3[D:E4;LD_I9$Q M4''\O:E]VOY:-XD_4G7+XT]]5](!;"\*M<#6\?Z[-P/AXL]G\4.P%?]D-;TOV&>_0=02P,$% @ KSFI6 \VTL_F! MMPL !@ !X;"]W;W)KHRRI.'+0%^F*+Y,SA MF<.9(4^VVCS9',"Q[X54]C3(G2OGPZ%-@2%*YDVA3.)H:+ MDY*OX0[<0WEC<#3L4%)1@+)"*V8@.PV6H_G9A.R]P:. K>U],XIDI?43#:[2 MTR B0B A<83 \6\#YR E 2&-YP8SZ+8DQ_YWB_[%QXZQK+B% \)+M+3^EVUKV_$D8$EEG2X:9V10"%7_\^^-#CV'6;3' M(6X<8L^[WLBSO.".+TZ,WC)#UHA&'SY4[XWDA*)#N7,&5P7ZN<67Y=4M>UQ^ M?;ADUY?+NX?;R^O+W^[O3H8.P U-P,V'H4LCN+)!WCC+M*QQQOOBY0+PQZYK(!=")M(;2L#EOV^ M7%EG,#G^>"_F&G+R/B05S-R6/('3 "O"@ME L/C\:708'7] >-(1GGR$_F^. MYC\!L?L<6*8EUJ50:^;X2J(>/A#EF%!UQ?O266$Y,X?FY[HHN7KY_&D6CZ;' MEF5"<94(+AFW%IQE7*5,"KX24CB!< 5PTCEEW+&,3F#C3X! L::3RAC:&^M* MU+Y"I2+A#OQN$C8@F<[\H.>="S#<)/D+JRQ".XUUZ,!@>0!VER3OV=HY^_+# ML6Ƃ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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 128 228 1 false 38 0 false 6 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.blackdiamondtherapeutics.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 0000007 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION Sheet http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION NATURE OF BUSINESS AND BASIS OF PRESENTATION Notes 7 false false R8.htm 0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 0000009 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS FAIR VALUE MEASUREMENTS Notes 9 false false R10.htm 0000010 - Disclosure - INVESTMENTS Sheet http://www.blackdiamondtherapeutics.com/role/INVESTMENTS INVESTMENTS Notes 10 false false R11.htm 0000011 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT PROPERTY AND EQUIPMENT Notes 11 false false R12.htm 0000012 - Disclosure - EQUITY METHOD INVESTMENT Sheet http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENT EQUITY METHOD INVESTMENT Notes 12 false false R13.htm 0000013 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Sheet http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Notes 13 false false R14.htm 0000014 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION STOCK-BASED COMPENSATION Notes 14 false false R15.htm 0000015 - Disclosure - NET LOSS PER SHARE Sheet http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE NET LOSS PER SHARE Notes 15 false false R16.htm 0000016 - Disclosure - LEASES Sheet http://www.blackdiamondtherapeutics.com/role/LEASES LEASES Notes 16 false false R17.htm 0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 17 false false R18.htm 0000018 - Disclosure - BENEFIT PLANS Sheet http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS BENEFIT PLANS Notes 18 false false R19.htm 0000019 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTS SUBSEQUENT EVENTS Notes 19 false false R20.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 20 false false R21.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 21 false false R22.htm 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 22 false false R23.htm 9954472 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS 23 false false R24.htm 9954473 - Disclosure - INVESTMENTS (Tables) Sheet http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables INVESTMENTS (Tables) Tables http://www.blackdiamondtherapeutics.com/role/INVESTMENTS 24 false false R25.htm 9954474 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables PROPERTY AND EQUIPMENT (Tables) Tables http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT 25 false false R26.htm 9954475 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) Sheet http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) Tables http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES 26 false false R27.htm 9954476 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables STOCK-BASED COMPENSATION (Tables) Tables http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION 27 false false R28.htm 9954477 - Disclosure - NET LOSS PER SHARE (Tables) Sheet http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables NET LOSS PER SHARE (Tables) Tables http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE 28 false false R29.htm 9954478 - Disclosure - LEASES (Tables) Sheet http://www.blackdiamondtherapeutics.com/role/LEASESTables LEASES (Tables) Tables http://www.blackdiamondtherapeutics.com/role/LEASES 29 false false R30.htm 9954479 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details) Sheet http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details) Details http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION 30 false false R31.htm 9954480 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Sheet http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Details 31 false false R32.htm 9954481 - Disclosure - INVESTMENTS - Schedule of Marketable Securities (Details) Sheet http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails INVESTMENTS - Schedule of Marketable Securities (Details) Details 32 false false R33.htm 9954482 - Disclosure - INVESTMENTS - Additional Information (Details) Sheet http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails INVESTMENTS - Additional Information (Details) Details 33 false false R34.htm 9954483 - Disclosure - PROPERTY AND EQUIPMENT (Details) Sheet http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails PROPERTY AND EQUIPMENT (Details) Details http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables 34 false false R35.htm 9954484 - Disclosure - EQUITY METHOD INVESTMENT (Details) Sheet http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails EQUITY METHOD INVESTMENT (Details) Details http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENT 35 false false R36.htm 9954485 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) Sheet http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) Details http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables 36 false false R37.htm 9954486 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) Sheet http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails STOCK-BASED COMPENSATION - Narrative (Details) Details 37 false false R38.htm 9954487 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details) Sheet http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details) Details 38 false false R39.htm 9954488 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details) Sheet http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details) Details 39 false false R40.htm 9954489 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details) Sheet http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details) Details 40 false false R41.htm 9954490 - Disclosure - NET LOSS PER SHARE - Computation of Net Loss per Share (Details) Sheet http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails NET LOSS PER SHARE - Computation of Net Loss per Share (Details) Details 41 false false R42.htm 9954491 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details) Sheet http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details) Details 42 false false R43.htm 9954492 - Disclosure - LEASES - Narrative (Details) Sheet http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails LEASES - Narrative (Details) Details 43 false false R44.htm 9954493 - Disclosure - LEASES - Summary of Lease Cost and Other Operating Lease Information (Details) Sheet http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails LEASES - Summary of Lease Cost and Other Operating Lease Information (Details) Details 44 false false R45.htm 9954494 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details) Sheet http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails LEASES - Schedule of Future Minimum Lease Payments (Details) Details 45 false false R46.htm 9954495 - Disclosure - BENEFIT PLANS (Details) Sheet http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails BENEFIT PLANS (Details) Details http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS 46 false false R47.htm 9954496 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTSDetails SUBSEQUENT EVENTS (Details) Details http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTS 47 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: ecd:TrdArrDuration, us-gaap:LesseeOperatingLeaseRenewalTerm - bdtx-20240331.htm 4 bdtx-20240331.htm bdtx-20240331.xsd bdtx-20240331_cal.xml bdtx-20240331_def.xml bdtx-20240331_lab.xml bdtx-20240331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 65 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bdtx-20240331.htm": { "nsprefix": "bdtx", "nsuri": "http://www.blackdiamondtherapeutics.com/20240331", "dts": { "inline": { "local": [ "bdtx-20240331.htm" ] }, "schema": { "local": [ "bdtx-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "bdtx-20240331_cal.xml" ] }, "definitionLink": { "local": [ "bdtx-20240331_def.xml" ] }, "labelLink": { "local": [ "bdtx-20240331_lab.xml" ] }, "presentationLink": { "local": [ "bdtx-20240331_pre.xml" ] } }, "keyStandard": 216, "keyCustom": 12, "axisStandard": 14, "axisCustom": 0, "memberStandard": 22, "memberCustom": 12, "hidden": { "total": 11, "http://xbrl.sec.gov/dei/2023": 5, "http://xbrl.sec.gov/ecd/2023": 2, "http://fasb.org/us-gaap/2023": 4 }, "contextCount": 128, "entityCount": 1, "segmentCount": 38, "elementCount": 432, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 427, "http://xbrl.sec.gov/dei/2023": 30, "http://xbrl.sec.gov/ecd/2023": 17 }, "report": { "R1": { "role": "http://www.blackdiamondtherapeutics.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "unique": true } }, "R3": { "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "longName": "0000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "unique": true } }, "R6": { "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-8", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-8", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION", "longName": "0000007 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION", "shortName": "NATURE OF BUSINESS AND BASIS OF PRESENTATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "longName": "0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS", "longName": "0000009 - Disclosure - FAIR VALUE MEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.blackdiamondtherapeutics.com/role/INVESTMENTS", "longName": "0000010 - Disclosure - INVESTMENTS", "shortName": "INVESTMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT", "longName": "0000011 - Disclosure - PROPERTY AND EQUIPMENT", "shortName": "PROPERTY AND EQUIPMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENT", "longName": "0000012 - Disclosure - EQUITY METHOD INVESTMENT", "shortName": "EQUITY METHOD INVESTMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES", "longName": "0000013 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION", "longName": "0000014 - Disclosure - STOCK-BASED COMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE", "longName": "0000015 - Disclosure - NET LOSS PER SHARE", "shortName": "NET LOSS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.blackdiamondtherapeutics.com/role/LEASES", "longName": "0000016 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "0000017 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS", "longName": "0000018 - Disclosure - BENEFIT PLANS", "shortName": "BENEFIT PLANS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTS", "longName": "0000019 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true }, "uniqueAnchor": null }, "R21": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "longName": "9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables", "longName": "9954472 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables", "longName": "9954473 - Disclosure - INVESTMENTS (Tables)", "shortName": "INVESTMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables", "longName": "9954474 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables", "longName": "9954475 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables", "longName": "9954476 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "shortName": "STOCK-BASED COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables", "longName": "9954477 - Disclosure - NET LOSS PER SHARE (Tables)", "shortName": "NET LOSS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.blackdiamondtherapeutics.com/role/LEASESTables", "longName": "9954478 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails", "longName": "9954479 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)", "shortName": "NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-32", "name": "bdtx:SaleOfStockAuthorizedConsideration", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "unique": true } }, "R31": { "role": "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "longName": "9954480 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)", "shortName": "FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-52", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-52", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails", "longName": "9954481 - Disclosure - INVESTMENTS - Schedule of Marketable Securities (Details)", "shortName": "INVESTMENTS - Schedule of Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails", "longName": "9954482 - Disclosure - INVESTMENTS - Additional Information (Details)", "shortName": "INVESTMENTS - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails", "longName": "9954483 - Disclosure - PROPERTY AND EQUIPMENT (Details)", "shortName": "PROPERTY AND EQUIPMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails", "longName": "9954484 - Disclosure - EQUITY METHOD INVESTMENT (Details)", "shortName": "EQUITY METHOD INVESTMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-81", "name": "us-gaap:GainLossOnDispositionOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-81", "name": "us-gaap:GainLossOnDispositionOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails", "longName": "9954485 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-3", "name": "bdtx:AccruedContractResearchServiceFeesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "bdtx:AccruedContractResearchServiceFeesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "longName": "9954486 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)", "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails", "longName": "9954487 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details)", "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-95", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "unique": true } }, "R39": { "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails", "longName": "9954488 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)", "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "unique": true } }, "R40": { "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails", "longName": "9954489 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details)", "shortName": "STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-99", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-99", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails", "longName": "9954490 - Disclosure - NET LOSS PER SHARE - Computation of Net Loss per Share (Details)", "shortName": "NET LOSS PER SHARE - Computation of Net Loss per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true }, "uniqueAnchor": null }, "R42": { "role": "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails", "longName": "9954491 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)", "shortName": "NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails", "longName": "9954492 - Disclosure - LEASES - Narrative (Details)", "shortName": "LEASES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "bdtx:LesseeOperatingLeaseNumberOfContracts", "unitRef": "contract", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "bdtx:LesseeOperatingLeaseNumberOfContracts", "unitRef": "contract", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails", "longName": "9954493 - Disclosure - LEASES - Summary of Lease Cost and Other Operating Lease Information (Details)", "shortName": "LEASES - Summary of Lease Cost and Other Operating Lease Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails", "longName": "9954494 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details)", "shortName": "LEASES - Schedule of Future Minimum Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails", "longName": "9954495 - Disclosure - BENEFIT PLANS (Details)", "shortName": "BENEFIT PLANS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTSDetails", "longName": "9954496 - Disclosure - SUBSEQUENT EVENTS (Details)", "shortName": "SUBSEQUENT EVENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-124", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdtx-20240331.htm", "unique": true } } }, "tag": { "bdtx_A2020EmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240331", "localname": "A2020EmployeeStockPurchasePlanMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2020 ESPP", "label": "2020 Employee Stock Purchase Plan [Member]", "documentation": "2020 Employee Stock Purchase Plan" } } }, "auth_ref": [] }, "bdtx_A2020StockOptionPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240331", "localname": "A2020StockOptionPlanMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2020 Stock Option Plan", "label": "2020 Stock Option Plan [Member]", "documentation": "2020 Stock Option Plan" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" ], "lang": { "en-us": { "role": { "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r12", "r441" ] }, "bdtx_AccruedContractResearchServiceFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240331", "localname": "AccruedContractResearchServiceFeesCurrent", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contracted research services", "label": "Accrued Contract Research Service Fees, Current", "documentation": "Accrued Contract Research Service Fees, Current" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails", "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total accrued expenses and other current liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r14" ] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Professional and consulting fees", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r14" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r28", "r93", "r359" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r18", "r19", "r46", "r95", "r356", "r370", "r371" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income (loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r6", "r19", "r271", "r274", "r312", "r366", "r367", "r542", "r543", "r544", "r549", "r550", "r551" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r490" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r41", "r441", "r614" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r259", "r260", "r261", "r375", "r549", "r550", "r551", "r604", "r615" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r496" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r496" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r496" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r496" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r32", "r33", "r225" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r461", "r472", "r482", "r507" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r464", "r475", "r485", "r510" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r496" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r503" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r468", "r476", "r486", "r503", "r511", "r515", "r523" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r521" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r254", "r262" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r134" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r22" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r22" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r71", "r94", "r112", "r139", "r143", "r145", "r185", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r266", "r268", "r289", "r352", "r397", "r441", "r452", "r573", "r574", "r610" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r89", "r96", "r112", "r185", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r266", "r268", "r289", "r441", "r573", "r574", "r610" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r35" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets:", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "bdtx_AtMarketEquityProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240331", "localname": "AtMarketEquityProgramMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails", "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ATM Program", "label": "At Market Equity Program [Member]", "documentation": "At Market Equity Program" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r154" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r155" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r151", "r194", "r351" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r152", "r194", "r347", "r553" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Debt Securities, Available-for-Sale, Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r148", "r194" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r518" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r519" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r514" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r514" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r514" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r514" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r514" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r514" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r517" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r516" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r515" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r515" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of consolidation and unaudited interim financial information", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "lang": { "en-us": { "role": { "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r58" ] }, "bdtx_BrentHatzisSchochMember": { "xbrltype": "domainItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240331", "localname": "BrentHatzisSchochMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Brent Hatzis-Schoch [Member]", "documentation": "Brent Hatzis-Schoch" } } }, "auth_ref": [] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION" ], "lang": { "en-us": { "role": { "terseLabel": "NATURE OF BUSINESS AND BASIS OF PRESENTATION", "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r38", "r58", "r59" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents, end of period", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r21", "r91", "r428" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents:", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "totalLabel": "Cash, cash equivalents and restricted cash, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r21", "r55", "r111" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r55" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r494" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r495" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r495" ] }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "verboseLabel": "Commercial paper", "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents." } } }, "auth_ref": [ "r575", "r605" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note\u00a011)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r16", "r36", "r353", "r384" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r63", "r201", "r202", "r427", "r572" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r442", "r443", "r444", "r446", "r447", "r448", "r449", "r549", "r550", "r604", "r613", "r615" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r40" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r40", "r385" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r40" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r7", "r40", "r385", "r403", "r615", "r616" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock; $0.0001 par value; 500,000,000 shares authorized at March\u00a031, 2024 and December\u00a031, 2023; 52,527,626 shares issued and outstanding at March\u00a031, 2024 and 51,645,557 shares issued and outstanding at December\u00a031, 2023", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r40", "r355", "r441" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r500" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r499" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r501" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r498" ] }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS" ], "lang": { "en-us": { "role": { "terseLabel": "BENEFIT PLANS", "label": "Compensation and Employee Benefit Plans [Text Block]", "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans." } } }, "auth_ref": [ "r65", "r66", "r67", "r68" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r20", "r100", "r102", "r106", "r348", "r364" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive loss:", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r34", "r429" ] }, "us-gaap_CorporateBondSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateBondSecuritiesMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate bonds", "verboseLabel": "Corporate bonds", "label": "Corporate Bond Securities [Member]", "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded", "crdr": "debit", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of fair value assets", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Not Previously Recorded", "documentation": "Amount of expense for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), for which no credit loss was previously recorded." } } }, "auth_ref": [ "r198" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Marketable Securities", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566" ] }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "crdr": "debit", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employer contribution amount", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employer contribution, percent of each participant's salary", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employer contribution, matching contribution percentage", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "documentation": "Percentage employer matches of the employee's percentage contribution matched." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r4", "r27" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION" ], "lang": { "en-us": { "role": { "terseLabel": "STOCK-BASED COMPENSATION", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r223", "r227", "r255", "r256", "r258", "r439" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r456" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r489" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, basic (in dollars per share)", "verboseLabel": "Net loss per share, basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r107", "r118", "r119", "r120", "r121", "r122", "r127", "r129", "r131", "r132", "r133", "r137", "r278", "r279", "r349", "r365", "r430" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, diluted (in dollars per share)", "verboseLabel": "Net loss per share, diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r107", "r118", "r119", "r120", "r121", "r122", "r129", "r131", "r132", "r133", "r137", "r278", "r279", "r349", "r365", "r430" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE" ], "lang": { "en-us": { "role": { "terseLabel": "NET LOSS PER SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r126", "r134", "r135", "r136" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payroll and related expenses", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r14" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation cost, recognition period (in years)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r257" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation cost", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r602" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation cost, options", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r602" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issuable under employee stock purchase plan", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock options", "terseLabel": "Options to purchase common stock", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r454" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r454" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r529" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r454" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r528" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r454" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r454" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r454" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r454" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r7", "r87", "r103", "r104", "r105", "r113", "r114", "r115", "r117", "r123", "r125", "r138", "r187", "r188", "r216", "r259", "r260", "r261", "r264", "r265", "r270", "r271", "r272", "r273", "r274", "r275", "r277", "r290", "r291", "r292", "r293", "r294", "r295", "r312", "r366", "r367", "r368", "r375", "r423" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r181", "r182", "r184" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investment, ownership percentage", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r181" ] }, "bdtx_EquityMethodInvestmentSharesReceivedInNoncashExchange": { "xbrltype": "sharesItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240331", "localname": "EquityMethodInvestmentSharesReceivedInNoncashExchange", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common shares received from equity method investment (in shares)", "label": "Equity Method Investment, Shares Received in Noncash Exchange", "documentation": "Equity Method Investment, Shares Received in Noncash Exchange" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investment", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r141", "r180", "r539", "r570" ] }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "lang": { "en-us": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsDisclosureTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENT" ], "lang": { "en-us": { "role": { "terseLabel": "EQUITY METHOD INVESTMENT", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group." } } }, "auth_ref": [ "r85", "r183", "r186", "r530" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r497" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r461", "r472", "r482", "r507" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r458", "r469", "r479", "r504" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r503" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r281", "r282", "r285" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r281", "r282", "r285" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r212", "r217", "r218", "r219", "r220", "r221", "r222", "r282", "r319", "r320", "r321", "r434", "r435", "r436", "r437", "r438" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r281", "r282", "r283", "r284", "r286" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE MEASUREMENTS", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r280" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r212", "r217", "r222", "r282", "r319", "r436", "r437", "r438" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r212", "r217", "r222", "r282", "r320", "r434", "r435", "r436", "r437", "r438" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a03", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r212", "r217", "r218", "r219", "r220", "r221", "r222", "r282", "r321", "r434", "r435", "r436", "r437", "r438" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r212", "r217", "r218", "r219", "r220", "r221", "r222", "r319", "r320", "r321", "r434", "r435", "r436", "r437", "r438" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r280", "r286" ] }, "bdtx_FangNiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240331", "localname": "FangNiMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Fang Ni [Member]", "documentation": "Fang Ni" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r189", "r190", "r191", "r192", "r193", "r195", "r196", "r197", "r213", "r215", "r276", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r363", "r433", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r566", "r567", "r568", "r569" ] }, "bdtx_FollowOnOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240331", "localname": "FollowOnOfferingMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Follow-on Offering", "label": "Follow-on Offering [Member]", "documentation": "Follow-on Offering" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r465", "r476", "r486", "r511" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r465", "r476", "r486", "r511" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r465", "r476", "r486", "r511" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r465", "r476", "r486", "r511" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r465", "r476", "r486", "r511" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and fixtures", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainLossOnDispositionOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnDispositionOfIntangibleAssets", "crdr": "credit", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on sale of IP", "label": "Gain (Loss) on Disposition of Intangible Assets", "documentation": "Amount of gain (loss) on sale or disposal of intangible assets." } } }, "auth_ref": [ "r546" ] }, "bdtx_GainLossOnSaleOfEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240331", "localname": "GainLossOnSaleOfEquipment", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on sale of equipment", "label": "Gain (Loss) on Sale of Equipment", "documentation": "Gain (Loss) on Sale of Equipment" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r50", "r407" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r49" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss recognized from equity method investment", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r4", "r47", "r73", "r140", "r180", "r361" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r199", "r200", "r408" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r200", "r408" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable, Trade", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": [ "r545" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in current assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "bdtx_IncreaseDecreaseInOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240331", "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current operating lease liabilities", "label": "Increase (Decrease) in Operating Lease Liabilities", "documentation": "Increase (Decrease) in Operating Lease Liabilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r468", "r476", "r486", "r503", "r511", "r515", "r523" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r521" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r457", "r527" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r457", "r527" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r457", "r527" ] }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "(Accretion) amortization on investments", "label": "Investment Income, Net, Amortization of Discount and Premium", "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities." } } }, "auth_ref": [ "r52" ] }, "us-gaap_InvestmentIncomeNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeNonoperating", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Nonoperating", "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations." } } }, "auth_ref": [ "r51" ] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments:", "label": "Investments, Fair Value Disclosure", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": [ "r281" ] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "INVESTMENTS", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r70", "r75", "r76", "r86", "r147", "r149", "r287", "r288" ] }, "bdtx_LaunchpadTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240331", "localname": "LaunchpadTherapeuticsIncMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Launchpad Therapeutics, Inc.", "label": "Launchpad Therapeutics, Inc. [Member]", "documentation": "Launchpad Therapeutics, Inc." } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseContractualTermAxis", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Contractual Term [Axis]", "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": [ "r531" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseContractualTermDomain", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Contractual Term [Domain]", "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": [ "r531" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r303", "r440" ] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostAbstract", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Cost", "label": "Lease, Cost [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lease Cost and Other Operating Lease Information", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r608" ] }, "bdtx_LeaseOtherInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240331", "localname": "LeaseOtherInformationAbstract", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Operating Lease Information", "label": "Lease, Other Information [Abstract]", "documentation": "Lease, Other Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r62" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r302" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r302" ] }, "bdtx_LesseeOperatingLeaseArea": { "xbrltype": "areaItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240331", "localname": "LesseeOperatingLeaseArea", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Area leased (square feet)", "label": "Lessee, Operating Lease, Area", "documentation": "Lessee, Operating Lease, Area" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Lease Payments", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r609" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r311" ] }, "bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240331", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Four", "documentation": "Lessee, Operating Lease, Liability, Payments, Due after Year Four" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r311" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r311" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r311" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r311" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 (excluding the three months ended March\u00a031, 2024)", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r609" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r311" ] }, "bdtx_LesseeOperatingLeaseNumberOfContracts": { "xbrltype": "integerItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240331", "localname": "LesseeOperatingLeaseNumberOfContracts", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of leases", "label": "Lessee, Operating Lease, Number Of Contracts", "documentation": "Lessee, Operating Lease, Number Of Contracts" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease term, optional extension (in years)", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r607" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease term (in years)", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r607" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r297" ] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letter of credit outstanding", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r13", "r112", "r185", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r267", "r268", "r269", "r289", "r383", "r431", "r452", "r573", "r610", "r611" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r45", "r72", "r358", "r441", "r548", "r571", "r606" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Stockholders' Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r15", "r90", "r112", "r185", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r267", "r268", "r269", "r289", "r441", "r573", "r610", "r611" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r495" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r495" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r514" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r575" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r522" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r496" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r110" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r110" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r55", "r56", "r57" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "verboseLabel": "Net loss", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r48", "r57", "r74", "r88", "r99", "r101", "r105", "r112", "r116", "r118", "r119", "r120", "r121", "r124", "r125", "r130", "r139", "r142", "r144", "r146", "r185", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r279", "r289", "r362", "r405", "r421", "r422", "r432", "r450", "r573" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently issued accounting pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r495" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r465", "r476", "r486", "r503", "r511" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r493" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r492" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r503" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r522" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r522" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r51" ] }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Activity", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares." } } }, "auth_ref": [ "r11" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r139", "r142", "r144", "r146", "r432" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r304", "r440" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, to be Paid [Abstract]", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total lease liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r299" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of operating lease liability", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r299" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r300" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r299" ] }, "bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240331", "localname": "OperatingLeaseOfficeAndLaboratorySpaceNYMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Office and Laboratory Space, NY", "label": "Operating Lease, Office and Laboratory Space, NY [Member]", "documentation": "Operating Lease, Office and Laboratory Space, NY" } } }, "auth_ref": [] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of lease liability", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r301", "r308" ] }, "bdtx_OperatingLeasePrincipalOfficeTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240331", "localname": "OperatingLeasePrincipalOfficeTwoMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal office, lease two", "label": "Operating Lease, Principal Office, Two [Member]", "documentation": "Operating Lease, Principal Office, Two" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r298" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r310", "r440" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term (in years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r309", "r440" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "bdtx_OtherAwardTypeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240331", "localname": "OtherAwardTypeMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Purchase Plan and Other", "label": "Other Award Type [Member]", "documentation": "Other Award Type" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on investments, net", "verboseLabel": "Unrealized gain (loss) on investments", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r97", "r98" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss):", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeAndExpensesAbstract", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense):", "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense)", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r53" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r495" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r463", "r474", "r484", "r509" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r466", "r477", "r487", "r512" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r466", "r477", "r487", "r512" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r491" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r54" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r494" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r494" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r493" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r503" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r496" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r492" ] }, "bdtx_PerformanceRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240331", "localname": "PerformanceRestrictedStockUnitsMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Performance restricted stock units", "label": "Performance Restricted Stock Units [Member]", "documentation": "Performance Restricted Stock Units" } } }, "auth_ref": [] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PerformanceSharesMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Unvested performance restricted stock units", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r39", "r214" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r39", "r385" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r39", "r214" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r39", "r385", "r403", "r615", "r616" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March\u00a031, 2024 and December\u00a031, 2023; no shares issued or outstanding at March\u00a031, 2024 and December\u00a031, 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r39", "r354", "r441" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r541" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock, net of issuance costs", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of common stock options and ESPP", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised." } } }, "auth_ref": [ "r2", "r10" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from equity financing", "label": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r2", "r373" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales and maturities of investments", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r108", "r109", "r554" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r5" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT" ], "lang": { "en-us": { "role": { "terseLabel": "PROPERTY AND EQUIPMENT", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r61", "r80", "r83", "r84" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r62", "r92", "r360" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Total Property and Equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r5", "r350", "r360", "r441" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property, Plant and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r5" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r62" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r491" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r491" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r458", "r469", "r479", "r504" ] }, "bdtx_RentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240331", "localname": "RentExpense", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Noncash rent expense", "label": "Rent Expense", "documentation": "Rent Expense" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "crdr": "debit", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development asset acquired other than through business combination, written-off", "label": "Research and Development Asset Acquired Other than Through Business Combination, Writeoff", "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination." } } }, "auth_ref": [ "r26", "r603" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r37", "r263", "r612" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r459", "r470", "r480", "r505" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r460", "r471", "r481", "r506" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r467", "r478", "r488", "r513" ] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 }, "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "verboseLabel": "Restricted cash, end of period", "label": "Restricted Cash, Noncurrent", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r77", "r540", "r547" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Unvested restricted stock", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r22" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "negatedTerseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r42", "r64", "r357", "r369", "r371", "r374", "r386", "r441" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r87", "r113", "r114", "r115", "r117", "r123", "r125", "r187", "r188", "r259", "r260", "r261", "r264", "r265", "r270", "r272", "r273", "r275", "r277", "r366", "r368", "r375", "r615" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r522" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r522" ] }, "bdtx_SaleOfStockAuthorizedConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240331", "localname": "SaleOfStockAuthorizedConsideration", "crdr": "debit", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, authorized consideration", "label": "Sale of Stock, Authorized Consideration", "documentation": "Sale of Stock, Authorized Consideration" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails", "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, net of offering costs", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails", "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails", "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares sold (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock price (in dollars per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Expenses", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Computation of Net Loss per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r552" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-Based Compensation", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r31" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r181", "r182", "r184" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Line Items]", "label": "Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r112", "r181", "r182", "r184", "r185", "r289" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/EQUITYMETHODINVESTMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Table]", "label": "Schedule of Equity Method Investments [Table]", "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available." } } }, "auth_ref": [ "r88", "r112", "r181", "r182", "r184", "r185", "r289" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r281", "r282" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r224", "r226", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r8", "r9", "r30" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of each class", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r453" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Name of each exchange on which registered", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r455" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r3" ] }, "bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding": { "xbrltype": "percentItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase of authorized shares, percent of common stock outstanding", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r244" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r242" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units outstanding (in shares)", "periodStartLabel": "Unvested restricted common stock, beginning balance (in shares)", "periodEndLabel": "Unvested restricted common stock, ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r239", "r240" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number\u00a0of shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Unvested restricted common stock, beginning balance (in dollars per share)", "periodEndLabel": "Unvested restricted common stock, ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r239", "r240" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant\u00a0date fair value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units vested (in shares)", "negatedTerseLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r243" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of units vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r246" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r243" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r224", "r226", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253" ] }, "bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount", "crdr": "credit", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum employee subscription amount", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum employee subscription rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan." } } }, "auth_ref": [ "r29" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of additional shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Life and Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r233" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r233" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Expired (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r238" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Canceled or forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r237" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r235" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options outstanding, intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r29" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning balance (in shares)", "periodEndLabel": "Outstanding, ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r231", "r232" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning balance (in dollars per share)", "periodEndLabel": "Outstanding, ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r231", "r232" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested or expected to vest, intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r247" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested or expected to vest (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r247" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested or expected to vest (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r247" ] }, "bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award purchase period (in months)", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period", "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued under share-based compensation plan", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": [ "r29" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r236" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expired (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r238" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cancelled or forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r237" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r235" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable, intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r29" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable, remaining life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r29" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options outstanding, remaining life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r69" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested or expected to vest, remaining life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r247" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum percent of fair market value of common stock", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Surrender of shares for taxes (in shares)", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "bdtx_ShelfRegistrationStatementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.blackdiamondtherapeutics.com/20240331", "localname": "ShelfRegistrationStatementMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shelf Registration Statement", "label": "Shelf Registration Statement [Member]", "documentation": "Shelf Registration Statement" } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term lease cost", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r305", "r440" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r7", "r17", "r87", "r103", "r104", "r105", "r113", "r114", "r115", "r117", "r123", "r125", "r138", "r187", "r188", "r216", "r259", "r260", "r261", "r264", "r265", "r270", "r271", "r272", "r273", "r274", "r275", "r277", "r290", "r291", "r292", "r293", "r294", "r295", "r312", "r366", "r367", "r368", "r375", "r423" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r113", "r114", "r115", "r138", "r346", "r372", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r385", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r398", "r399", "r400", "r401", "r402", "r404", "r406", "r407", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r423", "r445" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r113", "r114", "r115", "r138", "r346", "r372", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r385", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r398", "r399", "r400", "r401", "r402", "r404", "r406", "r407", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r423", "r445" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r462", "r473", "r483", "r508" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock related to ESPP (in shares)", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r7", "r39", "r40", "r64" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock, net of issuance costs (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r7", "r39", "r40", "r64", "r373", "r423", "r426" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting of restricted stock units (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r7", "r39", "r40", "r64" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r7", "r39", "r40", "r64" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercise of common stock options (in shares)", "negatedLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r7", "r39", "r40", "r64", "r236" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock related to ESPP", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r7", "r39", "r40", "r64" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails", "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock, net of issuance costs", "verboseLabel": "Sale of stock, gross", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r7", "r39", "r40", "r64", "r375", "r423", "r426", "r451" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of common stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r7", "r17", "r64" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r40", "r43", "r44", "r60", "r387", "r403", "r424", "r425", "r441", "r452", "r548", "r571", "r606", "r615" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubleaseIncome", "crdr": "credit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": { "parentTag": "us-gaap_LeaseCost", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Sublease income", "label": "Sublease Income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": [ "r307", "r440" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r296", "r314" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r296", "r314" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r296", "r314" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r296", "r314" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r296", "r314" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTS" ], "lang": { "en-us": { "role": { "terseLabel": "SUBSEQUENT EVENTS", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r313", "r315" ] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "documentation": "Different names of stock transactions and the different attributes of each transaction." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails", "http://www.blackdiamondtherapeutics.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockLineItems", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiary, Sale of Stock [Line Items]", "label": "Subsidiary, Sale of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r502" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r494" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r501" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r521" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r523" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol(s)", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r213", "r215", "r276", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r363", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r566", "r567", "r568", "r569" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r524" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r525" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r523" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r523" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r526" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r524" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r520" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r23", "r24", "r25", "r78", "r79", "r81", "r82" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease cost", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r306", "r440" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants to purchase common stock", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r442", "r443", "r446", "r447", "r448", "r449" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares outstanding, diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r128", "r133" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares outstanding, basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r127", "r133" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//710/tableOfContent" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "712", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//712/tableOfContent" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715/tableOfContent" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//940-320/tableOfContent" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//942-320/tableOfContent" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//946-320/tableOfContent" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "323", "Publisher": "FASB", "URI": "https://asc.fasb.org//323/tableOfContent" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "(b)", "Publisher": "SEC" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r430": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r431": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r432": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r433": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r434": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r435": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r436": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r439": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r441": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r442": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r444": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r449": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r450": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r451": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r452": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r453": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r454": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r457": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r458": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r459": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r460": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r461": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r462": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r463": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r464": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r465": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r466": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r467": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r468": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r469": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r470": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r471": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r472": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r473": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r474": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r475": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r476": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r477": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r478": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r479": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r480": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r481": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r482": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r483": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r484": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r485": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r486": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r487": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r488": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r489": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r491": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r492": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r493": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r494": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r495": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r496": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r497": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r498": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r499": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r500": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r501": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r502": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r503": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r504": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r505": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r506": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r507": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r508": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r509": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r510": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r511": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r512": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r513": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r514": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r515": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r516": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r517": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r518": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r519": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r520": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r521": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r522": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r523": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r524": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r525": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r526": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r527": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r528": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r529": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r530": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "323", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481543/323-740-50-2" }, "r531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r537": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r538": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r539": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r540": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r541": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r542": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r543": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r544": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r545": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r546": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r547": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r548": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r549": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r550": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r551": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r552": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r553": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r554": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r555": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r556": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r557": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r558": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r559": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r560": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r561": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r562": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r563": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r564": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r565": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r566": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r567": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r568": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r569": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r570": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r573": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 66 0001701541-24-000022-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001701541-24-000022-xbrl.zip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

^H]GP-22^]B"0$A!,0QCP7G(B"Z>^J ?R0!P4R: MSQXV/ W9=97IV:N516[2*"#!.9:1,J$2T3"!0ZPYEC=9MH>6B@-?6Y(!*QL[ M+"'O>)(]DKP)=2D0$?%U@XV*M+%0U^5_,7BRP.7(L(BE&

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ⅅ$*R#TK7MS1C@ U4*IPC.:>F!@((&1SEI^Z=&94P' MN8[=+$I[:85_0O_C6>D-_1G&_B.TC3I?^@E<=DZ_/G*""=D'I8FP"FWEHR'E M<@)"8]+":2Y8J+W1OVSB0UV+N#QP+K* (B29,(A"M7*DGS)18P0P1V5GP M2G?#TX.K\H?#X:3?NH/IJ6$^A3B=(ROAN;P M:QQ,$Z0R^(M>II-6+:-\!),WHZ;Y!.-6*QM4BG:,J(-*TFWJL%*EZ=W(7GV/ M[#@?^O&P/_Q8[LUNH5VETE0Y;FXB)8R7XQ=>9G0Z=$)70WJ;G4J*RE6G&R*:5:)I\%11[HA.)J/3)B5QV6>2&4#PP** [OI]U9!@6_6G.^'N\BK4 MK1M_;TI1-Q/\Q;?%#VC+C50(P20:B:+:H&EK)7=$[)T<:9K(;)K94RKX.NHBO8^;#NJB-T7,JQ$T@TMN0O&<6=< ML"&5NC9'I)".!"K+2.4,-,N @=.C8-I]-:P_*M'6,>!6.X1E*X04I6J.>S?? M4XDN$:TX];@*<+1L96;M48>PNG9;N=O7.DKOOMO71=,H'IT R4B2!5EFFN _ M]418'V/R6EE7>X[9DUKG3EFPN;*[G@_FD+11+.3$B2JW2$IK44A%*=$^!\"9 MT("K?49] 8Q'9OU-%=W!!C NAGDT/O?#^>'[9@Y+*"UL-I8(5RY)XJE][,@<3+"13!!0B>2*3,2B@ M]4A*CG.1@-- _!F5O=V>>/0%<6$8MP&8$0P47K;B$R 6=;"9::'+@Y MS=32]KXD05I)?L=GCWV<3/W@/8S/V^TA:1+P$#F)P:'73K,@3FH@8*04C%J% M E6GSF(LNTH_5+/U+0Y5T'D'4?(B7'/?9_'>NM0(D-5+]= MHNY*UT/I'/I+#G!ZY3RE)*B6M2/I;9/BGGWZ;7-B'8U7;WB/,RBZ M<<./+;YWX_XP]C_YP7'._0COOXPN8D!C9O<8*$^QCI4%77M6>%F:_T/>#94;9R6_=, M*TTOLVQ4H.78)&@D;ID.7>+$<"ELRBYZ*E9BPTJOVP4)ZD<>':FW@SS;(I!E M&%Q![ 679=)>$P@RHP(4SES,*.)U8,H#.M2Z]J;:_:@>!T\ZLD(GKN1MA"

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end XML 68 bdtx-20240331_htm.xml IDEA: XBRL DOCUMENT 0001701541 2024-01-01 2024-03-31 0001701541 2024-05-06 0001701541 2024-03-31 0001701541 2023-12-31 0001701541 2023-01-01 2023-03-31 0001701541 2022-12-31 0001701541 2023-03-31 0001701541 us-gaap:CommonStockMember 2022-12-31 0001701541 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001701541 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001701541 us-gaap:RetainedEarningsMember 2022-12-31 0001701541 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001701541 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001701541 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001701541 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001701541 us-gaap:CommonStockMember 2023-03-31 0001701541 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001701541 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001701541 us-gaap:RetainedEarningsMember 2023-03-31 0001701541 us-gaap:CommonStockMember 2023-12-31 0001701541 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001701541 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001701541 us-gaap:RetainedEarningsMember 2023-12-31 0001701541 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001701541 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001701541 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001701541 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001701541 us-gaap:CommonStockMember 2024-03-31 0001701541 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001701541 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001701541 us-gaap:RetainedEarningsMember 2024-03-31 0001701541 bdtx:ShelfRegistrationStatementMember 2022-11-14 2022-11-14 0001701541 bdtx:AtMarketEquityProgramMember 2022-11-14 2022-11-14 0001701541 bdtx:AtMarketEquityProgramMember 2024-01-01 2024-03-31 0001701541 bdtx:FollowOnOfferingMember 2023-07-05 2023-07-05 0001701541 bdtx:FollowOnOfferingMember 2023-07-05 0001701541 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-03-31 0001701541 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-03-31 0001701541 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-03-31 0001701541 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2024-03-31 0001701541 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2024-03-31 0001701541 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2024-03-31 0001701541 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2024-03-31 0001701541 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2024-03-31 0001701541 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2024-03-31 0001701541 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2024-03-31 0001701541 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2024-03-31 0001701541 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2024-03-31 0001701541 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001701541 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001701541 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001701541 us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001701541 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001701541 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001701541 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001701541 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2023-12-31 0001701541 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2023-12-31 0001701541 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2023-12-31 0001701541 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2023-12-31 0001701541 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2023-12-31 0001701541 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001701541 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001701541 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001701541 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001701541 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001701541 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001701541 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001701541 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001701541 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2024-03-31 0001701541 us-gaap:CorporateBondSecuritiesMember 2024-03-31 0001701541 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2023-12-31 0001701541 us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001701541 2023-01-01 2023-12-31 0001701541 us-gaap:FurnitureAndFixturesMember 2024-03-31 0001701541 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001701541 us-gaap:LeaseholdImprovementsMember 2024-03-31 0001701541 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001701541 bdtx:LaunchpadTherapeuticsIncMember 2022-12-31 0001701541 bdtx:LaunchpadTherapeuticsIncMember 2024-03-31 0001701541 bdtx:LaunchpadTherapeuticsIncMember 2022-12-01 0001701541 2022-01-01 2022-12-31 0001701541 bdtx:LaunchpadTherapeuticsIncMember 2022-01-01 2022-12-31 0001701541 bdtx:A2020StockOptionPlanMember 2020-01-14 0001701541 bdtx:A2020StockOptionPlanMember 2024-01-01 2024-01-01 0001701541 bdtx:A2020StockOptionPlanMember 2024-01-01 0001701541 bdtx:A2020EmployeeStockPurchasePlanMember 2020-01-14 0001701541 bdtx:A2020EmployeeStockPurchasePlanMember 2024-01-01 2024-01-01 0001701541 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001701541 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001701541 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001701541 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001701541 bdtx:OtherAwardTypeMember 2024-01-01 2024-03-31 0001701541 bdtx:OtherAwardTypeMember 2023-01-01 2023-03-31 0001701541 us-gaap:EmployeeStockOptionMember bdtx:A2020StockOptionPlanMember 2024-01-01 2024-03-31 0001701541 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0001701541 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001701541 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-03-31 0001701541 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001701541 us-gaap:RestrictedStockMember 2023-12-31 0001701541 us-gaap:RestrictedStockMember 2024-01-01 2024-03-31 0001701541 us-gaap:RestrictedStockMember 2024-03-31 0001701541 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 0001701541 us-gaap:PerformanceSharesMember 2023-12-31 0001701541 bdtx:PerformanceRestrictedStockUnitsMember 2024-01-01 2024-03-31 0001701541 us-gaap:PerformanceSharesMember 2024-01-01 2024-03-31 0001701541 bdtx:PerformanceRestrictedStockUnitsMember 2024-03-31 0001701541 us-gaap:EmployeeStockMember bdtx:A2020EmployeeStockPurchasePlanMember 2024-01-01 2024-03-31 0001701541 us-gaap:EmployeeStockMember bdtx:A2020EmployeeStockPurchasePlanMember 2024-03-31 0001701541 us-gaap:EmployeeStockMember bdtx:A2020EmployeeStockPurchasePlanMember 2023-01-01 2023-03-31 0001701541 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001701541 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001701541 us-gaap:RestrictedStockMember 2024-01-01 2024-03-31 0001701541 us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0001701541 us-gaap:EmployeeStockMember 2024-01-01 2024-03-31 0001701541 us-gaap:EmployeeStockMember 2023-01-01 2023-03-31 0001701541 us-gaap:PerformanceSharesMember 2024-01-01 2024-03-31 0001701541 us-gaap:PerformanceSharesMember 2023-01-01 2023-03-31 0001701541 us-gaap:WarrantMember 2024-01-01 2024-03-31 0001701541 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001701541 bdtx:OperatingLeasePrincipalOfficeTwoMember 2020-07-31 0001701541 bdtx:OperatingLeasePrincipalOfficeTwoMember 2023-08-31 0001701541 bdtx:OperatingLeaseOfficeAndLaboratorySpaceNYMember 2020-12-31 0001701541 us-gaap:SubsequentEventMember bdtx:AtMarketEquityProgramMember 2024-04-01 2024-04-30 0001701541 us-gaap:SubsequentEventMember bdtx:AtMarketEquityProgramMember 2024-05-01 2024-05-09 0001701541 bdtx:FangNiMember 2024-01-01 2024-03-31 0001701541 bdtx:FangNiMember 2024-03-31 0001701541 bdtx:BrentHatzisSchochMember 2024-01-01 2024-03-31 0001701541 bdtx:BrentHatzisSchochMember 2024-03-31 shares iso4217:USD iso4217:USD shares pure bdtx:contract utr:sqft false Q1 2024 0001701541 --12-31 http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent P5Y P5Y P365D P365D 10-Q true 2024-03-31 false 001-38501 BLACK DIAMOND THERAPEUTICS, INC. DE 81-4254660 One Main Street, 14th Floor Cambridge MA 02142 (617) 252-0848 Common stock, par value $0.0001 BDTX NASDAQ Yes Yes Non-accelerated Filer true true false false 56252794 25422000 56221000 89777000 75179000 3607000 2634000 118806000 134034000 1644000 1730000 819000 823000 21252000 21980000 142521000 158567000 1176000 2324000 15678000 17322000 16854000 19646000 21361000 22185000 38215000 41831000 0.0001 0.0001 10000000 10000000 0 0 0 0 0 0 0.0001 0.0001 500000000 500000000 52527626 52527626 51645557 51645557 7000 7000 540050000 534187000 -95000 -27000 -435656000 -417431000 104306000 116736000 142521000 158567000 13545000 14753000 6701000 6808000 20246000 21561000 -20246000 -21561000 637000 622000 1384000 64000 2021000 686000 -18225000 -20875000 -0.35 -0.35 -0.57 -0.57 51808849 51808849 36483878 36483878 -18225000 -20875000 -68000 648000 -18293000 -20227000 -18225000 -20875000 1713000 2671000 86000 122000 932000 -109000 728000 690000 0 -37000 973000 -383000 -1128000 1169000 -1644000 -3583000 -824000 -754000 -21199000 -20031000 38500000 24806000 52234000 0 -13734000 24806000 150000 51000 3980000 0 4130000 51000 -30803000 4826000 57044000 35483000 26241000 40309000 25422000 39141000 819000 1168000 26241000 40309000 36434297 5000 452503000 -1824000 -334989000 115695000 23575 3903 33202 51000 51000 24776 2671000 2671000 648000 648000 -20875000 -20875000 36511947 5000 455225000 -1176000 -355864000 98190000 51645557 7000 534187000 -27000 -417431000 116736000 800000 4000000 4000000 47741 86000 86000 1250 26659 64000 64000 6419 1713000 1713000 -68000 -68000 -18225000 -18225000 52527626 7000 540050000 -95000 -435656000 104306000 NATURE OF BUSINESS AND BASIS OF PRESENTATION<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Black Diamond Therapeutics, Inc. (the Company) is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing and incurring research and development costs related to the development and advancement of its product candidates identified by its Mutation-Allostery-Pharmacology (MAP) drug discovery engine. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to clinical-stage companies in the biotechnology industry. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On November 14, 2022, the Company filed a shelf registration statement on Form S-3 (the Shelf Registration Statement), with the Securities and Exchange Commission (the SEC), which covers the offering, issuance and sale of the Company’s common stock, preferred stock, debt securities, warrants and/or units of any combination thereof up to a maximum offering price of $500 million. The Company simultaneously entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with Jefferies LLC (Jefferies), as sales agent, to provide for the issuance and sale by the Company of up to $150 million of its common stock from time to time through Jefferies (the ATM Program). The Shelf Registration Statement became effective on November 22, 2022. As of March 31, 2024, the Company sold 800,000 shares of its common stock pursuant to the ATM Program, resulting in gross proceeds to the Company of approximately $4.0 million ($3.9 million net of offering costs).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On July 5, 2023, the Company completed an underwritten public offering (the Follow-on Offering) of 15,000,000 shares of the Company’s common stock at a price to the public of $5.00 per share. The aggregate net proceeds from the Follow-on Offering totaled approximately $71.9 million, after deducting underwriting discounts and commissions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. Historically, the Company has funded its operations primarily with proceeds from the sale of common stock and preferred stock. The Company has had recurring losses and negative cash flows from operations in all periods since inception and had an accumulated deficit of $435.7 million as of March 31, 2024. The Company expects to continue to generate operating losses for the foreseeable future. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of May 9, 2024, the issuance date of the condensed consolidated financial statements, the Company expects that its cash, cash equivalents and investments will be sufficient to fund its currently planned operations for at least the next 12 months from the filing date of these condensed consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company will seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, or reduce headcount and general and administrative costs, which could adversely affect its business prospects. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Black Diamond Therapeutics, Inc. (the Company) is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing and incurring research and development costs related to the development and advancement of its product candidates identified by its Mutation-Allostery-Pharmacology (MAP) drug discovery engine. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to clinical-stage companies in the biotechnology industry. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Principles of consolidation </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics Security Corporation and Black Diamond Therapeutics (Canada), Inc., after elimination of all significant intercompany accounts and transactions. On October 10, 2023, Black Diamond Therapeutics (Canada), Inc. was dissolved by way of voluntary dissolution.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Unaudited interim financial information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. In the opinion of the Company’s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.</span></div> 500000000 150000000 800000 4000000 3900000 15000000 5.00 71900000 -435700000 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a summary of significant accounting policies followed in the preparation of these condensed consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Principles of consolidation </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics Security Corporation and Black Diamond Therapeutics (Canada), Inc., after elimination of all significant intercompany accounts and transactions. On October 10, 2023, Black Diamond Therapeutics (Canada), Inc. was dissolved by way of voluntary dissolution.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Unaudited interim financial information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. In the opinion of the Company’s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company continues to monitor the impact of global economic developments, political unrest, high inflation, disruptions in capital markets, changes in international trade relationships and military conflicts, and health crises, on all aspects of its business, and has considered the impact of these factors on estimates within its financial statements. The extent to which future developments may impact the Company’s business, results of operations or financial condition are uncertain and cannot be predicted with confidence and there may be changes to estimates in future periods. As of the date of issuance of these condensed consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of these factors and is not aware of any specific related event or circumstance that would require it to update its estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (ASU 2023-09). ASU 2023-09 requires that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate). The standard is effective for annual and interim periods beginning after December 15, 2024. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The adoption is not expected to have a material impact on the Company’s consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> Improvements to Reportable Segment Disclosures (Topic 280) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ASU 2023-07) which requires enhanced disclosure of (1) significant segment expenses that are regularly provided to the chief operating decision maker (CODM) and included within each reported measure of segment profit or loss, (2) the amount and description of the composition of other segment items which reconcile to segment profit or loss, and (3) the title and position of the entity’s CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and allocating resources. The amendments also expand the interim segment disclosure requirements. This new guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this ASU apply retrospectively to all prior periods presented in the financial statements. The Company is in the process of assessing the impact on its financial statements from the adoption of the new guidance and the period in which the new guidance will be adopted.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In October 2023, the FASB issued ASU 2023-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Disclosure Improvements - Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ASU 2023-06). The standard is effective for annual and interim periods beginning after December 15, 2024. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The adoption is not expected to have a material impact on the Company’s consolidated financial statements.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Principles of consolidation </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics Security Corporation and Black Diamond Therapeutics (Canada), Inc., after elimination of all significant intercompany accounts and transactions. On October 10, 2023, Black Diamond Therapeutics (Canada), Inc. was dissolved by way of voluntary dissolution.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates </span></div>The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (ASU 2023-09). ASU 2023-09 requires that public business entities on an annual basis (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5 percent of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate). The standard is effective for annual and interim periods beginning after December 15, 2024. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The adoption is not expected to have a material impact on the Company’s consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> Improvements to Reportable Segment Disclosures (Topic 280) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ASU 2023-07) which requires enhanced disclosure of (1) significant segment expenses that are regularly provided to the chief operating decision maker (CODM) and included within each reported measure of segment profit or loss, (2) the amount and description of the composition of other segment items which reconcile to segment profit or loss, and (3) the title and position of the entity’s CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and allocating resources. The amendments also expand the interim segment disclosure requirements. This new guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this ASU apply retrospectively to all prior periods presented in the financial statements. The Company is in the process of assessing the impact on its financial statements from the adoption of the new guidance and the period in which the new guidance will be adopted.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In October 2023, the FASB issued ASU 2023-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Disclosure Improvements - Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ASU 2023-06). The standard is effective for annual and interim periods beginning after December 15, 2024. Adoption of the standard requires certain changes to be made prospectively, with some changes to be made retrospectively. The adoption is not expected to have a material impact on the Company’s consolidated financial statements.</span></div> FAIR VALUE MEASUREMENTS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value measurements at March 31, 2024 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,498 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,498 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">82,830 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">82,830 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,947 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,947 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,498 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">89,777 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">110,275 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value measurements at December 31, 2023 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">44,871 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">44,871 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30,803 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">75,179 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">105,982 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">When developing fair value estimates, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. When available, the Company uses quoted market prices to measure fair value. The valuation technique used to measure fair value for the Company's Level 1 and Level 2 assets is a market approach, using prices and other relevant information generated by market transactions involving identical or comparable assets. If market prices are not available, the fair value measurement is based on models that use primarily market-based parameters including yield curves, volatilities, credit ratings and currency rates. In certain cases where market rate assumptions are not available, the Company is required to make judgments about assumptions market participants would use to estimate the fair value of a financial instrument. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There were no transfers in or out of Level 3 categories in the periods presented.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value measurements at March 31, 2024 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,498 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,498 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">82,830 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">82,830 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,947 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,947 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,498 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">89,777 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">110,275 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value measurements at December 31, 2023 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">44,871 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">44,871 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30,803 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">75,179 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">105,982 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 20498000 0 0 20498000 0 82830000 0 82830000 0 6947000 0 6947000 20498000 89777000 0 110275000 30803000 0 0 30803000 0 44871000 0 44871000 0 30308000 0 30308000 30803000 75179000 0 105982000 INVESTMENTS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March 31, 2024, investments were comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.398%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">82,921 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(91)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">82,830 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,951 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,947 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">89,872 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(95)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">89,777 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December 31, 2023, investments were comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.398%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">44,880 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">44,871 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30,326 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">75,206 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(31)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">75,179 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March 31, 2024, all marketable securities held by the Company had remaining contractual maturities of one year or less.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December 31, 2023, all marketable securities held by the Company had remaining contractual maturities of one year or less.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March 31, 2024, the Company reviewed its investment portfolio to assess the unrealized losses on its available-for-sale investments. The Company evaluated whether it intended to sell the security and whether it was more likely than not that the Company would be required to sell the security before recovering its amortized cost basis. The Company also determined no portion of the unrealized losses relate to a credit loss. There have been no impairments of the Company’s assets measured and carried at fair value during the three months ended March 31, 2024 and the year ended December 31, 2023.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March 31, 2024, investments were comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.398%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">82,921 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(91)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">82,830 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,951 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,947 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">89,872 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(95)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">89,777 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December 31, 2023, investments were comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.398%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">44,880 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">44,871 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30,326 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30,308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">75,206 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(31)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">75,179 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 82921000 0 91000 82830000 6951000 0 4000 6947000 89872000 0 95000 89777000 44880000 4000 13000 44871000 30326000 0 18000 30308000 75206000 4000 31000 75179000 0 0 PROPERTY AND EQUIPMENT<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,529 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,529 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(885)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(799)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total Property and Equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,644 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,730 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Depreciation expense for the three months ended March 31, 2024 and 2023 was $86 and $122, respectively.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,529 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,529 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(885)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(799)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total Property and Equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,644 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,730 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 17000 17000 2512000 2512000 2529000 2529000 885000 799000 1644000 1730000 86000 122000 EQUITY METHOD INVESTMENT<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In December 2022, the Company received 9,000,000 shares of common stock in a newly formed antibody-focused precision oncology company, Launchpad Therapeutics, Inc. (Launchpad), in exchange for contributing early discovery-stage antibody programs and granting Launchpad a license to use its MAP drug discovery engine to discover, develop and commercialize large molecule therapeutics. As of the transaction date and as of March 31, 2024, the Company has a 39.1% voting interest in Launchpad and one seat on Launchpad’s Board of Directors which provide the Company with significant influence over Launchpad. The remaining voting interest in Launchpad is held by Versant Ventures and New Enterprise Associates (NEA), who are shareholders of the Company. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company accounted for the transaction under the equity method and recorded the carrying value of the Company’s investment in Launchpad common shares of $2,250 in equity method investments in the consolidated balance sheets. The contributed in process research and development (IPR&amp;D) had zero basis on the Company’s books prior to the transaction, therefore the Company recognized a gain on sale of IPR&amp;D of $2,232 in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2022. The Company also recognized a loss from investments in equity method investee of $1,540 in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2022, associated with the Company’s proportionate share of Launchpad’s losses. The assets contributed by the Company were principally IPR&amp;D and were not deemed a business by Launchpad, therefore the Company determined its remaining basis difference of $710 was substantially related to IPR&amp;D and immediately expensed it. As of December 31, 2022, the carrying value of the investment in Launchpad was reduced to zero. Since the Company has no obligation to provide financing support to Launchpad, the Company is not required to record further losses exceeding the carrying value of the investment. The Company also determined that its investment in Launchpad is not material or significant to its operations or financial position. As of March 31, 2024, the carrying value of the investment in Launchpad was zero.</span></div> 9000000 0.391 2250000 2232000 -1540000 710000 0 0 ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Contracted research services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,984 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,071 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Payroll and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,510 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Professional and consulting fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">963 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-326"><span style="-sec-ix-hidden:f-327">Current portion of operating lease liability</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15,678 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17,322 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.118%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Contracted research services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,984 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,071 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Payroll and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,510 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Professional and consulting fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">963 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-326"><span style="-sec-ix-hidden:f-327">Current portion of operating lease liability</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15,678 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17,322 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 8984000 8071000 2510000 5175000 1000000 963000 3184000 3113000 15678000 17322000 STOCK-BASED COMPENSATION<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2020 Stock Option and Incentive Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The 2020 Stock Option and Incentive Plan (the 2020 Plan) was approved by the Company’s board of directors on December 5, 2019, and the Company’s stockholders on January 14, 2020 and became effective on the date immediately prior to the date on which the registration statement for the Company’s initial public offering (IPO) was declared effective. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company’s officers, employees, directors and consultants. The 2020 Plan provides for an annual increase, to be added on the first day of each fiscal year, by up to 4% of the Company’s outstanding shares of common stock as of the last day of the prior year. On January 1, 2024, 2,065,822 shares of common stock, representing 4% of the Company’s outstanding shares of common stock as of December 31, 2023, were added to the 2020 Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The 2020 Employee Stock Purchase Plan (the 2020 ESPP) was approved by the Company’s board of directors on December 5, 2019, and the Company’s stockholders on January 14, 2020, and became effective on the date immediately prior to the date on which the registration statement for the Company’s IPO was declared effective. The 2020 ESPP provides for an annual increase, to be added on the first day of each fiscal year, by up to 1% of the number of shares of the Company’s common stock outstanding on the immediately preceding December 31. The number of authorized shares reserved for issuance under the 2020 ESPP was increased by 326,364 shares effective as of January 1, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation expense </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following award type categories included within the condensed consolidated statements of operations and comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top">Three Months Ended<br/>March 31,</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,623 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,455 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Employee Stock Purchase Plan and Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,713 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,671 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, the Company issued 6,419 shares of common stock under its 2020 Plan in accordance with its policy where non-employee directors may elect to receive their compensation in the form of common stock in lieu of cash.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>March 31,</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">635 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">949 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,078 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,722 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,713 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,671 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Options </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity under the Company’s equity awards plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:46.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.456%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Exercise</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Price</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Life</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(in Years)</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Outstanding December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,135,711 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.85 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,146 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,895,550 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(47,741)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(16,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.82 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Outstanding March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,966,720 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.09 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options vested or expected to vest at March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,966,720 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.09 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,996 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options exercisable at March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,242,313 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,488 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, total unrecognized compensation cost related to the unvested stock-options was $18,345, which is expected to be recognized over a weighted average period of 3.1 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Restricted stock units </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The fair values of restricted stock units are based on the market value of the Company’s stock on the date of the grant. Under terms of the time-based restricted stock agreements covering the common stock, shares of restricted common stock are subject to a vesting schedule. The following table summarizes time-based restricted stock activity since January 1, 2024:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Number of</span></div><div style="margin-bottom:0.75pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">shares</span></div></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">average</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">grant date</span></div><div style="margin-bottom:0.75pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">fair value</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unvested restricted common stock as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,799 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.41 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unvested restricted common stock as of March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19,549 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.32 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The total fair value of time-based restricted stock units vested during the three months ended March 31, 2024 was $5. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, total unrecognized compensation cost related to the time-based unvested restricted stock units was $6, which is expected to be recognized over a weighted average period of 0.1 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company had 19,000 performance restricted stock units outstanding at the year ended December 31, 2023. For the three months ended March 31, 2024, the Company granted no performance restricted stock units to its employees, released no performance restricted stock units due to the achievement of certain financing milestones, and had no performance restricted stock units forfeited. As of March 31, 2024, the Company had 19,000 performance restricted stock units outstanding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Recognition of stock-based compensation expense associated with performance restricted stock units commences when the performance conditions are considered probable of achievement, using management’s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of March 31, 2024, for performance-based restricted stock units that were outstanding, the achievement of the milestones that had not been met was considered not probable, and therefore no expense has been recognized related to these awards in the three months ended March 31, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Employee stock purchase plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The 2020 ESPP enables eligible employees to purchase shares of the Company's common stock at the end of each six-month offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Eligible employees generally included all employees. Offering periods begin on the first trading day of January and July of each year and end on the last trading day in June and December of each year, except for the first offering period which began on the first trading day in March and ended on the last trading day in June. Share purchases are funded through payroll deductions of up to 10% of an employee’s eligible compensation for each payroll period, up to $25 each calendar year.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024 and 2023, there were 26,659 and 33,202 shares, respectively, issued under the 2020 ESPP.</span></div> 0.04 2065822 0.04 0.01 326364 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following award type categories included within the condensed consolidated statements of operations and comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top">Three Months Ended<br/>March 31,</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,623 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,455 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Employee Stock Purchase Plan and Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,713 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,671 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>March 31,</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">635 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">949 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,078 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,722 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,713 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,671 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 1623000 2455000 16000 112000 74000 104000 1713000 2671000 6419 635000 949000 1078000 1722000 1713000 2671000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity under the Company’s equity awards plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:46.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.454%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.456%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Exercise</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Price</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Life</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(in Years)</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Outstanding December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,135,711 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.85 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,146 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,895,550 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(47,741)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(16,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.82 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Outstanding March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,966,720 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.09 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,996 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options vested or expected to vest at March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,966,720 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.09 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,996 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options exercisable at March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,242,313 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,488 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 8135711 7.85 P8Y 1146000 2895550 4.85 47741 1.78 16500 1.82 300 7.73 10966720 7.09 P8Y3M18D 11996000 10966720 7.09 P8Y3M18D 11996000 4242313 11.65 P6Y8M12D 3488000 18345000 P3Y1M6D The following table summarizes time-based restricted stock activity since January 1, 2024:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Number of</span></div><div style="margin-bottom:0.75pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">shares</span></div></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">average</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">grant date</span></div><div style="margin-bottom:0.75pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">fair value</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unvested restricted common stock as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,799 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.41 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unvested restricted common stock as of March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19,549 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.32 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 20799 2.41 1250 3.79 19549 2.32 5000 6000 P0Y1M6D 19000 0 0 0 19000 0 P6M 0.85 0.10 25000 26659 33202 NET LOSS PER SHARE<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Net loss per share</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the computation of basic and diluted net loss per share attributable to common shareholders of the Company (in thousands, except share and per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(18,225)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(20,875)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">51,808,849 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,483,878 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(0.35)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(0.57)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company’s potentially dilutive securities, which include options, unvested restricted stock and warrants to purchase common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,966,720 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,710,285 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unvested restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19,549 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">86,290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Shares issuable under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">86,858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">102,351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unvested performance restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">229,859 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,757 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,757 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,102,884 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,139,542 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the computation of basic and diluted net loss per share attributable to common shareholders of the Company (in thousands, except share and per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(18,225)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(20,875)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">51,808,849 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,483,878 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(0.35)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(0.57)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> -18225000 -20875000 51808849 51808849 36483878 36483878 -0.35 -0.35 -0.57 -0.57 The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,966,720 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,710,285 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unvested restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19,549 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">86,290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Shares issuable under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">86,858 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">102,351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unvested performance restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">229,859 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,757 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,757 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,102,884 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,139,542 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 10966720 7710285 19549 86290 86858 102351 19000 229859 10757 10757 11102884 8139542 LEASES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has historically entered into lease arrangements for its facilities. As of March 31, 2024, the Company had two operating leases with required future minimum payments. The Company determined the classification of these leases to be operating leases and recorded right-of-use assets and lease liabilities as of the effective dates. The Company’s leases generally do not include termination or purchase options. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Operating leases </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a seven-year agreement with an option to extend for <span style="-sec-ix-hidden:f-431">five</span> additional years to lease two floors totaling approximately 25,578 square feet of office space for its principal office, which is located in Cambridge, MA. The lease on the first floor commenced on August 1, 2020 and the lease on the second floor commenced March 9, 2021. The Company recognized the respective lease balances on the condensed consolidated balance sheets when the lease of each floor commenced. Under the terms of the lease, the Company was required to issue a $1,168 letter of credit as security for the lease, which was reduced to $779 in August 2023 pursuant to the terms of the lease agreement. Additionally, on December 12, 2022, the Company entered into a sublease for one floor of its Cambridge, Massachusetts office space. The sublease terminates on August 31, 2028, which is also the date on which the Company's lease terminates. Sublease income is recognized on a straight-line basis over the term of the sublease agreement. The Company was not relieved of its primary obligation under the Cambridge office lease as a result of the sublease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In December 2020, the Company entered into an eleven-year agreement to lease approximately 18,120 square feet of office and laboratory space in New York, NY. The Company has an option to extend the lease for <span style="-sec-ix-hidden:f-437">five</span> additional years. The lease commenced August 26, 2021 and the related lease balance was recognized on the condensed consolidated balance sheet.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating lease for the three months ended March 31, 2024 and 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.977%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended March 31,</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lease Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,054 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,054 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">256 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(456)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">852 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,192 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.436%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Operating Lease Information</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,080 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,051 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The variable lease costs for the three months ended March 31, 2024 and 2023 include common area maintenance and other operating charges. As the Company’s leases do not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Future minimum lease payments under the Company’s operating leases as of March 31, 2024 were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.480%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.320%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">As of March 31, 2024</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024 (excluding the three months ended March 31, 2024)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,279 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,599 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,926 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,324 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">29,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(4,784)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">24,545 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2 P7Y 25578 1168000 779000 P11Y 18120 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating lease for the three months ended March 31, 2024 and 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.977%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended March 31,</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lease Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,054 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,054 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">256 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(456)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">852 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,192 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.434%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.436%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Operating Lease Information</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,080 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,051 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr></table></div> 1054000 1054000 17000 17000 237000 256000 456000 135000 852000 1192000 1080000 1051000 P6Y8M12D P7Y7M6D 0.053 0.053 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Future minimum lease payments under the Company’s operating leases as of March 31, 2024 were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.480%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.320%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">As of March 31, 2024</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024 (excluding the three months ended March 31, 2024)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,279 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,599 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,926 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,324 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">29,329 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(4,784)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">24,545 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3279000 4477000 4599000 4724000 3926000 8324000 29329000 4784000 24545000 COMMITMENTS AND CONTINGENCIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company enters into contracts in the normal course of business with contract research organizations (CROs), contract manufacturing organizations (CMOs) and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of service providers, up to the date of cancellation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">License agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is a party to license agreements, which include contingent payments. These payments will become payable if and when certain development, regulatory and commercial milestones are achieved. As of March 31, 2024, the satisfaction and timing of the contingent payments is uncertain and not reasonably estimable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Indemnification agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of March 31, 2024 or December 31, 2023. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Legal proceedings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is not currently party to and is not aware of any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.</span></div> BENEFIT PLANS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has a tax-qualified 401(k) and Profit Sharing defined contribution plan (the 401(k) Plan). Under the 401(k) Plan, the Company provides an employer safe harbor matching contribution equal to 100% of a participant’s eligible contributions of up to 6% of eligible compensation, subject to limits established by the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the Code). All matching contributions are fully vested when made. During the three months ended March 31, 2024 and 2023, the Company contributed $348 and $376, respectively, to the 401(k) Plan.</span></div> 1 0.06 348000 376000 SUBSEQUENT EVENTS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In April 2024, the Company sold 1,000,000 shares of its common stock pursuant to the ATM Program, resulting in gross proceeds to the Company of approximately $5.4 million ($5.3 million net of offering costs).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In May 2024, the Company sold 2,690,853 shares of its common stock pursuant to the ATM Program, resulting in gross proceeds to the Company of approximately $15.6 million ($15.3 million net of offering costs).</span></div> 1000000 5400000 5300000 2690853 15600000 15300000 false false false <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On March 28, 2024, Fang Ni, our Chief Business Officer and Chief Financial Officer, entered into a trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Ni 10b5-1 Plan). The Ni 10b5-1 Plan is scheduled to commence on June 29, 2024, and will run through June 29, 2025. The aggregate maximum number of shares of common stock that may be sold pursuant to the Ni 10b5-1 Plan is up to 40,470 shares.</span></div> March 28, 2024 Fang Ni Chief Business Officer true 40470 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On March 27, 2024, Brent Hatzis-Schoch, our Chief Operating Officer and General Counsel, entered into a trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Hatzis-Schoch 10b5-1 Plan). The Hatzis-Schoch 10b5-1 Plan is scheduled to commence on July 1, 2024, and will run through July 1, 2025. The aggregate maximum number of shares of common stock that may be sold pursuant to the Hatzis-Schoch 10b5-1 Plan is up to 72,400 shares.</span></div> March 27, 2024 Brent Hatzis-Schoch Chief Operating Officer true 72400